<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Mirtazapine adjunct for people with schizophrenia - Perry, LA - 2018 | Cochrane Library</title> <meta content="Mirtazapine adjunct for people with schizophrenia - Perry, LA - 2018 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011943.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Mirtazapine adjunct for people with schizophrenia - Perry, LA - 2018 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011943.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD011943.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Mirtazapine adjunct for people with schizophrenia" name="citation_title"/> <meta content="Luke A Perry" name="citation_author"/> <meta content="Monash University" name="citation_author_institution"/> <meta content="lukeaperry@gmail.com" name="citation_author_email"/> <meta content="Dhruvesh Ramson" name="citation_author"/> <meta content="Monash University" name="citation_author_institution"/> <meta content="Suzanne Stricklin" name="citation_author"/> <meta content="Miami University" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="5" name="citation_issue"/> <meta content="10.1002/14651858.CD011943.pub2" name="citation_doi"/> <meta content="2018" name="citation_date"/> <meta content="2018/05/26" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011943.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011943.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011943.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Schizophrenic Psychology; Antidepressive Agents, Tricyclic [adverse effects, *therapeutic use]; Antipsychotic Agents [*therapeutic use]; Chemotherapy, Adjuvant; Mianserin [adverse effects, *analogs &amp; derivatives, therapeutic use]; Mirtazapine; Patient Dropouts [statistics &amp; numerical data]; Quality of Life; Randomized Controlled Trials as Topic; Schizophrenia [*drug therapy]; Weight Gain" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011943.pub2&amp;doi=10.1002/14651858.CD011943.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011943.pub2&amp;doi=10.1002/14651858.CD011943.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011943.pub2&amp;doi=10.1002/14651858.CD011943.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011943.pub2&amp;doi=10.1002/14651858.CD011943.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011943.pub2&amp;doi=10.1002/14651858.CD011943.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011943.pub2&amp;doi=10.1002/14651858.CD011943.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011943.pub2&amp;doi=10.1002/14651858.CD011943.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011943.pub2&amp;doi=10.1002/14651858.CD011943.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011943.pub2&amp;doi=10.1002/14651858.CD011943.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011943.pub2&amp;doi=10.1002/14651858.CD011943.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011943.pub2&amp;doi=10.1002/14651858.CD011943.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011943.pub2&amp;doi=10.1002/14651858.CD011943.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011943.pub2&amp;doi=10.1002/14651858.CD011943.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011943.pub2&amp;doi=10.1002/14651858.CD011943.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011943.pub2&amp;doi=10.1002/14651858.CD011943.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011943.pub2&amp;doi=10.1002/14651858.CD011943.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011943.pub2&amp;doi=10.1002/14651858.CD011943.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011943.pub2&amp;doi=10.1002/14651858.CD011943.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011943.pub2&amp;doi=10.1002/14651858.CD011943.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011943.pub2&amp;doi=10.1002/14651858.CD011943.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011943.pub2&amp;doi=10.1002/14651858.CD011943.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011943.pub2&amp;doi=10.1002/14651858.CD011943.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011943.pub2&amp;doi=10.1002/14651858.CD011943.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="6iOnQIUh";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD011943\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD011943\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011943\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011943\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANS","ru","pt","ms","fr","fa"],languageCode:"en",accessStatus:"not-found",doi:"10.1002/14651858.CD011943.pub2",title:"Mirtazapine adjunct for people with schizophrenia",firstPublishedDate:"May 26, 2018 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Schizophrenia Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=6iOnQIUh&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011943.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011943.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD011943.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD011943.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011943.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD011943.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011943.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD011943.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011943.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD011943.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Conclusiones de los autores&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Antecedentes&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Objetivos&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Métodos&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Discusión&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD011943.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD011943.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD011943.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD011943.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>5977 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD011943.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011943.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011943.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011943.pub2/full#CD011943-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011943.pub2/full#CD011943-sec-0218"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011943.pub2/full#CD011943-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011943.pub2/full#CD011943-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011943.pub2/full#CD011943-sec-0035"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011943.pub2/full#CD011943-sec-0036"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011943.pub2/full#CD011943-sec-0117"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011943.pub2/full#CD011943-sec-0202"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD011943.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011943.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011943.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011943.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD011943.pub2/media/CDSR/CD011943/table_n/CD011943StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD011943.pub2/media/CDSR/CD011943/table_n/CD011943StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011943.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011943.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011943.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011943.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011943.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD011943.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2018 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD011943.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Mirtazapine adjunct for people with schizophrenia</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011943.pub2/information#CD011943-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Luke A Perry</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011943.pub2/information#CD011943-cr-0003">Dhruvesh Ramson</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011943.pub2/information#CD011943-cr-0004">Suzanne Stricklin</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD011943.pub2/information/en#CD011943-sec-0229">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 26 May 2018 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD011943.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD011943.pub2">https://doi.org/10.1002/14651858.CD011943.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD011943-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011943-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011943-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011943-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011943-abs-0003">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011943-abs-0002">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD011943-abs-0001" lang="en"> <section id="CD011943-sec-0001"> <h3 class="title" id="CD011943-sec-0001">Background</h3> <p>Many individuals who have a diagnosis of schizophrenia experience a range of distressing and debilitating symptoms. These can include positive symptoms (such as delusions, hallucinations, disorganised speech), cognitive symptoms (such as trouble focusing or paying attention or using information to make decisions), and negative symptoms (such as diminished emotional expression, avolition, alogia, and anhedonia). Antipsychotic drugs are often only partially effective, particularly in treating negative symptoms, indicating the need for additional treatment. Mirtazapine is an antidepressant drug that when taken in addition to an antipsychotic may offer some benefit for negative symptoms. </p> </section> <section id="CD011943-sec-0002"> <h3 class="title" id="CD011943-sec-0002">Objectives</h3> <p>To systematically assess the effects of mirtazapine as adjunct treatment for people with schizophrenia. </p> </section> <section id="CD011943-sec-0003"> <h3 class="title" id="CD011943-sec-0003">Search methods</h3> <p>The Information Specialist of Cochrane Schizophrenia searched the Cochrane Schizophrenia Group’s Study‐Based Register of Trials (including registries of clinical trials) up to May 2018. </p> </section> <section id="CD011943-sec-0004"> <h3 class="title" id="CD011943-sec-0004">Selection criteria</h3> <p>All randomised‐controlled trials (RCTs) with useable data focusing on mirtazapine adjunct for people with schizophrenia. </p> </section> <section id="CD011943-sec-0005"> <h3 class="title" id="CD011943-sec-0005">Data collection and analysis</h3> <p>We extracted data independently. For binary outcomes, we calculated risk ratio (RR) and its 95% confidence interval (CI), on an intention‐to‐treat (ITT) basis. For continuous data, we estimated the mean difference (MD) between groups and its 95% CI. We employed a fixed‐effect model for analyses. For included studies we assessed risk of bias and created 'Summary of findings' table using GRADE. </p> </section> <section id="CD011943-sec-0006"> <h3 class="title" id="CD011943-sec-0006">Main results</h3> <p>We included nine RCTs with a total of 310 participants. All studies compared mirtazapine adjunct with placebo adjunct and were of short‐term duration. We considered five studies to have a high risk of bias for either incomplete outcome data, selective reporting, or other bias. </p> <p>Our main outcomes of interest were clinically important change in mental state (negative and positive symptoms), leaving the study early for any reason, clinically important change in global state, clinically important change in quality of life, number of days in hospital and incidence of serious adverse events. </p> <p>One trial defined a reduction in the Scale for the Assessment of Negative Symptoms (SANS) overall score from baseline of at least 20% as no important response for negative symptoms. There was no evidence of a clear difference between the two treatments with similar numbers of participants from each group showing no important response to treatment (RR 0.81, 95% CI 0.57 to 1.14, 1 RCT, n = 20, very low‐quality evidence). </p> <p>Clinically important change in positive symptoms was not reported, however, clinically important change in overall mental state was reported by two trials and data for this outcome showed a favourable effect for mirtazapine (RR 0.69, 95% CI 0.51 to 0.92; I<sup>2</sup> = 75%, 2 RCTs, n = 77, very low‐quality evidence). There was no evidence of a clear difference for numbers of participants leaving the study early (RR 1.03, 95% CI 0.64 to 1.66, 9 RCTs, n = 310, moderate‐quality evidence), and no evidence of a clear difference in global state Clinical Global Impressions Scale (CGI) severity scores (MD ‐0.10, 95% CI ‐0.68 to 0.48, 1 RCT, n = 39, very low‐quality evidence). A favourable effect for mirtazapine adjunct was found for the outcome clinically important change in akathisia (RR 0.33, 95% CI 0.20 to 0.52, 2 RCTs, n = 86, low‐quality evidence; I<sup>2</sup> = 61%I). No data were reported for quality life or number of days in hospital. </p> <p>In addition to the main outcomes of interest, there was evidence relating to adverse events that the mirtazapine adjunct groups were associated with an increased risk of weight gain (RR 3.19, 95% CI 1.17 to 8.65, 4 RCTs, n = 127) and sedation/drowsiness (RR 1.64, 95% CI 1.01 to 2.68, 7 RCTs, n = 223). </p> </section> <section id="CD011943-sec-0007"> <h3 class="title" id="CD011943-sec-0007">Authors' conclusions</h3> <p>The available evidence is primarily of very low quality and indicates that mirtazapine adjunct is not clearly associated with an effect for negative symptoms, but there is some indication of a positive effect on overall mental state and akathisia. No effect was found for global state or leaving the study early and data were not available for quality of life or service use. Due to limitations of the quality and applicability of the evidence it is not possible to make any firm conclusions, the role of mirtazapine adjunct in routine clinical practice remains unclear. This underscores the need for new high‐quality evidence to further evaluate mirtazapine adjunct for schizophrenia. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD011943-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011943-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD011943-abs-0006">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD011943-abs-0012">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011943-abs-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011943-abs-0011">Français</a> </li> <li class="section-language"> <a class="" href="full/ms#CD011943-abs-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pt#CD011943-abs-0009">Português</a> </li> <li class="section-language"> <a class="" href="full/ru#CD011943-abs-0008">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011943-abs-0007">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD011943-abs-0005" lang="en"> <h3>Mirtazapine as an add‐on treatment for schizophrenia</h3> <p><b>Review question</b> </p> <p>Is adding mirtazapine, an antidepressant medication, to standard care an effective and safe treatment for people with schizophrenia? </p> <p><b>Background</b> </p> <p>Schizophrenia is a severe mental illness. Those affected typically exhibit abnormal social behaviour and an inability to judge what is real. There are three main types of symptoms. Positive symptoms are where patients hear voices or see things that are not there and can also have fixed false beliefs (delusions). Examples of negative symptoms are lack of motivation and withdrawal from social activities. Cognitive symptoms include a reduced ability to concentrate or difficulty in using information to make decisions. Schizophrena can be extremely debilitating, greatly affecting a person's social functioning and their ability to live independently. </p> <p>Antipsychotic medications are the main treatment for schizophrenia and are effective in treating the positive symptoms of schizophrenia but often do not fully treat the negative symptoms. Additional treatments (adjuncts) are often used alongside antipsychotics to help treat the negative symptoms. Antidepressant medications, such as mirtazapine, can be used as adjunct treatment. Mirtazapine may have the potential to improve the negative symptoms of schizophrenia, but also has the potential to cause unpleasant side effects. Evidence summarising mirtazapine's benefits and harms for people with schizophrenia is needed. </p> <p><b>Searching</b> </p> <p>The Information Specialist of Cochrane Schizophrenia searched their specialised register for clinical trials that randomly allocated people with schizophrenia to receive either mirtazapine or another treatment in addition their standard care. The latest search was in May 2018 and we found a total of 35 references to potential trials. We carefully inspected the full‐text articles of these references for inclusion or exclusion from this review. </p> <p><b>Results</b> </p> <p>Nine randomised controlled trials met the review requirements and provided useable data. The participants in the studies received either mirtazapine plus their standard care or their standard care plus a placebo. </p> <p>Results showed adding mirtazapine to standard treatment may slightly improve overall mental state but does not appear to specifically have a clinically important effect on negative symptoms. Adding mirtazapine to standard care may slightly improve the symptoms akathisia, a side effect of antipsychotics where a person is very restless and unable to keep still. No effect was found for global state or leaving the study early and data were not available for quality of life or hospital admission. In addition, some results showed mirtazapine was associated with a higher risk of weight gain and sedation. However, these results are based on evidence that is mainly very ‐ow quality. </p> <p><b>Conclusions</b> </p> <p>Mirtazapine may have some positive effects for people with schizophrenia. However, these results are mainly based on very low‐quality evidence and we are uncertain about these effects. Firm conclusions regarding the effectiveness and safety of mirtazapine as an add on treatment for people with schizophrenia can not be made without more high‐quality research. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD011943-sec-0218" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011943-sec-0218">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011943-sec-0344">Español</a> </li> </nav> </div> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD011943-sec-0218"></div> <h3 class="title" id="CD011943-sec-0219">Implications for practice</h3> <section id="CD011943-sec-0219"> <section id="CD011943-sec-0220"> <h5 class="title">1. For people with schizophrenia</h5> <p>Mirtazapine added on to antipsychotic medication may improve overall mental state and help with the adverse effect akathisia, but the data are not yet convincing. The current level of evidence is therefore insufficient to recommend the routine use of mirtazapine adjunct in people with schizophrenia. It is also noteworthy that there is a lack of any evidence for several important patient‐centred outcomes of interest, such as quality of life. </p> </section> <section id="CD011943-sec-0221"> <h5 class="title">2. For clinicians</h5> <p>All studies included in this review are short term, and several have methodological shortcomings. The overall results suggest that mirtazapine adjunct is associated with a clinically important change in overall mental state, and for those with akathisia, a clinically important improvement of akathisia. Data showed no effect for clinically important improvement in negative symptoms but a difference in endpoint scores on SANS and PANSS negative subscale, favouring mirtazapine adjunct, were reported. The full clinical meaning of these findings are unclear. There is some evidence that mirtazapine adjunct is associated with an increased risk of weight gain and sedation/drowsiness. Depending on the clinical context, mirtazapine adjunct may perhaps be offered to people with schizophrenia when negative symptoms are severe and other avenues of management have been exhausted. However, the current level of evidence is not strong enough to firmly support or reject adjunct mirtazapine's place in routine clinical practice. </p> </section> <section id="CD011943-sec-0222"> <h5 class="title">3. For hospital administrators and policymakers</h5> <p>There is no information on economic and service utilisation outcomes available on this subject that would be of potential use to hospital administrators and policymakers. Should further studies report these outcomes, we will include these data in subsequent updates of this review. </p> </section> </section> <h3 class="title" id="CD011943-sec-0223">Implications for research</h3> <section id="CD011943-sec-0223"> <section id="CD011943-sec-0224"> <h5 class="title">1. General</h5> <p>Reporting of methodology in schizophrenia trials is often poor. Future trials should describe accurately and comprehensively the exact methods used to randomise, conceal allocation, blind participants and personnel, and rate outcomes in accordance with the CONSORT statement (<a href="./references#CD011943-bbs2-0066" title="SchulzKF , AltmanDG , MoherD . CONSORT 2010 Statement: Updated guidelines for reporting parallel group randomised trials. Journal of Clinical Epidemiology2010;63(8):834‐40. [PUBMED: 20346629] ">Schulz 2010</a>). Furthermore, the statistical method used to account for missing data should be clearly detailed such that the reader could repeat the experiment. Trials should be prospectively registered and their protocols made publicly available. It is noteworthy that initiatives such as ALLTrials are now endorsed by an ever‐increasing body of key worldwide organisations including in Australia the National Health and Medical Research Council of Australia, Royal Australian and New Zealand College of Psychiatrists and Medical Journal of Australia. Hopefully, ongoing support for this initiative will encourage prospective researchers to ensure that contributions made by altruistic participants in research are not made in vain. </p> </section> <section id="CD011943-sec-0225"> <h5 class="title">2. Specific</h5> <p>This review showed evidence that mirtazapine adjunct may be effective in treating the negative symptoms of schizophrenia, but the results were not conclusive. Key limitations of the design of included studies included the absence of pragmatic and holistic outcomes such as quality of life and service utilisation as well as their universally short‐term duration. See <a href="#CD011943-tbl-0002">Table 1</a> for a suggested design of future studies. </p> <div class="table" id="CD011943-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Suggested design of future study</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Methods</b> </p> <p><b>Participants</b> </p> <p><b>Interventions</b> </p> <p><b>Outcomes</b> </p> <p><b>General</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Allocation:</b> random (with adequate description of sequence generation and allocation concealment) </p> <p><b>Blinding:</b> double (described and tested) </p> <p><b>Duration:</b> 6 months </p> <p><b>Setting:</b> multiple centres, inpatient and outpatient units </p> <p><b>Diagnosis:</b> schizophrenia (DSM‐V / ICD ‐ 10) </p> <p><b>Age:</b> adults </p> <p><b>Size:</b> N &gt; 300 </p> <p><b>Sex:</b> both </p> <p><b>Stage of illness:</b> any </p> <p><b>Antipsychotic:</b> any </p> <p><b>Exclusions:</b> current major depressive episode or antidepressant drug use </p> <p>1. mirtazapine 30 mg plus regular antipsychotic</p> <p>2. placebo plus regular antipsychotic</p> <p><b>Primary outcome:</b> quality of life </p> <p><b>Other outcomes:</b> family/caretaker satisfaction, service utilisation, employment, leaving the study early, mental state (PANSS including subscales), global impression (CGI), adverse events. </p> <p>Prospectively registered and free from industry funding.</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CGI: Clinical Global Impression</p> <p>DSM‐V: American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders ‐ 5th edition </p> <p>ICD ‐ 10: International Statistical Classification of Diseases and Related Health Problems 10th Revision </p> <p>mg: milligram</p> <p>N: number</p> <p>PANSS: Positive and Negative Syndrome Scale</p> </div> </div> </section> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD011943-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD011943-sec-0029"></div> <div class="table" id="CD011943-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Mirtazapine adjunct versus placebo adjunct</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Mirtazapine versus placebo</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> schizophrenia<br/> <b>Setting: inpatient</b> <br/> <b>Intervention:</b> mirtazapine plus standard care<br/> <b>Comparison:</b> placebo plus standard care </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with mirtazapine</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mental state: specific negative symptoms ‐ clinically important change (no important response) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.81<br/> (0.57 to 1.14) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>20<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1, 2 ,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Clinically important change was defined as a reduction of 20% or greater on SANS.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1000 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>810 per 1000<br/> (570 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mental state: overall mental state ‐ clinically important change*</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 0.69<br/> (0.51 to 0.92) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>77<br/> (2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>6, 8,9</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>* Mental state: clinically important change positive symptoms data not available.</p> <p>Improvement in overall mental state was defined by</p> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1711231310158220868921020452083%26format=REVMAN#STD-Abbasi-2010" target="_blank">Abbasi 2010</a> as improvement in PANSS total of &gt;50%. <a href="https://archie.cochrane.org/sections/documents/view?version=z1711231310158220868921020452083%26format=REVMAN#STD-Terevnikov-2013" target="_blank">Terevnikov 2013</a>: defined as improvement of PANSS total by &gt; 20%. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>816 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>563 per 1000<br/> (416 to 751 </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Leaving the study early for any reason</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.03<br/> (0.64 to 1.66) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>310<br/> (9 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>162 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>167 per 1000<br/> (104 to 269) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Global state: average endpoint score (CGI severity, high = poor)*</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean global state: average score at endpoint (CGI severity) was 4</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.10 lower<br/> (0.68 lower to 0.48 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1,3,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data for clinically important change not reported.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life: clinically important change</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported data for this important outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Service utilisation: number of days in hospital</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported data for this important outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse effects: extrapyramidal ‐ clinically important change akathisia</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.33<br/> (0.20 to 0.52) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>86<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>6,7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Both studies defined important change as reduction of BAS by at least 2</p> <p>Adverse events ‐ incidence of serious adverse events: data on variability was not available, preventing meta‐analysis of these count data. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>930 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>307 per 1000<br/> (186 to 484) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>BAS:</b> Barnes Akathisa Scale; <b>BPRS:</b> Brief Psychiatric Rating Scale; <b>CGI:</b> Clinical Global Impression; <b>CI:</b> Confidence interval; <b>HAM‐D:</b> Hamilton Depression Rating Scale; <b>MD:</b> Mean difference; <b>RR:</b> Risk ratio; <b>RCT:</b> Randomised controlled trial; <b>SANS:</b> Scale for the Assessment of Negative Symptoms. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Risk of bias: serious (downgraded by 1). This study did not describe blinding of outcome assessors, only analysed data from study completers (per protocol analysis) </p> <p><sup>2</sup> Risk of bias: serious (downgraded by 1).This study recorded depressive symptoms with HAM‐D at baseline, and used the depressive subscale of BPRS at follow‐up. </p> <p><sup>3</sup> Imprecision (downgraded by 1). Although the CI around the estimate of effect is relatively tight, the sample size was smaller than the optimal information size (one small study only N &lt; 200). </p> <p><sup>4</sup> Risk of bias: serious (downgraded by 1). Several studies have unclear risk of bias, particularly regarding random sequence generation and blinding, as well as failure to describe allocation concealment. This bias is likely to lower confidence in the estimate of the effect. </p> <p><sup>5</sup> Indirectness: serious (downgraded by 1). Not clinically meaningful binary data </p> <p><sup>6</sup> Imprecision: serious (downgraded by 1). Although the CI around the estimate of effect is relatively tight, the sample size was smaller than the optimal information size (two small studies N &lt; 200) </p> <p><sup>7</sup>Risk of bias: serious (downgraded by 1). One of the included studies did not report intention‐to‐treat data and had a high risk of bias. </p> <p><sup>8</sup> There was a moderate‐high degree of heterogeneity for this outcome I<sup>2</sup> = 75% </p> <p><sup>9</sup> The two studies had different cutoffs for clinical significance. <a href="https://archie.cochrane.org/sections/documents/view?version=z1711231310158220868921020452083%26format=REVMAN#STD-Abbasi-2010" target="_blank">Abbasi 2010</a>: defined as improvement in PANSS total of &gt;50%. <a href="https://archie.cochrane.org/sections/documents/view?version=z1711231310158220868921020452083%26format=REVMAN#STD-Terevnikov-2013" target="_blank">Terevnikov 2013</a>: defined as improvement of PANSS total by &gt; 20%. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD011943-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011943-sec-0030">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011943-sec-0241">Español</a> </li> </nav> </div> </div> <section class="background" lang="en"> <div class="section-header" id="CD011943-sec-0030"></div> <section id="CD011943-sec-0031"> <h3 class="title" id="CD011943-sec-0031">Description of the condition</h3> <p>Schizophrenia is a chronic mental illness that is characterised by positive symptoms (e.g. delusions, hallucinations, disorganised speech, and abnormal motor behaviour), negative symptoms (e.g. diminished emotional expression, avolition, alogia, and anhedonia), and cognitive symptoms (e.g. trouble focusing or paying attention or using information to make decisions). Diagnosis is made on the basis of the co‐occurrence of at least one positive symptom with one or more other symptoms for a significant portion of a one‐month period, with associated problems over a period of six months or greater (<a href="./references#CD011943-bbs2-0013" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th Edition. Washington, DC: American Psychiatric Association, 2013. ">American Psychiatric Association 2013</a>). </p> <p>While people with schizophrenia are not typically diagnosed with depression, many of the negative and cognitive symptoms of schizophrenia are very similar to those of depression as identified in the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders (DSM) (<a href="./references#CD011943-bbs2-0013" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th Edition. Washington, DC: American Psychiatric Association, 2013. ">American Psychiatric Association 2013</a>). These include loss of interest or pleasure in almost all activities, fatigue or loss of energy and trouble thinking, concentrating or making decisions. </p> <p>Over 21 million people worldwide are affected by schizophrenia (<a href="./references#CD011943-bbs2-0082" title="World Health Organization. Mental health: schizophrenia. Retrieved from http://www.who.int/mental_health/management/schizophrenia/en/2015. ">WHO 2015</a>). Estimated lifetime prevalence ranges between 1.4 and 4.6 per 1000, and the yearly incidence is between 0.16 and 0.42 per 1000, with these numbers remaining consistent for more than 25 years (<a href="./references#CD011943-bbs2-0045" title="JablenskyA , SartoriusN , ErnbergG , AnkerM , KortenA , CooperJE , et al. Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten‐country study. Psychological Medicine Monograph Supplement1992;20:1‐97. ">Jablensky 1992</a>; <a href="./references#CD011943-bbs2-0046" title="JablenskyA . Epidemiology of schizophrenia: the global burden of disease and disability. European Archives of Psychiatry and Clinical Neuroscience2002;250(6):274‐85. ">Jablensky 2000</a>; <a href="./references#CD011943-bbs2-0057" title="McGrathJ , SahaS , ChantD , WelhamJ . Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiologic Reviews2008;30:67‐76. ">McGrath 2008</a>). Schizophrenia has a multi‐factorial and complex aetiology, wherein biological and environmental stress diatheses and genetic risk factors are implicated (<a href="./references#CD011943-bbs2-0042" title="HoughCJ , UrsanoRJ . A guide to the genetics of psychiatric disease. Psychiatry2006;69(1):1‐20. ">Hough 2006</a>; <a href="./references#CD011943-bbs2-0078" title="WalkerEF , DiforioD . Schizophrenia: a neural diathesis‐stress model. Psychological Review1997;104(4):667‐85. ">Walker 1997</a>). The incidence and prevalence of schizophrenia show prominent variation between locations. Males are more likely to develop schizophrenia than females (1.4:1). Migrant status, urban birth or residence, advanced paternal age, prenatal infection, and malnutrition are also associated with an increased risk of schizophrenia (<a href="./references#CD011943-bbs2-0058" title="McGrathJJ , SusserES . New directions in the epidemiology of schizophrenia. Medical Journal of Australia2009;190(4 Suppl):S7‐9. ">McGrath 2009</a>). </p> <p>Approximately 80% to 90% of people diagnosed with schizophrenia are unable to maintain consistent gainful employment (<a href="./references#CD011943-bbs2-0055" title="MarwahaS , JohnsonS . Schizophrenia and employment ‐ a review. Social Psychiatry and Psychiatric Epidemiology2004;39(5):337‐49. ">Marwaha 2004</a>). Individuals with schizophrenia have a two‐ to three‐fold increased mortality risk compared with the general population. Additionally, it is estimated that up to 50% of individuals with schizophrenia will attempt suicide (<a href="./references#CD011943-bbs2-0059" title="MeltzerHY . Treatment of suicidality in schizophrenia. Annals of the New York Academy of Sciences2001;932(1):44‐58. ">Meltzer 2001</a>), and 5% will die by an act of suicide (<a href="./references#CD011943-bbs2-0030" title="EnglischS , ZinkM . Treatment‐resistant schizophrenia: evidence‐based strategies. Mens Sana Monographs2012;10(1):20‐32. ">Englisch 2012</a>). These figures underscore the devastating consequences schizophrenia can have for affected individuals. </p> <p>The management of schizophrenia commonly includes the use of antipsychotic drugs, which can compound the negative symptoms that are already present (<a href="./references#CD011943-bbs2-0060" title="MollerHJ . Novel antipsychotics and negative symptoms. International Clinical Psychopharmacology1998;13(Suppl 3):S43‐7. [PUBMED: 9690970] ">Moller 1998</a>). </p> </section> <section id="CD011943-sec-0032"> <h3 class="title" id="CD011943-sec-0032">Description of the intervention</h3> <p>Antipsychotic medications, such as chlorpromazine (since the 1950s), and olanzapine (since the 1990s), are the mainstay treatment for schizophrenia (<a href="./references#CD011943-bbs2-0016" title="American Psychiatric Association. Practice Guideline for the Treatment of Patients with Major Depressive Disorder 3rd edition. psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf2010. ">APA 2010</a>; <a href="./references#CD011943-bbs2-0020" title="Canadian Agency for Drugs and Technologies in Health (CADTH). Optimal use report: optimal use of atypical antipsychotics for schizophrenia. Canadian Agency for Drugs and Technologies in Health (CADTH)2012; Vol. 1, issue 1D:1‐42. [https://www.cadth.ca/media/pdf/H0503_AAP‐Current‐Practice‐Study_e.pdf] ">CADTH 2012</a>). One reason for the increased use of newer antipsychotic medications in recent years is that they were thought to assist in ameliorating the negative symptoms of schizophrenia; however, study results are mixed (<a href="./references#CD011943-bbs2-0050" title="LeoRJ , DelRegnoP . Atypical antipsychotic use in the treatment of psychosis in primary care. Primary Care Companion to the Journal of Clinical Psychiatry2000;2(6):194‐204. ">Leo 2000</a>; <a href="./references#CD011943-bbs2-0063" title="PhanSV , KreysTJ . Adjunct mirtazapine for negative symptoms of schizophrenia. Pharmacotherapy2011;31(10):1017‐30. ">Phan 2011</a>). These mixed results are evidenced in the National Institute of Mental Health (United States) issuing a consensus statement describing the treatment of these negative symptoms as an unmet therapeutic need (<a href="./references#CD011943-bbs2-0049" title="KirkpatrickB , FentonWS , CarpenterWTJr , MarderSR . The NIMH‐MATRICS consensus statement on negative symptoms. Schizophrenia Bulletin2006;32(2):214‐9. ">Kirkpatrick 2006</a>). Further evidence of the problem comes from studies indicating that negative symptoms are more closely aligned with poor functional outcomes than are positive symptoms (delusions and hallucinations), and caregivers report negative symptoms as causing significant strain (<a href="./references#CD011943-bbs2-0031" title="FervahaF , FoussiasG , AgidO , RemingtonG . Impact of primary negative symptoms on functional outcomes in schizophrenia. European Psychiatry2014;29(7):449‐55. [DOI: 10.1016/j.eurpsy.2014.01.007] ">Fervaha 2014</a>; <a href="./references#CD011943-bbs2-0049" title="KirkpatrickB , FentonWS , CarpenterWTJr , MarderSR . The NIMH‐MATRICS consensus statement on negative symptoms. Schizophrenia Bulletin2006;32(2):214‐9. ">Kirkpatrick 2006</a>; <a href="./references#CD011943-bbs2-0061" title="MurphyBP , ChungYC , ParkTW , McGorryPD . Pharmacological treatment of primary negative symptoms in schizophrenia: a systematic review. Schizophrenia Research2006;88(1‐3):5‐25. ">Murphy 2006</a>). Thus, exploring effective options for those experiencing these negative symptoms continues to be the focus of much research. </p> <p>Antidepressant medications have long been the central focus and most established treatment for depression (<a href="./references#CD011943-bbs2-0016" title="American Psychiatric Association. Practice Guideline for the Treatment of Patients with Major Depressive Disorder 3rd edition. psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf2010. ">APA 2010</a>; <a href="./references#CD011943-bbs2-0032" title="FournierJC , DeRubeisRJ , HollonSD , DimidjianS , AmsterdamJD , SheltonRC , et al. Antidepressant drug effects and depression severity: a patient‐level meta‐analysis. JAMA2010;303(1):47‐53. [DOI: 10.1001/jama.2009.1943] ">Fournier 2010</a>), and are one strategy being studied to help improve the persistent negative symptoms of schizophrenia (<a href="./references#CD011943-bbs2-0063" title="PhanSV , KreysTJ . Adjunct mirtazapine for negative symptoms of schizophrenia. Pharmacotherapy2011;31(10):1017‐30. ">Phan 2011</a>; <a href="./references#CD011943-bbs2-0077" title="VidalC , Reess , C , FischerBA , Chiapelli , J , HimelhochS . Meta‐analysis of efficacy of mirtazapine as an adjunctive treatment of negative symptoms in schizophrenia. Clinical Schizophrenia &amp; Related Psychoses2015;9(2):88‐95. ">Vidal 2015</a>). There are many types of antidepressants, with each classification affecting different neurotransmitters in particular ways. Due to its unique pharmacologic properties, mirtazapine, a second‐generation antidepressant, may be more effective than other antidepressants in decreasing negative symptoms. The usual starting dose is 15 mg once per day and it may be increased to 45 mg per day, with peak plasma concentrations occurring approximately two hours after oral administration. Seventy‐five per cent of elimination occurs through the urine and mirtazapine has a half‐life of approximately 20 to 40 hours, thus making it appropriate for once a day administration. It has a modest adverse effect profile, with some of the most common side effects being sedation, weight gain, constipation, dizziness, increased appetite, and dry mouth and these tend to decrease over time (<a href="./references#CD011943-bbs2-0038" title="HartmannPM . Mirtazapine: a newer antidepressant. American Family Physician1999;59(1):159‐61. ">Hartmann 1999</a>; <a href="./references#CD011943-bbs2-0056" title="MayoClinic . Drugs and supplements: mirtazapine (oral route). Mayo Clinic Site2015. [http://www.mayoclinic.org/drugs‐supplements/mirtazapine‐oral‐route/side‐effects/drg‐20067334] ">Mayo Clinic 2015</a>). </p> </section> <section id="CD011943-sec-0033"> <h3 class="title" id="CD011943-sec-0033">How the intervention might work</h3> <p>Though falling into the overall classification of antidepressant medications, mirtazapine is unique in its chemical make‐up. First introduced in 1996, mirtazapine is of the class of noradrenergic and selective serotoninergic antidepressants (NaSSA). Though the precise mechanism of antidepressant activity is unknown, mirtazapine exhibits antagonism of the central presynaptic alpha 2 noradrenergic receptor, resulting in enhanced serotonin and norepinephrine neurotransmission at the 5‐HT1A receptor (<a href="./references#CD011943-bbs2-0022" title="deBoerT , RuigtGS , BerendsenHH . The a2‐selective adrenoreceptor antagonist Org 3770 (mirtazapine Remeron) enhances noradrenergic and serotonergic neurotransmission. Human Psychopharmacology1995;10:S107‐18. ">de Boer 1995</a>), suspected of being responsible for the therapeutic effects of antidepressant medications. It is also functionally antagonistic toward 5‐HT2A receptors, thought to increase dopaminergic neurotransmission (<a href="./references#CD011943-bbs2-0022" title="deBoerT , RuigtGS , BerendsenHH . The a2‐selective adrenoreceptor antagonist Org 3770 (mirtazapine Remeron) enhances noradrenergic and serotonergic neurotransmission. Human Psychopharmacology1995;10:S107‐18. ">de Boer 1995</a>). While exhibiting antagonism at postsynaptic 5‐HT2A, 5‐HT2C, 5‐HT3, and histamine H1 receptors, mirtazapine blocks serotonin receptors 5‐HT2 and 5‐HT3, resulting in fewer adverse effects (such as sexual dysfunction) than other antidepressant classifications, including selective serotonin and serotonin‐norepinephrine reuptake inhibitors, while enhancing sleep and decreasing anxiety (<a href="./references#CD011943-bbs2-0023" title="deBoerT . The pharmacologic profile of mirtazapine. Journal of Clinical Psychiatry1996;57(Suppl 4):19‐25. ">de Boer 1996</a>). </p> </section> <section id="CD011943-sec-0034"> <h3 class="title" id="CD011943-sec-0034">Why it is important to do this review</h3> <p>Approximately one‐half to three‐quarters of those diagnosed with schizophrenia will have identifiable negative symptoms (<a href="./references#CD011943-bbs2-0068" title="SeltenJP , WiersmaD , van denBoschRJ . Distress attributed to negative symptoms in schizophrenia. Schizophrenia Bulletin2000;26(3):737‐44. ">Selten 2000</a>), and negative symptoms tend to persist longer than positive symptoms, as well as being more resistant to treatment. Negative symptoms are associated with a higher number of pharmacological treatments and co‐morbid conditions ‐ including obesity, dyslipidaemia and hypertension ‐ with resultant higher healthcare costs (<a href="./references#CD011943-bbs2-0070" title="Sicras‐MainarA , MaurinoJ , Ruiz‐BeatoE , Navarro‐ArtiedaR . Impact of negative symptoms on healthcare resource utilization and associated costs in adult out‐patients with schizophrenia: a population‐based study. BMC Psychiatry2014;14(1):225. [DOI: 10.1186/s12888‐014‐0225‐8] ">Sicras‐Mainar 2014</a>). Improvement in negative symptoms is frequently associated with an array of improved functional outcomes, including independent living skills, role and social functioning (<a href="./references#CD011943-bbs2-0076" title="VelliganDI , AlphsL , LancasterS , MorlockR , MintzJ . Association between changes on the Negative Symptom Assessment scale (NSA‐16) and measures of functional outcome in schizophrenia. Psychiatry Research2009;169(2):97‐100. ">Velligan 2009</a>), and successful ageing (<a href="./references#CD011943-bbs2-0044" title="IbrahimF , CohenCI , RamerizPM . Successful aging in older adults with schizophrenia: prevalence and associated factors. American Journal of Geriatric Psychiatry2010;18(10):879‐86. [DOI: 10.1097/JGP.0b013e3181d57441] ">Ibrahim 2010</a>). In addition, improvements in negative symptoms are often followed by improvements in global functioning outcomes (<a href="./references#CD011943-bbs2-0076" title="VelliganDI , AlphsL , LancasterS , MorlockR , MintzJ . Association between changes on the Negative Symptom Assessment scale (NSA‐16) and measures of functional outcome in schizophrenia. Psychiatry Research2009;169(2):97‐100. ">Velligan 2009</a>), thus addressing these negative symptoms in a meaningful, evidenced‐based manner may affect the quality of life of many people with schizophrenia. </p> <p>Mirtazapine may have the potential to alleviate harmful negative symptoms, but carries associated risks. There are the risks of adverse effects, increased burdens of cost and inconvenience to the user, and reduced adherence. Therefore, it is in the public interest that this important decision is backed by the highest quality evidence. The evidence base for this treatment dilemma has yet to be investigated in a Cochrane systematic review. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD011943-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011943-sec-0035">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011943-sec-0246">Español</a> </li> </nav> </div> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD011943-sec-0035"></div> <p>To systematically assess the effects of mirtazapine as an adjunct treatment for people with schizophrenia. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD011943-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011943-sec-0036">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011943-sec-0247">Español</a> </li> </nav> </div> </div> <section class="methods" lang="en"> <div class="section-header" id="CD011943-sec-0036"></div> <section id="CD011943-sec-0037"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD011943-sec-0038"> <h4 class="title">Types of studies</h4> <p>We considered all randomised controlled trials that met our inclusion criteria. If a trial had been described as 'double‐blind' but implied randomisation, we would have included it in a sensitivity analysis (see <a href="#CD011943-sec-0111">Sensitivity analysis</a>). We excluded all trials that were not randomised and those that did not report any useable data. Where individuals were given additional treatments within mirtazapine and placebo, we included data only if the adjunct treatment was evenly distributed between groups and only if the mirtazapine and placebo were randomised. </p> </section> <section id="CD011943-sec-0039"> <h4 class="title">Types of participants</h4> <p>We included adults, however defined, with schizophrenia or related disorders, including schizophreniform disorder, schizoaffective disorder, and delusional disorder, again, by any means of diagnosis . We only included trials where the majority (&gt; 50%) of participants had schizophrenia. </p> <p>We are interested in making sure that information was as relevant to the current care of people with schizophrenia as possible so, where information was available, we clearly highlighted the current clinical state (acute, early post‐acute, partial remission, remission) as well as the stage (prodromal, first episode, early illness, persistent) and whether the studies primarily focused on people with particular problems (for example, negative symptoms, treatment‐resistant illnesses). </p> </section> <section id="CD011943-sec-0040"> <h4 class="title">Types of interventions</h4> <section id="CD011943-sec-0041"> <h5 class="title">1. Mirtazapine (adjunct)</h5> <p>1.1 Mirtazapine: any dose or route of administration</p> </section> <section id="CD011943-sec-0042"> <h5 class="title">2. Comparator (adjunct)</h5> <p>2.1 Placebo: (active or inactive) or no treatment</p> </section> <section id="CD011943-sec-0043"> <h5 class="title">3. Standard care</h5> <p>3.1 The treatment a participant would normally receive had they not been involved in the trial </p> </section> </section> <section id="CD011943-sec-0044"> <h4 class="title">Types of outcome measures</h4> <p>We intended to categorise outcomes into either short term (less than six months), medium term (seven to 12 months), or long term (over one year). </p> <section id="CD011943-sec-0045"> <h5 class="title">Primary outcomes</h5> <section id="CD011943-sec-0046"> <h6 class="title">1. Mental state</h6> <section id="CD011943-sec-0047"> <p><b>1.1 Specific ‐ negative symptoms</b></p> <p>1.1.1 Clinically important change in negative symptoms ‐ as defined by each of the studies<br/> 1.1.2 Average endpoint/change score on negative symptoms scale </p> </section> </section> </section> <section id="CD011943-sec-0048"> <h5 class="title">Secondary outcomes</h5> <section id="CD011943-sec-0049"> <h6 class="title">1. Mental state</h6> <section id="CD011943-sec-0050"> <p><b>1.1 Specific ‐ positive symptoms</b></p> <p>1.1.1 Clinically important change in positive symptoms ‐ as defined by each of the studies<br/> 1.1.2 Average endpoint/change score positive symptoms scale </p> </section> <section id="CD011943-sec-0051"> <p><b>1.2 Overall</b></p> <p>1.2.1 Clinically important change in overall mental state ‐ as defined by each of the studies<br/> 1.2.2 Average endpoint/change score overall mental state scale </p> </section> <section id="CD011943-sec-0052"> <p><b>1.3 Specific ‐ depressive symptoms</b></p> <p>1.3.1 Clinically important change in depressive symptoms ‐ as defined by each of the studies<br/> 1.3.2 Average endpoint/change score depressive symptoms scale </p> </section> </section> <section id="CD011943-sec-0053"> <h6 class="title">2. Leaving the study early</h6> <p>2.1 for any reason<br/> 2.2 due to adverse effect </p> </section> <section id="CD011943-sec-0054"> <h6 class="title">3. Global state</h6> <p>3.1 Clinically important change in global state ‐ as defined by each of the studies<br/> 3.2 Average endpoint/change score global state scale </p> </section> <section id="CD011943-sec-0055"> <h6 class="title">4. Cognitive function</h6> <p>4.1 Clinically important change in cognitive function ‐ as defined by each of the studies<br/> 4.2 Average endpoint/change score cognitive function tests </p> </section> <section id="CD011943-sec-0056"> <h6 class="title">5. Quality of life</h6> <p>5.1 Clinically important change in quality of life for recipients of care ‐ as defined by each of the studies<br/> 5.2 Average endpoint/change score quality of life scale (recipients of care)<br/> 5.3 Clinically important change in quality of life for carers ‐ as defined by each of the studies<br/> 5.4 Average endpoint/change score quality of life scale (carers) </p> </section> <section id="CD011943-sec-0057"> <h6 class="title">6. Service utilisation</h6> <p>6.1 Days in the hospital<br/> 6.2 Requires new admission or readmission to hospital (binary) </p> </section> <section id="CD011943-sec-0058"> <h6 class="title">7. Adverse events/effects</h6> <section id="CD011943-sec-0059"> <p><b>7.1 General and specific adverse events (including death by suicide or natural causes, allergic reactions, and additional drug use)</b></p> </section> <section id="CD011943-sec-0060"> <p><b>7.2 Extrapyramidal</b></p> <p>7.2.1 Clinically important change extrapyramidal side effects ‐ as defined by each of the studies<br/> 7.2.2 Average endpoint/change score extrapyramidal side effects scale<br/> 7.2.3 Specific extrapyramidal side effects ‐ as defined by each of the studies<br/> 7.2.4 Use of medication for extrapyramidal side effects </p> </section> </section> <section id="CD011943-sec-0061"> <h6 class="title">8. Economic outcomes</h6> <p>We planned to describe/note any economic outcomes reported in included studies in <a href="#CD011943-sec-0118">Description of studies</a>. </p> </section> <section id="CD011943-sec-0062"> <h6 class="title">'Summary of findings' table</h6> <p>We used the GRADE approach to interpret findings (<a href="./references#CD011943-bbs2-0067" title="SchünemannHJ , OxmanAD , VistGE , HigginsJP , DeeksJJ , GlasziouP , et al. Chapter 12: Interpreting results and drawing conclusions. In Higgins JPT, Green S editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Schünemann 2011</a>), and we used <a href="http://community.cochrane.org/tools/review-production-tools/gradepro-gdt" target="_blank">GRADEpro GDT</a> to export data from our review to create a 'Summary of findings' table. This table provide outcome‐specific information concerning the overall quality of evidence from each included study in the comparison, the magnitude of effect of the interventions examined, and the sum of available data on all outcomes we rated as important to patient‐care and decision making. We considered the following main outcomes important for inclusion in the 'Summary of findings' table. </p> <p> <ol id="CD011943-list-0001"> <li> <p>Mental state: specific ‐ negative symptoms: clinically important change in negative symptoms ‐ as defined by each study </p> </li> <li> <p>Mental state: specific ‐ positive symptoms: clinically important change in positive symptoms ‐ as defined by each study </p> </li> <li> <p>Leaving the study early ‐ for any reason</p> </li> <li> <p>Global state ‐ clinically important change in global state ‐ as defined by each study</p> </li> <li> <p>Quality of life/satisfaction ‐ clinically important change in quality of life ‐ as defined by each study </p> </li> <li> <p>Service utilisation ‐ number of days in hospital</p> </li> <li> <p>Adverse events ‐ incidence of serious adverse events ‐ as defined by each study</p> </li> </ol> </p> <p>If data were not available for these outcomes but were available for ones that were similar, we presented the closest outcome to the one in the list above, but took this into account when grading the finding (see <a href="#CD011943-sec-0233">Differences between protocol and review</a>). </p> </section> </section> </section> </section> <section id="CD011943-sec-0063"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD011943-sec-0064"> <h4 class="title">Electronic searches</h4> <section id="CD011943-sec-0065"> <h5 class="title">Cochrane Schizophrenia Group's Study‐Based Register of Trials</h5> <p>On 3 November 2015, 4 February 2016 and 3 May 2018, the Information Specialist searched the Register using the following search strategy: </p> <p>(*Mirtazapine* AND *Placebo*) in Intervention of STUDY.</p> <p>In such study‐based register, searching the major concept retrieves all the synonyms and relevant studies because all the studies have already been organised based on their interventions and linked to the relevant topics (<a href="./references#CD011943-bbs2-0069" title="ShokranehF , AdamsCE . Study‐based registers of randomized controlled trials: Starting a systematic review with data extraction or meta‐analysis. BioImpacts2017;7(4):209‐17. [DOI: 10.15171/bi.2017.25] ">Shokraneh 2017</a>). </p> <p>This register is compiled by systematic searches of major resources (AMED, BIOSIS, CENTRAL, CINAHL, ClinicalTrials.Gov, Embase, MEDLINE, PsycINFO, PubMed, WHO ICTRP) and their monthly updates, ProQuest Dissertations and Theses A&amp;I and its quarterly update, Chinese databases (CBM, CNKI, and Wanfang) and their annual updates, handsearches, grey literature, and conference proceedings (see <a href="http://schizophrenia.cochrane.org/register-trials" target="_blank">Group's website</a>). There is no language, date, document type, or publication status limitations for inclusion of records into the register. </p> </section> </section> <section id="CD011943-sec-0066"> <h4 class="title">Searching other resources</h4> <section id="CD011943-sec-0067"> <h5 class="title">1. Reference searching</h5> <p>We inspected the references of all included studies for further relevant studies.</p> </section> <section id="CD011943-sec-0068"> <h5 class="title">2. Personal contact</h5> <p>We contacted the first author of each included study for information regarding unpublished trials. We noted the outcome of this contact in the included or awaiting assessment studies tables. </p> </section> </section> </section> <section id="CD011943-sec-0069"> <h3 class="title" id="CD011943-sec-0069">Data collection and analysis</h3> <section id="CD011943-sec-0070"> <h4 class="title">Selection of studies</h4> <p>Review authors SMS and DMR independently inspected citations from the searches and identified relevant abstracts. LAP independently re‐inspected a random 20% sample to ensure reliability. Where disputes arose, we acquired the full‐text report for more detailed scrutiny. Review author SMS obtained full‐text reports of the abstracts meeting the review criteria. LAP independently inspected a random 20% of these full reports in order to ensure reliable selection. If it had not been possible to resolve disagreement by discussion, we planned to contact the authors of the study for clarification. </p> </section> <section id="CD011943-sec-0071"> <h4 class="title">Data extraction and management</h4> <section id="CD011943-sec-0072"> <h5 class="title">1. Extraction</h5> <p>Review authors SMS and DMR extracted data from all included studies. In addition, to ensure reliability, LAP independently extracted data from a random sample of these studies, comprising more than 10% of the total. Again, we discussed any disagreements and documented decisions. LAP helped clarify issues and we documented those final decisions. We extracted data presented only in graphs and figures whenever possible, but included the data only if two review authors independently had the same result. If studies had been multicentre, where possible, we planned to extract data relevant to each component centre separately. </p> </section> <section id="CD011943-sec-0073"> <h5 class="title">2. Management</h5> <section id="CD011943-sec-0074"> <h6 class="title">2.1 Forms</h6> <p>We extracted data onto standard, pre‐designed, simple forms.</p> </section> <section id="CD011943-sec-0075"> <h6 class="title">2.2 Scale‐derived data</h6> <p>We included continuous data from rating scales only if:</p> <p>a) the psychometric properties of the measuring instrument had been described in a peer‐reviewed journal (<a href="./references#CD011943-bbs2-0054" title="MarshallM , LockwoodA , BradleyC , AdamsC , JoyC , FentonM . Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry2000;176:249‐52. ">Marshall 2000</a>);<br/> b) the measuring instrument has not been written or modified by one of the trialists for that particular trial;<br/> c) the instrument should be a global assessment of an area of functioning and not sub‐scores which are not, in themselves, validated or shown to be reliable. However there are exceptions, we included sub‐scores from mental state scales measuring positive and negative symptoms of schizophrenia. </p> <p>Ideally, the measuring instrument should either be i. a self‐report or ii. completed by an independent rater or relative (not the therapist). We realise that this is not often reported clearly, we noted in <a href="#CD011943-sec-0118">Description of studies</a> if this was the case or not. </p> </section> <section id="CD011943-sec-0076"> <h6 class="title">2.3 Endpoint versus change data</h6> <p>There are advantages of both endpoint and change data. Change data can remove a component of between‐person variability from the analysis. On the other hand, calculation of change needs two assessments (baseline and endpoint), which can be difficult in unstable and difficult to measure conditions such as schizophrenia. We decided primarily to use endpoint data, and only use change data if the former were not available. We combined endpoint and change data in the analysis as we preferred to use mean differences (MD) rather than standardised mean differences (SMD) throughout (<a href="./references#CD011943-bbs2-0025" title="DeeksJJ , HigginsJP , AltmanDG . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JP, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Deeks 2011</a>). </p> </section> <section id="CD011943-sec-0077"> <h6 class="title">2.4 Skewed data</h6> <p>Continuous data on clinical and social outcomes are often not normally distributed. To avoid the pitfall of applying parametric tests to non‐parametric data, we applied the following standards to relevant data before inclusion. </p> <p>Please note, we planned to enter data from studies of at least 200 participants in the analysis, because skewed data pose less of a problem in large studies. We also planned to enter all relevant change data as when continuous data are presented on a scale that includes a possibility of negative values (such as change data), it is difficult to tell whether data are skewed or not. </p> <p>For endpoint data from studies &lt; 200 participants:</p> <p>(a) when a scale starts from the finite number zero, we subtracted the lowest possible value from the mean, and divided this by the standard deviation. If this value was lower than 1, it strongly suggests a skew and we excluded these data. If this ratio was higher than one but below 2, there is suggestion of skew. We entered these data and tested whether its inclusion or exclusion change the results substantially. Finally, if the ratio was larger than 2 we included these data, because skew is less likely (<a href="./references#CD011943-bbs2-0012" title="AltmanDG , BlandJM . Detecting skewness from summary information. BMJ1996;313(7066):1200. ">Altman 1996</a>; <a href="./references#CD011943-bbs2-0040" title="HigginsJP , GreenS . Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011a</a>). </p> <p>(b) if a scale starts from a positive value (such as the Positive and Negative Syndrome Scale (PANSS), (<a href="./references#CD011943-bbs2-0048" title="KaySR , OplerLA , FiszbeinA . Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi‐Health Systems, 1986. ">Kay 1986</a>)) which can have values from 30 to 210), we modified the calculation described above to take the scale starting point into account. In these cases skew is present if 2 SD &gt; (S‐S min), where S is the mean score and 'S min' is the minimum score. </p> </section> <section id="CD011943-sec-0078"> <h6 class="title">2.5 Common measure</h6> <p>To facilitate comparison between trials, we converted variables that can be reported in different metrics, such as days in hospital (mean days per year, per week or per month) to a common metric (e.g. mean days per month). </p> </section> <section id="CD011943-sec-0079"> <h6 class="title">2.6 Conversion of continuous to binary</h6> <p>Where possible, we made efforts to convert outcome measures to dichotomous data. This was done by identifying cut‐off points on rating scales and dividing participants accordingly into 'clinically improved' or 'not clinically improved'. It is generally assumed that if there is a 50% reduction in a scale‐derived score such as the Brief Psychiatric Rating Scale (BPRS, <a href="./references#CD011943-bbs2-0062" title="OverallJE , GorhamDR . The brief psychiatric rating scale. Psychological Reports1962;10:799‐812. ">Overall 1962</a>) or the Positive and Negative Syndrome Scale (PANSS, <a href="./references#CD011943-bbs2-0048" title="KaySR , OplerLA , FiszbeinA . Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi‐Health Systems, 1986. ">Kay 1986</a>), this could be considered as a clinically significant response (<a href="./references#CD011943-bbs2-0052" title="LeuchtS , KaneJM , KisslingW , HamannJ , EtschelE , EngelR . Clinical implications of brief psychiatric rating scale scores. British Journal of Psychiatry2005;187:366‐71. [PUBMED: 16199797] ">Leucht 2005</a>). When data based on these thresholds were not available, we used the primary cut‐off presented by the original authors. </p> </section> <section id="CD011943-sec-0080"> <h6 class="title">2.7 Direction of graphs</h6> <p>Where possible, we entered data in such a way that the area to the left of the line of no effect indicates a favourable outcome for mirtazapine adjunct. Where keeping to this made it impossible to avoid outcome titles with clumsy double‐negatives (e.g. 'Not un‐improved') we reported data where the left of the line indicates an unfavourable outcome. We noted this in the relevant graphs. </p> </section> </section> </section> <section id="CD011943-sec-0081"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Review authors SMS, LAP, and DMR independently assessed risk of bias within the included studies by using criteria described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> to assess trial quality (<a href="./references#CD011943-bbs2-0041" title="HigginsJP , AltmanDG , SterneJA . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011b</a>). This set of criteria is based on evidence of associations between overestimate of effect and high risk of bias of the article such as sequence generation, allocation concealment, blinding, incomplete outcome data and selective reporting. </p> <p>If the raters disagreed, we made the final rating by consensus with all review authors. Where inadequate details of randomisation and other characteristics of trials were provided, we contacted authors of the studies in order to obtain further information. If non‐concurrence occurred, we reported this. </p> <p>We noted the level of risk of bias in the text of the review and in <a href="#CD011943-fig-0001">Figure 1</a> , <a href="#CD011943-fig-0002">Figure 2</a> and <a href="./full#CD011943-tbl-0001">summary of findings Table for the main comparison</a>. </p> <div class="figure" id="CD011943-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011943-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011943.pub2/media/CDSR/CD011943/image_n/nCD011943-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <div class="figure" id="CD011943-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD011943-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011943.pub2/media/CDSR/CD011943/image_n/nCD011943-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> </section> <section id="CD011943-sec-0082"> <h4 class="title">Measures of treatment effect</h4> <section id="CD011943-sec-0083"> <h5 class="title">1. Binary data</h5> <p>For binary outcomes, we calculated a standard estimation of the risk ratio (RR) and its 95% confidence interval (CI). It has been shown that RR is more intuitive than odds ratios (ORs) (<a href="./references#CD011943-bbs2-0019" title="BoisselJP , CucheratM , LiW , ChatellierG , GueyffierF , BuyseM , et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use [Apercu sur la problematique des indices d'efficacite therapeutique, 3: Comparaison des indices et utilisation. Groupe d'Etude des Indices D'efficacite]. Therapie1999;54(4):405‐11. [PUBMED: 10667106] ">Boissel 1999</a>), and that ORs tend to be interpreted as RR by clinicians (<a href="./references#CD011943-bbs2-0024" title="DeeksJ . Issues in the selection for meta‐analyses of binary data. Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25‐28; Cape Town. Cape Town: The Cochrane Collaboration, 2000. ">Deeks 2000</a>). The number needed to treat for an additional beneficial outcome/ number needed to treat for an additional harmful outcome (NNTB/H) statistic with its confidence intervals is intuitively attractive to clinicians but is problematic both in its accurate calculation in meta‐analyses and interpretation (<a href="./references#CD011943-bbs2-0043" title="HuttonJL . Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials. British Journal of Haematology2009;146(1):27‐30. ">Hutton 2009</a>). For binary data presented in the 'Summary of findings' table, where possible, we calculated illustrative comparative risks. </p> </section> <section id="CD011943-sec-0084"> <h5 class="title">2. Continuous data</h5> <p>For continuous outcomes, we estimated the mean difference (MD) between groups. We preferred not to calculate effect size measures (standardised mean difference (SMD). However, if scales of very considerable similarity were used, we presumed there was a small difference in measurement, and we calculated the effect size and transformed the effect back to the units of one or more of the specific instruments. </p> </section> </section> <section id="CD011943-sec-0085"> <h4 class="title">Unit of analysis issues</h4> <section id="CD011943-sec-0086"> <h5 class="title">1. Cluster trials</h5> <p>Studies increasingly employ 'cluster randomisation' (such as randomisation by clinician or practice), but analysis and pooling of clustered data poses problems. Firstly, authors often fail to account for intra‐class correlation in clustered studies, leading to a 'unit of analysis' error (<a href="./references#CD011943-bbs2-0026" title="DivineGW , BrownJT , FrazierLM . The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine1992;7(6):623‐9. ">Divine 1992</a>), whereby P values are spuriously low, confidence intervals unduly narrow and statistical significance overestimated. This causes type I errors (<a href="./references#CD011943-bbs2-0018" title="BlandJM . Statistics notes. Trials randomised in clusters. BMJ1997;315:600. ">Bland 1997</a>; <a href="./references#CD011943-bbs2-0035" title="GullifordMC . Components of variance and intraclass correlations for the design of community‐based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology1999;149(9):876‐83. ">Gulliford 1999</a>). </p> <p>If cluster‐randomised trials had been included and clustering had not been accounted for in primary studies, we planned to present the data in a table, with a (*) symbol to indicate the presence of a probable unit of analysis error. If clustering had been incorporated into the analysis of primary studies, we planned to present these data as if from a non‐cluster randomised study, adjusting the data for the clustering effect. In subsequent versions of this review we will seek to contact first authors of studies to obtain intraclass correlation coefficients (ICCs) of their clustered data and to adjust for this using accepted methods (<a href="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007967.pub2/full#CD007967-bbs2-0068" target="_blank">Gulliford 1999</a>). </p> <p>We have sought statistical advice and have been advised that the binary data as presented in a report should be divided by a 'design effect'. This is calculated using the mean number of participants per cluster (m) and the ICC (design effect = 1+(m‐1)*ICC) (<a href="./references#CD011943-bbs2-0027" title="DonnerA , KlarN . Issues in the meta‐analysis of cluster randomized trials. Statistics in Medicine2002;21:2971‐80. ">Donner 2002</a>). If the ICC was not reported we planned to assume it to be 0.1 (<a href="./references#CD011943-bbs2-0074" title="UkoumunneOC , GuillifordMC , ChinnS , SternJA , BurneyPG . Methods for evaluating area‐wide and organisation‐based intervention in health and health care: a systematic review. Health Technology Assessment1999;3(5):1‐75. ">Ukoumunne 1999</a>). </p> <p>If cluster studies had been appropriately analysed taking into account ICCs and relevant data documented in the report, synthesis with other studies would have been possible using the generic inverse variance technique. </p> </section> <section id="CD011943-sec-0087"> <h5 class="title">2. Cross‐over trials</h5> <p>A major concern of cross‐over trials is the carry‐over effect. It occurs if an effect (e.g. pharmacological, physiological, or psychological) of the treatment in the first phase is carried over to the second phase. As a consequence, on entry to the second phase the participants can differ systematically from their initial state despite a wash‐out phase. For the same reason cross‐over trials are not appropriate if the condition of interest is unstable (<a href="./references#CD011943-bbs2-0029" title="ElbourneD , AltmanDG , HigginsJP , CurtinF , WorthingtonHV , VailA . Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology2002;31(1):140‐9. ">Elbourne 2002</a>). As both effects are very likely in severe mental illness, if we had included cross‐over studies, we would only have used data from the first phase of cross‐over studies. </p> </section> <section id="CD011943-sec-0088"> <h5 class="title">3. Studies with multiple treatment groups</h5> <p> If included and relevant, where a study involved more than two treatment arms, we would have presented the additional treatment arms in comparisons. If data were binary, we would have simply added and combined them within the two‐by‐two table. If data were continuous, we planned to combine data following the formula in Chapter 7 of the <i>Cochrane Handbook for Systematic Reviews of Interventions (</i><a href="./references#CD011943-bbs2-0040" title="HigginsJP , GreenS . Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011a</a>)<i>.</i> We would not have used data where the additional treatment arms were not relevant. We would not have double counted the data. </p> </section> </section> <section id="CD011943-sec-0089"> <h4 class="title">Dealing with missing data</h4> <section id="CD011943-sec-0090"> <h5 class="title">1. Overall loss of credibility</h5> <p>At some degree of loss of follow‐up, data must lose credibility (<a href="./references#CD011943-bbs2-0083" title="XiaJ , AdamsCE , BhagatN , BhagatV , BhoopathiP , El‐SayehH , et al. Loss to outcomes stakeholder survey: the LOSS study. Psychiatric Bulletin2009;33(7):254‐7. ">Xia 2009</a>). We planned that for any particular outcome, if more than 50% of data were unaccounted for, we would not reproduce these data or use them within analyses. We also planned that If more than 50% of those in one arm of a study were lost, but the total loss was less than 50%, we would address this within the 'Summary of findings' table by downgrading quality. Finally, we planned to downgrade quality within the 'Summary of findings' table when the loss was 25% to 50% in total.) </p> </section> <section id="CD011943-sec-0091"> <h5 class="title">2. Binary</h5> <p>In the case where attrition for a binary outcome was between 0% and 50% and where these data were not clearly described, we presented data on a 'once‐randomised‐always‐analyse' basis (assuming an intention‐to‐treat (ITT) analysis). Those leaving the study early were all assumed to have the same rates of negative outcome as those who completed, with the exception of the outcome of death and adverse effects. For these outcomes, we used the rate of those who stayed in the study ‐ in that particular arm of the trial ‐ for those who did not stay in the study. We undertook a sensitivity analysis to test how prone the primary outcomes were to change when data only from people who completed the study to that point were compared to the ITT analysis using the above assumptions. </p> </section> <section id="CD011943-sec-0092"> <h5 class="title">3. Continuous</h5> <section id="CD011943-sec-0093"> <h6 class="title">3.1 Attrition</h6> <p>In the case where attrition for a continuous outcome was between 0% and 50%, and data only from people who completed the study to that point were reported, we reproduced these. </p> </section> <section id="CD011943-sec-0094"> <h6 class="title">3.2 Standard deviations</h6> <p>If standard deviations(SDs) were not reported, we first tried to obtain the missing values from the authors. If not available, where there were missing measures of variance for continuous data, but an exact standard error (SE) and confidence intervals available for group means, and either a P value or t value available for differences in mean, we calculated them according to the rules described in the <i>Cochrane Handbook for Systematic reviews of Interventions</i> (<a href="./references#CD011943-bbs2-0040" title="HigginsJP , GreenS . Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011a</a>). When only the SE is reported, SDs are calculated by the formula SD = SE * square root (n). The <i>Cochrane Handbook for Systematic reviews of Interventions</i> (<a href="./references#CD011943-bbs2-0040" title="HigginsJP , GreenS . Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011a</a>), present detailed formulae for estimating SDs from P values, t or F values, confidence intervals, ranges or other statistics. If these formulae did not apply, we calculated the SDs according to a validated imputation method which is based on the SDs of the other included studies (<a href="./references#CD011943-bbs2-0033" title="FurukawaTA , BarbuiC , CiprianiA , BrambillaP , WatanabeN . Imputing missing standard deviations in meta‐analyses can provide accurate results. Journal of Clinical Epidemiology2006;59(7):7‐10. ">Furukawa 2006</a>). Although some of these imputation strategies can introduce error, the alternative would be to exclude a given study’s outcome and thus to lose information. We nevertheless examined the validity of the imputations in a sensitivity analysis excluding imputed values. </p> </section> <section id="CD011943-sec-0095"> <h6 class="title">3.3 Assumptions about participants who left the trials early or were lost to follow‐up</h6> <p>Various methods are available to account for participants who left the trials early or were lost to follow‐up. Some trials just present the results of study completers, others use the method of last observation carried forward (LOCF), while more recently methods such as multiple imputation or mixed‐effects models for repeated measurements (MMRM) have become more of a standard. While the latter methods seem to be somewhat better than LOCF (<a href="./references#CD011943-bbs2-0051" title="LeonAC , MallinckrodtCH , Chuang‐SteinC , ArchibaldDG , ArcherGE , ChartierK . Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology. Biological Psychiatry2006;59(11):1001‐5. [PUBMED: 16905632] ">Leon 2006</a>), we feel that the high percentage of participants leaving the studies early and differences in the reasons for leaving the studies early between groups is often the core problem in randomised schizophrenia trials. We therefore did not exclude studies based on the statistical approach used. However, we used the more sophisticated approaches. For example, we preferred MMRM or multiple‐imputation to LOCF and we only presented completer analyses if some kind of ITT data were not available. Moreover, we addressed this issue in the 'Incomplete outcome data' domain of the 'Risk of bias' tool. </p> </section> </section> </section> <section id="CD011943-sec-0096"> <h4 class="title">Assessment of heterogeneity</h4> <section id="CD011943-sec-0097"> <h5 class="title">1. Clinical heterogeneity</h5> <p>We considered all included studies initially, without seeing comparison data, to judge clinical heterogeneity. We inspected all studies for clearly outlying people or situations that we had not predicted would arise. We planned that where clear unforeseen issues were noted that could add obvious clinical heterogeneity, we would note these unforeseen issues and consider them in analyses, undertaking sensitivity analyses for our primary outcome. </p> </section> <section id="CD011943-sec-0098"> <h5 class="title">2. Methodological heterogeneity</h5> <p>We considered all included studies initially, without seeing comparison data, to judge methodological heterogeneity. We inspected all studies for clearly outlying methods that we had not predicted would arise. </p> </section> <section id="CD011943-sec-0099"> <h5 class="title">3. Statistical heterogeneity</h5> <section id="CD011943-sec-0100"> <h6 class="title">3.1 Visual inspection</h6> <p>We visually inspected graphs to investigate the possibility of statistical heterogeneity.</p> </section> <section id="CD011943-sec-0101"> <h6 class="title">3.2 Employing the I<sup>2</sup> statistic </h6> <p>We investigated heterogeneity between studies by considering the I<sup>2</sup> method alongside the Chi<sup>2</sup> P value. The I<sup>2</sup> provides an estimate of the percentage of inconsistency thought to be due to chance (<a href="./references#CD011943-bbs2-0039" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327(7414):557‐60. ">Higgins 2003</a>). The importance of the observed value of I<sup>2</sup> depends on i. magnitude and direction of effects and ii. strength of evidence for heterogeneity (e.g. P value from the Chi<sup>2</sup> test, or a confidence interval for I<sup>2</sup>). An I<sup>2</sup> estimate greater than or equal to around 50% accompanied by a statistically significant Chi<sup>2</sup> statistic, can be interpreted as evidence of substantial levels of heterogeneity (Chapter 9. <i>Cochrane Handbook for Systematic Reviews of Interventions</i><a href="./references#CD011943-bbs2-0025" title="DeeksJJ , HigginsJP , AltmanDG . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JP, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Deeks 2011</a>). We explored and discussed in the text potential reasons for substantial levels of heterogeneity (<a href="#CD011943-sec-0106">Subgroup analysis and investigation of heterogeneity</a>). </p> </section> </section> </section> <section id="CD011943-sec-0102"> <h4 class="title">Assessment of reporting biases</h4> <p>Reporting biases arise when the dissemination of research findings is influenced by the nature and direction of results (<a href="./references#CD011943-bbs2-0028" title="EggerM , Davey SmithG , SchneiderM , MinderC . Bias in meta‐analysis detected by a simple, graphical test. BMJ1997;315:629‐34. ">Egger 1997</a>. These are described in the <i>Cochrane Handbook for</i> Systematic<i>Reviews of Interventions</i> (<a href="./references#CD011943-bbs2-0072" title="SterneJA , EggerM , MoherD . Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Intervention. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Sterne 2011</a>). </p> <section id="CD011943-sec-0103"> <h5 class="title">1. Protocol versus full study</h5> <p>We tried to locate protocols of included randomised trials. If the protocol was available, we compared outcomes in the protocol and in the published report . If the protocol was not available, we compared outcomes listed in the methods section of the trial report with actually reported results. </p> </section> <section id="CD011943-sec-0104"> <h5 class="title">2. Funnel plot</h5> <p>We are aware that funnel plots may be useful in investigating reporting biases but are of limited power to detect small‐study effects. We did not intend to use funnel plots for outcomes where there were 10 or fewer studies, or where all studies were of similar size. In future versions, if funnel plots are possible, we will seek statistical advice in their interpretation. </p> </section> </section> <section id="CD011943-sec-0105"> <h4 class="title">Data synthesis</h4> <p>We understand that there is no closed argument for preference for use of fixed‐effect or random‐effects models. The random‐effects method incorporates an assumption that the different studies are estimating different, yet related, intervention effects. This often seems to be true to us and the random‐effects model takes into account differences between studies even if there is no statistically significant heterogeneity. There is, however, a disadvantage to the random‐effects model. It puts added weight onto small studies, which are often the most biased ones. Depending on the direction of effect, these studies can either inflate or deflate the effect size. We chose a fixed‐effect model for analyses. </p> </section> <section id="CD011943-sec-0106"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <section id="CD011943-sec-0107"> <h5 class="title">1. Subgroup analyses</h5> <section id="CD011943-sec-0108"> <h6 class="title">1.1 Primary outcomes</h6> <p>We did not anticipate any subgroup analyses.</p> </section> <section id="CD011943-sec-0109"> <h6 class="title">1.2 Clinical state, stage or problem</h6> <p>We undertook this review to provide an overview of the effects of mirtazapine adjunct for individuals with schizophrenia in general. We planned to attempt to report data on subgroups of individuals in the same clinical state, stage, and with similar problems, but this was not possible. </p> </section> </section> <section id="CD011943-sec-0110"> <h5 class="title">2. Investigation of heterogeneity</h5> <p>If data appeared clearly heterogeneous, we investigated if it had been entered correctly. If data were correct, we inspected the graph visually and we removed studies outside of the company of the rest to see if homogeneity was restored. For this review we planned that should this occur with data contributing to the summary finding of no more than around 10% of the total weighting, we would present these data. If not, we would not pool these data and we would discuss the issues. We know of no supporting research for this 10% cut‐off but are investigating use of prediction intervals as an alternative to this unsatisfactory state. </p> <p>We planned that when unanticipated clinical or methodological heterogeneity were obvious we would simply state hypotheses regarding these for future reviews or versions of this review. We did not anticipate undertaking analyses relating to these. </p> </section> </section> <section id="CD011943-sec-0111"> <h4 class="title">Sensitivity analysis</h4> <section id="CD011943-sec-0112"> <h5 class="title">1. Implication of randomisation</h5> <p>We would have included trials in a sensitivity analysis if they were described in some way as to imply randomisation. For the primary outcomes, if there was no substantive difference when the implied randomised studies were added to those with better description of randomisation, then we would have used relevant data from these studies. </p> </section> <section id="CD011943-sec-0113"> <h5 class="title">2. Assumptions for lost binary data</h5> <p>If assumptions had to be made regarding missing SD data (see <a href="#CD011943-sec-0089">Dealing with missing data</a>), we would have compared the findings of the primary outcomes when we used our assumption/s and when we used data only from people who completed the study to that point. We would have undertaken a sensitivity analysis to test how prone the results were to change when completer‐only data were compared to the imputed data using the above assumption. We planned that if there was a substantial difference we would report the results and discuss them, but would continue to employ our assumption. </p> </section> <section id="CD011943-sec-0114"> <h5 class="title">3. Risk of bias</h5> <p>We analysed the effects of excluding trials that we judged to be at high risk of bias across one or more of the domains of randomisation (see <a href="#CD011943-sec-0081">Assessment of risk of bias in included studies</a>) for the meta‐analysis of the primary outcome. If the exclusion of trials at high risk of bias did not substantially alter the direction of effect or the precision of the effect estimates, we included data from these trials in the analysis </p> </section> <section id="CD011943-sec-0115"> <h5 class="title">4. Imputed values</h5> <p>We also planned to undertake a sensitivity analysis to assess the effects of including data from trials where we used imputed values for ICC in calculating the design effect in cluster‐randomised trials. </p> <p>If substantial differences had been noted in the direction or precision of effect estimates in any of the sensitivity analyses listed above, we would not pool data from the excluded trials with the other trials contributing to the outcome, but would have present them separately. </p> </section> <section id="CD011943-sec-0116"> <h5 class="title">5. Fixed‐effect and random‐effects</h5> <p>We synthesised all data using a fixed‐effect model and we synthesised data for the primary outcome using a random‐effects model to evaluate whether this altered the significance of the results. Any differences were noted. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD011943-sec-0117" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD011943-sec-0117"></div> <section id="CD011943-sec-0118"> <h3 class="title">Description of studies</h3> <p>We included nine studies involving a total of 310 participants studies which are described below in <a href="#CD011943-sec-0120">Included studies</a>. For more detailed descriptions of each individual study, please refer to <a href="./references#CD011943-sec-0239" title="">Characteristics of included studies</a>. </p> <section id="CD011943-sec-0119"> <h4 class="title">Results of the search</h4> <p>Details of the search results are also illustrated in the study flow diagram (<a href="#CD011943-fig-0003">Figure 3</a>). </p> <div class="figure" id="CD011943-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD011943-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011943.pub2/media/CDSR/CD011943/image_n/nCD011943-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> <p>In the original 2015 search, we found 30 reports that were potentially relevant. These reports related to nine studies. An additional search in 2016 found four more records. Three of these related to one potential new study and one related to a study already awaiting assessment. In total we assessed 10 studies for inclusion or exclusion. We did not exclude any of these studies, one study is awaiting assessment and nine studies are included in the analyses. A further search in 2018 did not find any new studies but did find a record relating to the study awaiting assessment. </p> </section> <section id="CD011943-sec-0120"> <h4 class="title">Included studies</h4> <section id="CD011943-sec-0121"> <h5 class="title">1. Length of trials</h5> <p>All nine included studies provided short‐term outcome data only. Four studies were of eight‐week duration (<a href="./references#CD011943-bbs2-0001" title="AbbasiSH , BehpourniaH , GhoreshiA , SalehiB , RaznahanM , RezazadehSA , et al. The effect of mirtazapine add on therapy to risperidone in the treatment of schizophrenia: A double‐blind randomized placebo‐controlled trial. Schizophrenia Research2010;116(2‐3):101‐6. [MEDLINE: 19959338] ">Abbasi 2010</a>; <a href="./references#CD011943-bbs2-0004" title="BertolinoA . Placebo controlled randomized trial of augmentation of olanzapine treatment with mirtazapine in 30 patients with schizophrenia to ascertain possible effects on negative symptoms and working memory. Stanley Foundation Research Programs2002. CaforioG , DiGiorgioA , RampinoA , RizzoM , RomanoR , TaurisanoP , et al. Mirtazapine add‐on improves olanzapine effect on negative symptoms of schizophrenia. Journal of Clinical Psychopharmacology2013;33(6):810‐2. ">Caforio 2013</a>; <a href="./references#CD011943-bbs2-0005" title="ChoSJ , YookK , KimB , ChoiTK , LeeKS , KimYW , et al. Mirtazapine augmentation enhances cognitive and reduces negative symptoms in schizophrenia patients treated with risperidone: A randomized controlled trial. Progress in Neuro‐Psychopharmacology &amp; Biological Psychiatry2011;35(1):208‐11. LeeJ , SungJC , KangSL , YookK , AhYC , LeeS , et al. The tolerability of mirtazapine augmentation in schizophrenic patients treated with risperidone: A preliminary randomized placebo‐controlled trial. Clinical Psychopharmacology and Neuroscience2011;9(2):73‐7. LeeSH . Mirtazapine augmentation enhances cognitive and negative symptoms in schizophrenic patients treated with risperidone: a randomised controlled trial. www.controlled‐trials.com2009. ">Cho 2011</a>; <a href="./references#CD011943-bbs2-0009" title="ZoccaliR , MuscatelloMR , CedroC , NeriP , LaTorreD , SpinaE , et al. The effect of mirtazapine augmentation of clozapine in the treatment of negative symptoms of schizophrenia: a double‐blind, placebo‐controlled study. International Clinical Psychopharmacology2004;19(2):71‐6. [MEDLINE: 15076014] ZoccaliR , MuscatelloMR , TorreDL , MalaraG , CanaleA , CrucittiDDC , et al. Lack of a pharmacokinetic interaction between mirtazapine and the newer antipsychotics clozapine, risperidone and olanzapine in patients with chronic schizophrenia. Pharmacological Research2003;48(4):411‐4. ">Zoccali 2004</a>). Three studies were of six‐week duration (<a href="./references#CD011943-bbs2-0002" title="BerkM , IchimC , BrookS . Efficacy of mirtazapine add on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia: a double‐blind randomized placebo‐controlled study. Clinical Psychopharmacology2001;16(2):87‐92. [MEDLINE: 11236073] BerkM , IchimC , BrookS . Mirtazepine treatment of negative schizophrenia. Proceedings of the 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13‐18; Chicago, Illinois, USA. 2000. BerkM , IchimC , BrookS . Mirtazepine treatment of negative schizophrenia. Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. IchimC , BerkM , BrookS . Mirtazapine treatment of negative symptoms of schizophrenia: a double blind placebo controlled add on trial to treatment with haloperidol. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S112. ">Berk 2001</a>; <a href="./references#CD011943-bbs2-0003" title="BerkM , GamaCS , SundramS , HustigH , KoopowitzL , D'SouzaR , et al. Mirtazapine add‐on therapy in the treatment of schizophrenia with atypical antipsychotics: a double‐blind, randomised, placebo‐controlled clinical trial. Human Psychopharmacology2009;24(3):233‐8. [MEDLINE: 19330802] DoddS . Mirtazapine add‐on therapy in the treatment of schizophrenia with atypical neuroleptics: a double‐blind, randomised, placebo controlled trial. Australian New Zealand Clinical Trials Registry2004. DoddS , BerkM , D’SouzaR , HustigH , KoopowitzL , MonkhouseA , et al. Mirtazapine add‐on therapy in the treatment of schizophrenia with atypical antipsychotics: a double‐blind, randomised, placebo‐controlled clinical trial. International Journal of Neuropsychopharmacology2008;11(Suppl 1):139‐40. ">Berk 2009</a>; <a href="./references#CD011943-bbs2-0008" title="JoffeG . Efficacy of add‐on mirtazapine on clinical and neuropsychologic parameters in schizophrenic patients treated with conventional antipsychotics: a double‐blind, placebo‐controlled trial with an open‐label extension phase. isrctn.com/ISRCTN00721331. JoffeG . Mirtazapine for schizophrenia. Stanley Foundation Research Programs2009. JoffeG , TerevnikovV , JoffeM , StenbergJ‐H , BurkinM , TiihonenJ . Add‐on mirtazapine enhances antipsychotic effect of first generation antipsychotics in schizophrenia: a double‐blind, randomized, placebo‐controlled trial. Schizophrenia Research2009;108(1‐3):245‐51. [MEDLINE: 19144501] StenbergJ‐H , TerevnikovV , JoffeM , TiihonenJ , ChukhinE , BurkinM , et al. Predictors and mediators of add‐on mirtazapine‐induced cognitive enhancement in schizophrenia ‐ a path model investigation. Neuropharmacology2013;64:248‐53. StenbergJ‐H , TerevnikovV , JoffeM , TiihonenJ , TchoukhineE , BurkinM , et al. Effects of add‐on mirtazapine on neurocognition in schizophrenia ‐a double‐blind, randomized, placebo‐controlled study. Proceedings of the 15th Biennial Winter Workshop in Psychoses; 2009 Nov 15‐18; Barcelona, Spain. 2009. StenbergJ‐H , TerevnikovV , JoffeM , TiihonenJ , TchoukhineE , BurkinM , et al. More evidence on proneurocognitive effects of add‐on mirtazapine in schizophrenia. Progress in Neuro‐Psychopharmacology and Biological Psychiatry2011;35:1080‐6. StenbergJH , TerevnikovV , JoffeM , TiihonenJ , TchoukhineE , BurkinM , et al. Effects of add‐on mirtazapine on neurocognition in schizophrenia: A double‐blind, randomized, placebo‐controlled study. International Journal of Neuropsychopharmacology2010;13(4):433‐41. StenbergJH , TerevnikovV , JoffeM , TiihonenJ , TchoukhineE , BurkinM , et al. Effects of add‐on mirtazapine on neurocognition in schizophrenia: an open label extension phase of a double‐blind, randomized, placebo‐controlled study, and both phases. Schizophrenia Research2010;117(2‐3):377. TerevnikovV . Clinical effects of mirtazapine added to first generation antipsychotics in schizophrenia. Dissertation2013. TerevnikovV , StenbergJ H , TiihonenJ , ChukhinE , JoffeM , BurkinM , et al. Relationships between pharmacotherapy‐induced metabolic changes and improved psychopathology in schizophrenia: data from a mirtazapine and first‐generation antipsychotics combination trial. International Journal of Neuropsychopharmacology2013;16(7):1661‐6. TerevnikovV , StenbergJ‐H , TiihonenJ , JoffeM , BurkinM , TchoukhineE , et al. Add‐on mirtazapine improves depressive symptoms in schizophrenia: A double‐blind randomized placebo‐controlled study with an open‐label extension phase. Human Psychopharmacology2011;26(3):188‐93. TerevnikovV , StenbergJH , JoffeM , TiihonenJ , BurkinM , TchoukhineE , et al. More evidence on additive antipsychotic effect of adjunctive mirtazapine in schizophrenia: An extension phase of a randomized controlled trial. Human Psychopharmacology2010;25(6):431‐8. TerevnikovV , StenbergJH , TiihonenJ , BurkinM , JoffeG . Add‐on mirtazapine improves orgasmic functioning in patients with schizophrenia treated with first‐generation antipsychotics. Nordic Journal of Psychiatry2017;71(1):77‐80. TereynikovV , JoffeM , TiihonenJ , StenbergJ‐H , BurkinM , TchoukhineE , et al. More evidence on additive antipsychotic effect of adjunctive mirtazapine in schizophrenia: an extension phase of a randomized controlled trial. Proceedings of the 15th Biennial Winter Workshop in Psychoses; 2009 Nov 15‐18; Barcelona, Spain. 2009. ">Terevnikov 2013</a>). Two studies were of one‐week or less duration (<a href="./references#CD011943-bbs2-0006" title="PoyurovskyM . Mirtazapine for bipolar disorder and schizophrenia. Stanley Foundation Research Programs2009. PoyurovskyM , EpshteinS , FuchsC , SchneidmanM , WeizmanR , WeizmanA . Efficacy of low‐dose mirtazapine in neuroleptic‐induced akathisia: a double‐blind randomized placebo‐controlled pilot study. European Neuropsychopharmacology2002;12(Suppl. 3):S299. PoyurovskyM , EpshteinS , FuchsC , SchneidmanM , WeizmanR , WeizmanA . Efficacy of low‐dose mirtazapine in neuroleptic‐induced akathisia: a double‐blind randomized placebo‐controlled pilot study. Journal of Clinical Psychopharmacology2003;23(3):305‐8. [MEDLINE: 12826992] ">Poyurovsky 2003</a>; <a href="./references#CD011943-bbs2-0007" title="PoyurovskyM , PashinianA , WeizmanR , FuchsC , WeizmanA . Low‐dose mirtazapine: a new option in the treatment of antipsychotic‐induced akathisia. A randomized, double‐blind, placebo‐ and propranolol‐controlled trial. Biological Psychiatry2006;59(11):1071‐7. [MEDLINE: 16497273] ">Poyurovsky 2006</a>). </p> </section> <section id="CD011943-sec-0122"> <h5 class="title">2. Participants</h5> <section id="CD011943-sec-0123"> <h6 class="title">2.1 Diagnosis</h6> <p>Five studies included participants with a sole diagnosis of schizophrenia based on the DSM‐IV diagnostic model (<a href="./references#CD011943-bbs2-0001" title="AbbasiSH , BehpourniaH , GhoreshiA , SalehiB , RaznahanM , RezazadehSA , et al. The effect of mirtazapine add on therapy to risperidone in the treatment of schizophrenia: A double‐blind randomized placebo‐controlled trial. Schizophrenia Research2010;116(2‐3):101‐6. [MEDLINE: 19959338] ">Abbasi 2010</a>; <a href="./references#CD011943-bbs2-0002" title="BerkM , IchimC , BrookS . Efficacy of mirtazapine add on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia: a double‐blind randomized placebo‐controlled study. Clinical Psychopharmacology2001;16(2):87‐92. [MEDLINE: 11236073] BerkM , IchimC , BrookS . Mirtazepine treatment of negative schizophrenia. Proceedings of the 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13‐18; Chicago, Illinois, USA. 2000. BerkM , IchimC , BrookS . Mirtazepine treatment of negative schizophrenia. Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. IchimC , BerkM , BrookS . Mirtazapine treatment of negative symptoms of schizophrenia: a double blind placebo controlled add on trial to treatment with haloperidol. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S112. ">Berk 2001</a>; <a href="./references#CD011943-bbs2-0005" title="ChoSJ , YookK , KimB , ChoiTK , LeeKS , KimYW , et al. Mirtazapine augmentation enhances cognitive and reduces negative symptoms in schizophrenia patients treated with risperidone: A randomized controlled trial. Progress in Neuro‐Psychopharmacology &amp; Biological Psychiatry2011;35(1):208‐11. LeeJ , SungJC , KangSL , YookK , AhYC , LeeS , et al. The tolerability of mirtazapine augmentation in schizophrenic patients treated with risperidone: A preliminary randomized placebo‐controlled trial. Clinical Psychopharmacology and Neuroscience2011;9(2):73‐7. LeeSH . Mirtazapine augmentation enhances cognitive and negative symptoms in schizophrenic patients treated with risperidone: a randomised controlled trial. www.controlled‐trials.com2009. ">Cho 2011</a>; <a href="./references#CD011943-bbs2-0008" title="JoffeG . Efficacy of add‐on mirtazapine on clinical and neuropsychologic parameters in schizophrenic patients treated with conventional antipsychotics: a double‐blind, placebo‐controlled trial with an open‐label extension phase. isrctn.com/ISRCTN00721331. JoffeG . Mirtazapine for schizophrenia. Stanley Foundation Research Programs2009. JoffeG , TerevnikovV , JoffeM , StenbergJ‐H , BurkinM , TiihonenJ . Add‐on mirtazapine enhances antipsychotic effect of first generation antipsychotics in schizophrenia: a double‐blind, randomized, placebo‐controlled trial. Schizophrenia Research2009;108(1‐3):245‐51. [MEDLINE: 19144501] StenbergJ‐H , TerevnikovV , JoffeM , TiihonenJ , ChukhinE , BurkinM , et al. Predictors and mediators of add‐on mirtazapine‐induced cognitive enhancement in schizophrenia ‐ a path model investigation. Neuropharmacology2013;64:248‐53. StenbergJ‐H , TerevnikovV , JoffeM , TiihonenJ , TchoukhineE , BurkinM , et al. Effects of add‐on mirtazapine on neurocognition in schizophrenia ‐a double‐blind, randomized, placebo‐controlled study. Proceedings of the 15th Biennial Winter Workshop in Psychoses; 2009 Nov 15‐18; Barcelona, Spain. 2009. StenbergJ‐H , TerevnikovV , JoffeM , TiihonenJ , TchoukhineE , BurkinM , et al. More evidence on proneurocognitive effects of add‐on mirtazapine in schizophrenia. Progress in Neuro‐Psychopharmacology and Biological Psychiatry2011;35:1080‐6. StenbergJH , TerevnikovV , JoffeM , TiihonenJ , TchoukhineE , BurkinM , et al. Effects of add‐on mirtazapine on neurocognition in schizophrenia: A double‐blind, randomized, placebo‐controlled study. International Journal of Neuropsychopharmacology2010;13(4):433‐41. StenbergJH , TerevnikovV , JoffeM , TiihonenJ , TchoukhineE , BurkinM , et al. Effects of add‐on mirtazapine on neurocognition in schizophrenia: an open label extension phase of a double‐blind, randomized, placebo‐controlled study, and both phases. Schizophrenia Research2010;117(2‐3):377. TerevnikovV . Clinical effects of mirtazapine added to first generation antipsychotics in schizophrenia. Dissertation2013. TerevnikovV , StenbergJ H , TiihonenJ , ChukhinE , JoffeM , BurkinM , et al. Relationships between pharmacotherapy‐induced metabolic changes and improved psychopathology in schizophrenia: data from a mirtazapine and first‐generation antipsychotics combination trial. International Journal of Neuropsychopharmacology2013;16(7):1661‐6. TerevnikovV , StenbergJ‐H , TiihonenJ , JoffeM , BurkinM , TchoukhineE , et al. Add‐on mirtazapine improves depressive symptoms in schizophrenia: A double‐blind randomized placebo‐controlled study with an open‐label extension phase. Human Psychopharmacology2011;26(3):188‐93. TerevnikovV , StenbergJH , JoffeM , TiihonenJ , BurkinM , TchoukhineE , et al. More evidence on additive antipsychotic effect of adjunctive mirtazapine in schizophrenia: An extension phase of a randomized controlled trial. Human Psychopharmacology2010;25(6):431‐8. TerevnikovV , StenbergJH , TiihonenJ , BurkinM , JoffeG . Add‐on mirtazapine improves orgasmic functioning in patients with schizophrenia treated with first‐generation antipsychotics. Nordic Journal of Psychiatry2017;71(1):77‐80. TereynikovV , JoffeM , TiihonenJ , StenbergJ‐H , BurkinM , TchoukhineE , et al. More evidence on additive antipsychotic effect of adjunctive mirtazapine in schizophrenia: an extension phase of a randomized controlled trial. Proceedings of the 15th Biennial Winter Workshop in Psychoses; 2009 Nov 15‐18; Barcelona, Spain. 2009. ">Terevnikov 2013</a>; <a href="./references#CD011943-bbs2-0009" title="ZoccaliR , MuscatelloMR , CedroC , NeriP , LaTorreD , SpinaE , et al. The effect of mirtazapine augmentation of clozapine in the treatment of negative symptoms of schizophrenia: a double‐blind, placebo‐controlled study. International Clinical Psychopharmacology2004;19(2):71‐6. [MEDLINE: 15076014] ZoccaliR , MuscatelloMR , TorreDL , MalaraG , CanaleA , CrucittiDDC , et al. Lack of a pharmacokinetic interaction between mirtazapine and the newer antipsychotics clozapine, risperidone and olanzapine in patients with chronic schizophrenia. Pharmacological Research2003;48(4):411‐4. ">Zoccali 2004</a>). Two studies included participants with a sole diagnosis of schizophrenia but did not specify the diagnostic model (<a href="./references#CD011943-bbs2-0003" title="BerkM , GamaCS , SundramS , HustigH , KoopowitzL , D'SouzaR , et al. Mirtazapine add‐on therapy in the treatment of schizophrenia with atypical antipsychotics: a double‐blind, randomised, placebo‐controlled clinical trial. Human Psychopharmacology2009;24(3):233‐8. [MEDLINE: 19330802] DoddS . Mirtazapine add‐on therapy in the treatment of schizophrenia with atypical neuroleptics: a double‐blind, randomised, placebo controlled trial. Australian New Zealand Clinical Trials Registry2004. DoddS , BerkM , D’SouzaR , HustigH , KoopowitzL , MonkhouseA , et al. Mirtazapine add‐on therapy in the treatment of schizophrenia with atypical antipsychotics: a double‐blind, randomised, placebo‐controlled clinical trial. International Journal of Neuropsychopharmacology2008;11(Suppl 1):139‐40. ">Berk 2009</a>; <a href="./references#CD011943-bbs2-0004" title="BertolinoA . Placebo controlled randomized trial of augmentation of olanzapine treatment with mirtazapine in 30 patients with schizophrenia to ascertain possible effects on negative symptoms and working memory. Stanley Foundation Research Programs2002. CaforioG , DiGiorgioA , RampinoA , RizzoM , RomanoR , TaurisanoP , et al. Mirtazapine add‐on improves olanzapine effect on negative symptoms of schizophrenia. Journal of Clinical Psychopharmacology2013;33(6):810‐2. ">Caforio 2013</a>). One study included participants with a diagnosis of schizophrenia and neuroleptic‐induced akathisia based on the DSM‐IV diagnostic model (<a href="./references#CD011943-bbs2-0006" title="PoyurovskyM . Mirtazapine for bipolar disorder and schizophrenia. Stanley Foundation Research Programs2009. PoyurovskyM , EpshteinS , FuchsC , SchneidmanM , WeizmanR , WeizmanA . Efficacy of low‐dose mirtazapine in neuroleptic‐induced akathisia: a double‐blind randomized placebo‐controlled pilot study. European Neuropsychopharmacology2002;12(Suppl. 3):S299. PoyurovskyM , EpshteinS , FuchsC , SchneidmanM , WeizmanR , WeizmanA . Efficacy of low‐dose mirtazapine in neuroleptic‐induced akathisia: a double‐blind randomized placebo‐controlled pilot study. Journal of Clinical Psychopharmacology2003;23(3):305‐8. [MEDLINE: 12826992] ">Poyurovsky 2003</a>). One study included mixed participants with schizophrenia (70), delusional disorder (7), or major depressive disorder with psychotic features (3), each also having neuroleptic‐induced akathisia based on the DSM‐IV diagnostic model (<a href="./references#CD011943-bbs2-0007" title="PoyurovskyM , PashinianA , WeizmanR , FuchsC , WeizmanA . Low‐dose mirtazapine: a new option in the treatment of antipsychotic‐induced akathisia. A randomized, double‐blind, placebo‐ and propranolol‐controlled trial. Biological Psychiatry2006;59(11):1071‐7. [MEDLINE: 16497273] ">Poyurovsky 2006</a>). </p> <p>All studies included a combination of male and female participants, each with a male preponderance. Studies included participants of a variety of ages, with mean ages ranging between 28 and 48 years. </p> </section> <section id="CD011943-sec-0124"> <h6 class="title">2.2 Excluded</h6> <p>One study did not reported specific exclusion criteria. (<a href="./references#CD011943-bbs2-0006" title="PoyurovskyM . Mirtazapine for bipolar disorder and schizophrenia. Stanley Foundation Research Programs2009. PoyurovskyM , EpshteinS , FuchsC , SchneidmanM , WeizmanR , WeizmanA . Efficacy of low‐dose mirtazapine in neuroleptic‐induced akathisia: a double‐blind randomized placebo‐controlled pilot study. European Neuropsychopharmacology2002;12(Suppl. 3):S299. PoyurovskyM , EpshteinS , FuchsC , SchneidmanM , WeizmanR , WeizmanA . Efficacy of low‐dose mirtazapine in neuroleptic‐induced akathisia: a double‐blind randomized placebo‐controlled pilot study. Journal of Clinical Psychopharmacology2003;23(3):305‐8. [MEDLINE: 12826992] ">Poyurovsky 2003</a>). Of the eight studies with explicit exclusion criteria, six excluded either patients with a current depressive episode or patients on antidepressant drugs (<a href="./references#CD011943-bbs2-0001" title="AbbasiSH , BehpourniaH , GhoreshiA , SalehiB , RaznahanM , RezazadehSA , et al. The effect of mirtazapine add on therapy to risperidone in the treatment of schizophrenia: A double‐blind randomized placebo‐controlled trial. Schizophrenia Research2010;116(2‐3):101‐6. [MEDLINE: 19959338] ">Abbasi 2010</a>; <a href="./references#CD011943-bbs2-0002" title="BerkM , IchimC , BrookS . Efficacy of mirtazapine add on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia: a double‐blind randomized placebo‐controlled study. Clinical Psychopharmacology2001;16(2):87‐92. [MEDLINE: 11236073] BerkM , IchimC , BrookS . Mirtazepine treatment of negative schizophrenia. Proceedings of the 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13‐18; Chicago, Illinois, USA. 2000. BerkM , IchimC , BrookS . Mirtazepine treatment of negative schizophrenia. Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. IchimC , BerkM , BrookS . Mirtazapine treatment of negative symptoms of schizophrenia: a double blind placebo controlled add on trial to treatment with haloperidol. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S112. ">Berk 2001</a>; <a href="./references#CD011943-bbs2-0003" title="BerkM , GamaCS , SundramS , HustigH , KoopowitzL , D'SouzaR , et al. Mirtazapine add‐on therapy in the treatment of schizophrenia with atypical antipsychotics: a double‐blind, randomised, placebo‐controlled clinical trial. Human Psychopharmacology2009;24(3):233‐8. [MEDLINE: 19330802] DoddS . Mirtazapine add‐on therapy in the treatment of schizophrenia with atypical neuroleptics: a double‐blind, randomised, placebo controlled trial. Australian New Zealand Clinical Trials Registry2004. DoddS , BerkM , D’SouzaR , HustigH , KoopowitzL , MonkhouseA , et al. Mirtazapine add‐on therapy in the treatment of schizophrenia with atypical antipsychotics: a double‐blind, randomised, placebo‐controlled clinical trial. International Journal of Neuropsychopharmacology2008;11(Suppl 1):139‐40. ">Berk 2009</a>; <a href="./references#CD011943-bbs2-0005" title="ChoSJ , YookK , KimB , ChoiTK , LeeKS , KimYW , et al. Mirtazapine augmentation enhances cognitive and reduces negative symptoms in schizophrenia patients treated with risperidone: A randomized controlled trial. Progress in Neuro‐Psychopharmacology &amp; Biological Psychiatry2011;35(1):208‐11. LeeJ , SungJC , KangSL , YookK , AhYC , LeeS , et al. The tolerability of mirtazapine augmentation in schizophrenic patients treated with risperidone: A preliminary randomized placebo‐controlled trial. Clinical Psychopharmacology and Neuroscience2011;9(2):73‐7. LeeSH . Mirtazapine augmentation enhances cognitive and negative symptoms in schizophrenic patients treated with risperidone: a randomised controlled trial. www.controlled‐trials.com2009. ">Cho 2011</a>; <a href="./references#CD011943-bbs2-0008" title="JoffeG . Efficacy of add‐on mirtazapine on clinical and neuropsychologic parameters in schizophrenic patients treated with conventional antipsychotics: a double‐blind, placebo‐controlled trial with an open‐label extension phase. isrctn.com/ISRCTN00721331. JoffeG . Mirtazapine for schizophrenia. Stanley Foundation Research Programs2009. JoffeG , TerevnikovV , JoffeM , StenbergJ‐H , BurkinM , TiihonenJ . Add‐on mirtazapine enhances antipsychotic effect of first generation antipsychotics in schizophrenia: a double‐blind, randomized, placebo‐controlled trial. Schizophrenia Research2009;108(1‐3):245‐51. [MEDLINE: 19144501] StenbergJ‐H , TerevnikovV , JoffeM , TiihonenJ , ChukhinE , BurkinM , et al. Predictors and mediators of add‐on mirtazapine‐induced cognitive enhancement in schizophrenia ‐ a path model investigation. Neuropharmacology2013;64:248‐53. StenbergJ‐H , TerevnikovV , JoffeM , TiihonenJ , TchoukhineE , BurkinM , et al. Effects of add‐on mirtazapine on neurocognition in schizophrenia ‐a double‐blind, randomized, placebo‐controlled study. Proceedings of the 15th Biennial Winter Workshop in Psychoses; 2009 Nov 15‐18; Barcelona, Spain. 2009. StenbergJ‐H , TerevnikovV , JoffeM , TiihonenJ , TchoukhineE , BurkinM , et al. More evidence on proneurocognitive effects of add‐on mirtazapine in schizophrenia. Progress in Neuro‐Psychopharmacology and Biological Psychiatry2011;35:1080‐6. StenbergJH , TerevnikovV , JoffeM , TiihonenJ , TchoukhineE , BurkinM , et al. Effects of add‐on mirtazapine on neurocognition in schizophrenia: A double‐blind, randomized, placebo‐controlled study. International Journal of Neuropsychopharmacology2010;13(4):433‐41. StenbergJH , TerevnikovV , JoffeM , TiihonenJ , TchoukhineE , BurkinM , et al. Effects of add‐on mirtazapine on neurocognition in schizophrenia: an open label extension phase of a double‐blind, randomized, placebo‐controlled study, and both phases. Schizophrenia Research2010;117(2‐3):377. TerevnikovV . Clinical effects of mirtazapine added to first generation antipsychotics in schizophrenia. Dissertation2013. TerevnikovV , StenbergJ H , TiihonenJ , ChukhinE , JoffeM , BurkinM , et al. Relationships between pharmacotherapy‐induced metabolic changes and improved psychopathology in schizophrenia: data from a mirtazapine and first‐generation antipsychotics combination trial. International Journal of Neuropsychopharmacology2013;16(7):1661‐6. TerevnikovV , StenbergJ‐H , TiihonenJ , JoffeM , BurkinM , TchoukhineE , et al. Add‐on mirtazapine improves depressive symptoms in schizophrenia: A double‐blind randomized placebo‐controlled study with an open‐label extension phase. Human Psychopharmacology2011;26(3):188‐93. TerevnikovV , StenbergJH , JoffeM , TiihonenJ , BurkinM , TchoukhineE , et al. More evidence on additive antipsychotic effect of adjunctive mirtazapine in schizophrenia: An extension phase of a randomized controlled trial. Human Psychopharmacology2010;25(6):431‐8. TerevnikovV , StenbergJH , TiihonenJ , BurkinM , JoffeG . Add‐on mirtazapine improves orgasmic functioning in patients with schizophrenia treated with first‐generation antipsychotics. Nordic Journal of Psychiatry2017;71(1):77‐80. TereynikovV , JoffeM , TiihonenJ , StenbergJ‐H , BurkinM , TchoukhineE , et al. More evidence on additive antipsychotic effect of adjunctive mirtazapine in schizophrenia: an extension phase of a randomized controlled trial. Proceedings of the 15th Biennial Winter Workshop in Psychoses; 2009 Nov 15‐18; Barcelona, Spain. 2009. ">Terevnikov 2013</a>; <a href="./references#CD011943-bbs2-0009" title="ZoccaliR , MuscatelloMR , CedroC , NeriP , LaTorreD , SpinaE , et al. The effect of mirtazapine augmentation of clozapine in the treatment of negative symptoms of schizophrenia: a double‐blind, placebo‐controlled study. International Clinical Psychopharmacology2004;19(2):71‐6. [MEDLINE: 15076014] ZoccaliR , MuscatelloMR , TorreDL , MalaraG , CanaleA , CrucittiDDC , et al. Lack of a pharmacokinetic interaction between mirtazapine and the newer antipsychotics clozapine, risperidone and olanzapine in patients with chronic schizophrenia. Pharmacological Research2003;48(4):411‐4. ">Zoccali 2004</a>). Other common exclusion criteria were concomitant major medical or psychiatric illness other than schizophrenia, and current use of psychotropic medication other than an antipsychotic agent. </p> </section> <section id="CD011943-sec-0125"> <h6 class="title">2.3 History</h6> <p>Several studies reported data on the stage of illness of participants, which were typically presented as an average of months from diagnosis to recruitment. These figures ranged from about 33 months to 300 months, reflecting that the studies' populations were typically first diagnosed several years prior to recruitment. </p> </section> </section> <section id="CD011943-sec-0126"> <h5 class="title">3. Setting</h5> <p>Five studies were set in inpatient units (<a href="./references#CD011943-bbs2-0001" title="AbbasiSH , BehpourniaH , GhoreshiA , SalehiB , RaznahanM , RezazadehSA , et al. The effect of mirtazapine add on therapy to risperidone in the treatment of schizophrenia: A double‐blind randomized placebo‐controlled trial. Schizophrenia Research2010;116(2‐3):101‐6. [MEDLINE: 19959338] ">Abbasi 2010</a>; <a href="./references#CD011943-bbs2-0002" title="BerkM , IchimC , BrookS . Efficacy of mirtazapine add on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia: a double‐blind randomized placebo‐controlled study. Clinical Psychopharmacology2001;16(2):87‐92. [MEDLINE: 11236073] BerkM , IchimC , BrookS . Mirtazepine treatment of negative schizophrenia. Proceedings of the 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13‐18; Chicago, Illinois, USA. 2000. BerkM , IchimC , BrookS . Mirtazepine treatment of negative schizophrenia. Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. IchimC , BerkM , BrookS . Mirtazapine treatment of negative symptoms of schizophrenia: a double blind placebo controlled add on trial to treatment with haloperidol. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S112. ">Berk 2001</a>; <a href="./references#CD011943-bbs2-0004" title="BertolinoA . Placebo controlled randomized trial of augmentation of olanzapine treatment with mirtazapine in 30 patients with schizophrenia to ascertain possible effects on negative symptoms and working memory. Stanley Foundation Research Programs2002. CaforioG , DiGiorgioA , RampinoA , RizzoM , RomanoR , TaurisanoP , et al. Mirtazapine add‐on improves olanzapine effect on negative symptoms of schizophrenia. Journal of Clinical Psychopharmacology2013;33(6):810‐2. ">Caforio 2013</a>; <a href="./references#CD011943-bbs2-0006" title="PoyurovskyM . Mirtazapine for bipolar disorder and schizophrenia. Stanley Foundation Research Programs2009. PoyurovskyM , EpshteinS , FuchsC , SchneidmanM , WeizmanR , WeizmanA . Efficacy of low‐dose mirtazapine in neuroleptic‐induced akathisia: a double‐blind randomized placebo‐controlled pilot study. European Neuropsychopharmacology2002;12(Suppl. 3):S299. PoyurovskyM , EpshteinS , FuchsC , SchneidmanM , WeizmanR , WeizmanA . Efficacy of low‐dose mirtazapine in neuroleptic‐induced akathisia: a double‐blind randomized placebo‐controlled pilot study. Journal of Clinical Psychopharmacology2003;23(3):305‐8. [MEDLINE: 12826992] ">Poyurovsky 2003</a>; <a href="./references#CD011943-bbs2-0007" title="PoyurovskyM , PashinianA , WeizmanR , FuchsC , WeizmanA . Low‐dose mirtazapine: a new option in the treatment of antipsychotic‐induced akathisia. A randomized, double‐blind, placebo‐ and propranolol‐controlled trial. Biological Psychiatry2006;59(11):1071‐7. [MEDLINE: 16497273] ">Poyurovsky 2006</a>). Two studies were set in outpatient units (<a href="./references#CD011943-bbs2-0005" title="ChoSJ , YookK , KimB , ChoiTK , LeeKS , KimYW , et al. Mirtazapine augmentation enhances cognitive and reduces negative symptoms in schizophrenia patients treated with risperidone: A randomized controlled trial. Progress in Neuro‐Psychopharmacology &amp; Biological Psychiatry2011;35(1):208‐11. LeeJ , SungJC , KangSL , YookK , AhYC , LeeS , et al. The tolerability of mirtazapine augmentation in schizophrenic patients treated with risperidone: A preliminary randomized placebo‐controlled trial. Clinical Psychopharmacology and Neuroscience2011;9(2):73‐7. LeeSH . Mirtazapine augmentation enhances cognitive and negative symptoms in schizophrenic patients treated with risperidone: a randomised controlled trial. www.controlled‐trials.com2009. ">Cho 2011</a>; <a href="./references#CD011943-bbs2-0009" title="ZoccaliR , MuscatelloMR , CedroC , NeriP , LaTorreD , SpinaE , et al. The effect of mirtazapine augmentation of clozapine in the treatment of negative symptoms of schizophrenia: a double‐blind, placebo‐controlled study. International Clinical Psychopharmacology2004;19(2):71‐6. [MEDLINE: 15076014] ZoccaliR , MuscatelloMR , TorreDL , MalaraG , CanaleA , CrucittiDDC , et al. Lack of a pharmacokinetic interaction between mirtazapine and the newer antipsychotics clozapine, risperidone and olanzapine in patients with chronic schizophrenia. Pharmacological Research2003;48(4):411‐4. ">Zoccali 2004</a>). One study was set in both inpatient and outpatient units (<a href="./references#CD011943-bbs2-0008" title="JoffeG . Efficacy of add‐on mirtazapine on clinical and neuropsychologic parameters in schizophrenic patients treated with conventional antipsychotics: a double‐blind, placebo‐controlled trial with an open‐label extension phase. isrctn.com/ISRCTN00721331. JoffeG . Mirtazapine for schizophrenia. Stanley Foundation Research Programs2009. JoffeG , TerevnikovV , JoffeM , StenbergJ‐H , BurkinM , TiihonenJ . Add‐on mirtazapine enhances antipsychotic effect of first generation antipsychotics in schizophrenia: a double‐blind, randomized, placebo‐controlled trial. Schizophrenia Research2009;108(1‐3):245‐51. [MEDLINE: 19144501] StenbergJ‐H , TerevnikovV , JoffeM , TiihonenJ , ChukhinE , BurkinM , et al. Predictors and mediators of add‐on mirtazapine‐induced cognitive enhancement in schizophrenia ‐ a path model investigation. Neuropharmacology2013;64:248‐53. StenbergJ‐H , TerevnikovV , JoffeM , TiihonenJ , TchoukhineE , BurkinM , et al. Effects of add‐on mirtazapine on neurocognition in schizophrenia ‐a double‐blind, randomized, placebo‐controlled study. Proceedings of the 15th Biennial Winter Workshop in Psychoses; 2009 Nov 15‐18; Barcelona, Spain. 2009. StenbergJ‐H , TerevnikovV , JoffeM , TiihonenJ , TchoukhineE , BurkinM , et al. More evidence on proneurocognitive effects of add‐on mirtazapine in schizophrenia. Progress in Neuro‐Psychopharmacology and Biological Psychiatry2011;35:1080‐6. StenbergJH , TerevnikovV , JoffeM , TiihonenJ , TchoukhineE , BurkinM , et al. Effects of add‐on mirtazapine on neurocognition in schizophrenia: A double‐blind, randomized, placebo‐controlled study. International Journal of Neuropsychopharmacology2010;13(4):433‐41. StenbergJH , TerevnikovV , JoffeM , TiihonenJ , TchoukhineE , BurkinM , et al. Effects of add‐on mirtazapine on neurocognition in schizophrenia: an open label extension phase of a double‐blind, randomized, placebo‐controlled study, and both phases. Schizophrenia Research2010;117(2‐3):377. TerevnikovV . Clinical effects of mirtazapine added to first generation antipsychotics in schizophrenia. Dissertation2013. TerevnikovV , StenbergJ H , TiihonenJ , ChukhinE , JoffeM , BurkinM , et al. Relationships between pharmacotherapy‐induced metabolic changes and improved psychopathology in schizophrenia: data from a mirtazapine and first‐generation antipsychotics combination trial. International Journal of Neuropsychopharmacology2013;16(7):1661‐6. TerevnikovV , StenbergJ‐H , TiihonenJ , JoffeM , BurkinM , TchoukhineE , et al. Add‐on mirtazapine improves depressive symptoms in schizophrenia: A double‐blind randomized placebo‐controlled study with an open‐label extension phase. Human Psychopharmacology2011;26(3):188‐93. TerevnikovV , StenbergJH , JoffeM , TiihonenJ , BurkinM , TchoukhineE , et al. More evidence on additive antipsychotic effect of adjunctive mirtazapine in schizophrenia: An extension phase of a randomized controlled trial. Human Psychopharmacology2010;25(6):431‐8. TerevnikovV , StenbergJH , TiihonenJ , BurkinM , JoffeG . Add‐on mirtazapine improves orgasmic functioning in patients with schizophrenia treated with first‐generation antipsychotics. Nordic Journal of Psychiatry2017;71(1):77‐80. TereynikovV , JoffeM , TiihonenJ , StenbergJ‐H , BurkinM , TchoukhineE , et al. More evidence on additive antipsychotic effect of adjunctive mirtazapine in schizophrenia: an extension phase of a randomized controlled trial. Proceedings of the 15th Biennial Winter Workshop in Psychoses; 2009 Nov 15‐18; Barcelona, Spain. 2009. ">Terevnikov 2013</a>). One study did not describe the type of setting (<a href="./references#CD011943-bbs2-0003" title="BerkM , GamaCS , SundramS , HustigH , KoopowitzL , D'SouzaR , et al. Mirtazapine add‐on therapy in the treatment of schizophrenia with atypical antipsychotics: a double‐blind, randomised, placebo‐controlled clinical trial. Human Psychopharmacology2009;24(3):233‐8. [MEDLINE: 19330802] DoddS . Mirtazapine add‐on therapy in the treatment of schizophrenia with atypical neuroleptics: a double‐blind, randomised, placebo controlled trial. Australian New Zealand Clinical Trials Registry2004. DoddS , BerkM , D’SouzaR , HustigH , KoopowitzL , MonkhouseA , et al. Mirtazapine add‐on therapy in the treatment of schizophrenia with atypical antipsychotics: a double‐blind, randomised, placebo‐controlled clinical trial. International Journal of Neuropsychopharmacology2008;11(Suppl 1):139‐40. ">Berk 2009</a>). </p> </section> <section id="CD011943-sec-0127"> <h5 class="title">4. Study size</h5> <p>The largest study had 60 participants in the mirtazapine and placebo groups combined (<a href="./references#CD011943-bbs2-0007" title="PoyurovskyM , PashinianA , WeizmanR , FuchsC , WeizmanA . Low‐dose mirtazapine: a new option in the treatment of antipsychotic‐induced akathisia. A randomized, double‐blind, placebo‐ and propranolol‐controlled trial. Biological Psychiatry2006;59(11):1071‐7. [MEDLINE: 16497273] ">Poyurovsky 2006</a>). The rest of the studies had participant sizes ranging from 20 to 40. </p> </section> <section id="CD011943-sec-0128"> <h5 class="title">5. Interventions</h5> <section id="CD011943-sec-0129"> <h6 class="title">5.1 Mirtazapine adjunct</h6> <p>All included studies used an adjunct dose of mirtazapine of 30 mg/day except for two, in which both used doses of 15 mg/day (<a href="./references#CD011943-bbs2-0006" title="PoyurovskyM . Mirtazapine for bipolar disorder and schizophrenia. Stanley Foundation Research Programs2009. PoyurovskyM , EpshteinS , FuchsC , SchneidmanM , WeizmanR , WeizmanA . Efficacy of low‐dose mirtazapine in neuroleptic‐induced akathisia: a double‐blind randomized placebo‐controlled pilot study. European Neuropsychopharmacology2002;12(Suppl. 3):S299. PoyurovskyM , EpshteinS , FuchsC , SchneidmanM , WeizmanR , WeizmanA . Efficacy of low‐dose mirtazapine in neuroleptic‐induced akathisia: a double‐blind randomized placebo‐controlled pilot study. Journal of Clinical Psychopharmacology2003;23(3):305‐8. [MEDLINE: 12826992] ">Poyurovsky 2003</a>; <a href="./references#CD011943-bbs2-0007" title="PoyurovskyM , PashinianA , WeizmanR , FuchsC , WeizmanA . Low‐dose mirtazapine: a new option in the treatment of antipsychotic‐induced akathisia. A randomized, double‐blind, placebo‐ and propranolol‐controlled trial. Biological Psychiatry2006;59(11):1071‐7. [MEDLINE: 16497273] ">Poyurovsky 2006</a>). </p> </section> <section id="CD011943-sec-0130"> <h6 class="title">5.2 Placebo adjunct</h6> <p>Included studies compared mirtazapine plus usual antipsychotic medication versus placebo plus usual antipsychotic medication. The usual antipsychotics were typical antipsychotics in four studies and atypical antipsychotics in five studies. All participants in one study also received an anticholinergic medication (<a href="./references#CD011943-bbs2-0007" title="PoyurovskyM , PashinianA , WeizmanR , FuchsC , WeizmanA . Low‐dose mirtazapine: a new option in the treatment of antipsychotic‐induced akathisia. A randomized, double‐blind, placebo‐ and propranolol‐controlled trial. Biological Psychiatry2006;59(11):1071‐7. [MEDLINE: 16497273] ">Poyurovsky 2006</a>). </p> </section> </section> <section id="CD011943-sec-0131"> <h5 class="title">6. Outcomes</h5> <p>Our primary outcomes were mental state: clinically important change negative symptoms as defined by each of the studies and clinically important change in positive symptoms. Only one study reported clinically important change in negative symptoms (<a href="./references#CD011943-bbs2-0009" title="ZoccaliR , MuscatelloMR , CedroC , NeriP , LaTorreD , SpinaE , et al. The effect of mirtazapine augmentation of clozapine in the treatment of negative symptoms of schizophrenia: a double‐blind, placebo‐controlled study. International Clinical Psychopharmacology2004;19(2):71‐6. [MEDLINE: 15076014] ZoccaliR , MuscatelloMR , TorreDL , MalaraG , CanaleA , CrucittiDDC , et al. Lack of a pharmacokinetic interaction between mirtazapine and the newer antipsychotics clozapine, risperidone and olanzapine in patients with chronic schizophrenia. Pharmacological Research2003;48(4):411‐4. ">Zoccali 2004</a>), whereas seven studies reported on average endpoint scores on negative symptom scales (<a href="./references#CD011943-bbs2-0001" title="AbbasiSH , BehpourniaH , GhoreshiA , SalehiB , RaznahanM , RezazadehSA , et al. The effect of mirtazapine add on therapy to risperidone in the treatment of schizophrenia: A double‐blind randomized placebo‐controlled trial. Schizophrenia Research2010;116(2‐3):101‐6. [MEDLINE: 19959338] ">Abbasi 2010</a>; <a href="./references#CD011943-bbs2-0002" title="BerkM , IchimC , BrookS . Efficacy of mirtazapine add on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia: a double‐blind randomized placebo‐controlled study. Clinical Psychopharmacology2001;16(2):87‐92. [MEDLINE: 11236073] BerkM , IchimC , BrookS . Mirtazepine treatment of negative schizophrenia. Proceedings of the 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13‐18; Chicago, Illinois, USA. 2000. BerkM , IchimC , BrookS . Mirtazepine treatment of negative schizophrenia. Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. IchimC , BerkM , BrookS . Mirtazapine treatment of negative symptoms of schizophrenia: a double blind placebo controlled add on trial to treatment with haloperidol. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S112. ">Berk 2001</a>; <a href="./references#CD011943-bbs2-0003" title="BerkM , GamaCS , SundramS , HustigH , KoopowitzL , D'SouzaR , et al. Mirtazapine add‐on therapy in the treatment of schizophrenia with atypical antipsychotics: a double‐blind, randomised, placebo‐controlled clinical trial. Human Psychopharmacology2009;24(3):233‐8. [MEDLINE: 19330802] DoddS . Mirtazapine add‐on therapy in the treatment of schizophrenia with atypical neuroleptics: a double‐blind, randomised, placebo controlled trial. Australian New Zealand Clinical Trials Registry2004. DoddS , BerkM , D’SouzaR , HustigH , KoopowitzL , MonkhouseA , et al. Mirtazapine add‐on therapy in the treatment of schizophrenia with atypical antipsychotics: a double‐blind, randomised, placebo‐controlled clinical trial. International Journal of Neuropsychopharmacology2008;11(Suppl 1):139‐40. ">Berk 2009</a>; <a href="./references#CD011943-bbs2-0004" title="BertolinoA . Placebo controlled randomized trial of augmentation of olanzapine treatment with mirtazapine in 30 patients with schizophrenia to ascertain possible effects on negative symptoms and working memory. Stanley Foundation Research Programs2002. CaforioG , DiGiorgioA , RampinoA , RizzoM , RomanoR , TaurisanoP , et al. Mirtazapine add‐on improves olanzapine effect on negative symptoms of schizophrenia. Journal of Clinical Psychopharmacology2013;33(6):810‐2. ">Caforio 2013</a>; <a href="./references#CD011943-bbs2-0005" title="ChoSJ , YookK , KimB , ChoiTK , LeeKS , KimYW , et al. Mirtazapine augmentation enhances cognitive and reduces negative symptoms in schizophrenia patients treated with risperidone: A randomized controlled trial. Progress in Neuro‐Psychopharmacology &amp; Biological Psychiatry2011;35(1):208‐11. LeeJ , SungJC , KangSL , YookK , AhYC , LeeS , et al. The tolerability of mirtazapine augmentation in schizophrenic patients treated with risperidone: A preliminary randomized placebo‐controlled trial. Clinical Psychopharmacology and Neuroscience2011;9(2):73‐7. LeeSH . Mirtazapine augmentation enhances cognitive and negative symptoms in schizophrenic patients treated with risperidone: a randomised controlled trial. www.controlled‐trials.com2009. ">Cho 2011</a>; <a href="./references#CD011943-bbs2-0008" title="JoffeG . Efficacy of add‐on mirtazapine on clinical and neuropsychologic parameters in schizophrenic patients treated with conventional antipsychotics: a double‐blind, placebo‐controlled trial with an open‐label extension phase. isrctn.com/ISRCTN00721331. JoffeG . Mirtazapine for schizophrenia. Stanley Foundation Research Programs2009. JoffeG , TerevnikovV , JoffeM , StenbergJ‐H , BurkinM , TiihonenJ . Add‐on mirtazapine enhances antipsychotic effect of first generation antipsychotics in schizophrenia: a double‐blind, randomized, placebo‐controlled trial. Schizophrenia Research2009;108(1‐3):245‐51. [MEDLINE: 19144501] StenbergJ‐H , TerevnikovV , JoffeM , TiihonenJ , ChukhinE , BurkinM , et al. Predictors and mediators of add‐on mirtazapine‐induced cognitive enhancement in schizophrenia ‐ a path model investigation. Neuropharmacology2013;64:248‐53. StenbergJ‐H , TerevnikovV , JoffeM , TiihonenJ , TchoukhineE , BurkinM , et al. Effects of add‐on mirtazapine on neurocognition in schizophrenia ‐a double‐blind, randomized, placebo‐controlled study. Proceedings of the 15th Biennial Winter Workshop in Psychoses; 2009 Nov 15‐18; Barcelona, Spain. 2009. StenbergJ‐H , TerevnikovV , JoffeM , TiihonenJ , TchoukhineE , BurkinM , et al. More evidence on proneurocognitive effects of add‐on mirtazapine in schizophrenia. Progress in Neuro‐Psychopharmacology and Biological Psychiatry2011;35:1080‐6. StenbergJH , TerevnikovV , JoffeM , TiihonenJ , TchoukhineE , BurkinM , et al. Effects of add‐on mirtazapine on neurocognition in schizophrenia: A double‐blind, randomized, placebo‐controlled study. International Journal of Neuropsychopharmacology2010;13(4):433‐41. StenbergJH , TerevnikovV , JoffeM , TiihonenJ , TchoukhineE , BurkinM , et al. Effects of add‐on mirtazapine on neurocognition in schizophrenia: an open label extension phase of a double‐blind, randomized, placebo‐controlled study, and both phases. Schizophrenia Research2010;117(2‐3):377. TerevnikovV . Clinical effects of mirtazapine added to first generation antipsychotics in schizophrenia. Dissertation2013. TerevnikovV , StenbergJ H , TiihonenJ , ChukhinE , JoffeM , BurkinM , et al. Relationships between pharmacotherapy‐induced metabolic changes and improved psychopathology in schizophrenia: data from a mirtazapine and first‐generation antipsychotics combination trial. International Journal of Neuropsychopharmacology2013;16(7):1661‐6. TerevnikovV , StenbergJ‐H , TiihonenJ , JoffeM , BurkinM , TchoukhineE , et al. Add‐on mirtazapine improves depressive symptoms in schizophrenia: A double‐blind randomized placebo‐controlled study with an open‐label extension phase. Human Psychopharmacology2011;26(3):188‐93. TerevnikovV , StenbergJH , JoffeM , TiihonenJ , BurkinM , TchoukhineE , et al. More evidence on additive antipsychotic effect of adjunctive mirtazapine in schizophrenia: An extension phase of a randomized controlled trial. Human Psychopharmacology2010;25(6):431‐8. TerevnikovV , StenbergJH , TiihonenJ , BurkinM , JoffeG . Add‐on mirtazapine improves orgasmic functioning in patients with schizophrenia treated with first‐generation antipsychotics. Nordic Journal of Psychiatry2017;71(1):77‐80. TereynikovV , JoffeM , TiihonenJ , StenbergJ‐H , BurkinM , TchoukhineE , et al. More evidence on additive antipsychotic effect of adjunctive mirtazapine in schizophrenia: an extension phase of a randomized controlled trial. Proceedings of the 15th Biennial Winter Workshop in Psychoses; 2009 Nov 15‐18; Barcelona, Spain. 2009. ">Terevnikov 2013</a>; <a href="./references#CD011943-bbs2-0009" title="ZoccaliR , MuscatelloMR , CedroC , NeriP , LaTorreD , SpinaE , et al. The effect of mirtazapine augmentation of clozapine in the treatment of negative symptoms of schizophrenia: a double‐blind, placebo‐controlled study. International Clinical Psychopharmacology2004;19(2):71‐6. [MEDLINE: 15076014] ZoccaliR , MuscatelloMR , TorreDL , MalaraG , CanaleA , CrucittiDDC , et al. Lack of a pharmacokinetic interaction between mirtazapine and the newer antipsychotics clozapine, risperidone and olanzapine in patients with chronic schizophrenia. Pharmacological Research2003;48(4):411‐4. ">Zoccali 2004</a>). For <a href="./references#CD011943-bbs2-0002" title="BerkM , IchimC , BrookS . Efficacy of mirtazapine add on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia: a double‐blind randomized placebo‐controlled study. Clinical Psychopharmacology2001;16(2):87‐92. [MEDLINE: 11236073] BerkM , IchimC , BrookS . Mirtazepine treatment of negative schizophrenia. Proceedings of the 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13‐18; Chicago, Illinois, USA. 2000. BerkM , IchimC , BrookS . Mirtazepine treatment of negative schizophrenia. Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. IchimC , BerkM , BrookS . Mirtazapine treatment of negative symptoms of schizophrenia: a double blind placebo controlled add on trial to treatment with haloperidol. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S112. ">Berk 2001</a> and <a href="./references#CD011943-bbs2-0004" title="BertolinoA . Placebo controlled randomized trial of augmentation of olanzapine treatment with mirtazapine in 30 patients with schizophrenia to ascertain possible effects on negative symptoms and working memory. Stanley Foundation Research Programs2002. CaforioG , DiGiorgioA , RampinoA , RizzoM , RomanoR , TaurisanoP , et al. Mirtazapine add‐on improves olanzapine effect on negative symptoms of schizophrenia. Journal of Clinical Psychopharmacology2013;33(6):810‐2. ">Caforio 2013</a>, these data were skewed. </p> <p>Several scales and subscales were utilised by included studies to assess the effectiveness and safety of mirtazapine adjunct across the other outcomes assessed in this review. Descriptions of these are found below. </p> <p>All nine studies yielded at least some usable data on adverse events or effects. Reporting of specific adverse effects was generally good. Unfortunately, none of the included studies reported on quality of life/satisfaction, service utilisation, or economic outcomes. </p> <section id="CD011943-sec-0132"> <h6 class="title">6.1 Mental state scales</h6> <p>6.1.1 Positive and Negative Syndrome Scale (PANSS) (<a href="./references#CD011943-bbs2-0048" title="KaySR , OplerLA , FiszbeinA . Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi‐Health Systems, 1986. ">Kay 1986</a>) </p> <p>This is one of the most commonly used scales for measuring symptom severity in persons with schizophrenia. The PANSS includes 30 items, divided into three subscales; a composite score is also provided. The general psychopathology subscale is comprised of 14 items including anxiety and disorientation. The positive symptoms subscale (PANSS‐P) contains seven items incorporating delusions and hallucinations, with the negative symptoms subscale (PANSS‐N) made up of seven items inclusive of blunted affect and emotional withdrawal. All subscales use a seven‐point scoring system ranging from one (absent) to seven (extreme). A higher score indicates higher symptom severity. </p> <p>6.1.2 Scale for the Assessment of Negative Symptoms (SANS) (<a href="./references#CD011943-bbs2-0014" title="AndreasenNC . Scale for the Assessment of Negative Symptoms: SANS. Iowa: The University of Iowa1981. ">Andreasen 1981</a>) </p> <p>This scale is purposed to provide a global assessment of inappropriate affect by addressing five negative symptom complexes: affective blunting (decreased or lack of facial expression), alogia (responses to questions are short, lacking detail and/or individual does not initiate conversation), avolition/apathy (lack of interest in areas such as grooming), anhedonia/asociality (lack of interest in socialising) and attention issues. All items use a six‐point scoring system ranging from zero (not at all) to six (severe). A higher score indicates higher symptom severity. </p> <p>6.1.3 Scale for the Assessment of Positive Symptoms (SAPS) (<a href="./references#CD011943-bbs2-0015" title="AndreasenNC . Scale for the Assessment of Positive Symptoms: SAPS. Iowa: the University of Iowa1984. ">Andreasen 1984</a>) </p> <p>This scale was developed as a companion to the SANS. It addresses four positive symptom areas: hallucinations, delusions, bizarre behavior and positive formal thought disorder (disconnected thinking). All items use a six‐point scoring system ranging from zero (none) to five (severe), providing a global assessment of inappropriate affect. A higher score indicates higher symptom severity. </p> <p>6.1.4 Brief Psychiatric Rating Scale (BPRS) (<a href="./references#CD011943-bbs2-0062" title="OverallJE , GorhamDR . The brief psychiatric rating scale. Psychological Reports1962;10:799‐812. ">Overall 1962</a>) </p> <p>This scale is widely used to assess the severity of positive, negative and affective symptoms of schizophrenia. The original version contained 16 items and the current version includes 18 items, inclusive of anxiety, hostility and unusual thought content. All items use a seven‐point scoring system ranging from one (not present) to seven (extremely severe). A higher score indicates higher symptom severity. </p> </section> <section id="CD011943-sec-0133"> <h6 class="title">6.2 Global scales</h6> <p>6.2.1 Clinical Global Impressions Scale (CGI) (<a href="./references#CD011943-bbs2-0036" title="GuyW . ECDEU Assessment Manual for Psychopharmacology. Revised. Rockville: National Institute of Mental Health, 1976. ">Guy 1976</a>) </p> <p>This scale was developed for use in NIMH‐sponsored clinical trials. It is purposed as a brief global pre/post medication assessment that can stand‐alone and be administered by individual practitioners. This scale is used to assess illness severity (CGI‐S) and clinical improvement (CGI‐I). The practitioner asks themselves one question for the CGI‐S regarding how mentally ill the individual is at the current time. This question is answered using a seven‐point scoring system with one (not at all ill) and seven (among the most extremely ill patients). The practitioner also asks themselves one question for the CGI‐I in which they are comparing the individual’s current condition to their condition prior to medication initiation. The question is then answered using a seven‐point scoring system with one (very much improved since the initiation of treatment) and seven (very much worse since the initiation of treatment). A higher score indicates higher symptom severity. </p> <p>6.2.2 Patient Global Impression of Improvement (PGI‐I) (<a href="./references#CD011943-bbs2-0036" title="GuyW . ECDEU Assessment Manual for Psychopharmacology. Revised. Rockville: National Institute of Mental Health, 1976. ">Guy 1976</a>) </p> <p>This scale was developed as a companion to the CGI‐I. A question similar to that asked of the clinician in the CGI‐I, is asked of the patient in the PGI‐I, to determine the patient’s perception of their condition following intervention (usually medication initiation). The same seven‐point scoring system is used with one (very much better) and seven (very much worse). A higher score indicates higher symptom severity. This scale has been found reliable and valid for a variety of patient groups. </p> </section> <section id="CD011943-sec-0134"> <h6 class="title">6.3 Depression scales</h6> <p>6.3.1 Calgary Depression Severity Scale (CDSS) (<a href="./references#CD011943-bbs2-0011" title="AddingtonD , AddingtonJ , Maticka‐TyndaleE . Assessing depression in schizophrenia: the Calgary Depression Scale. British Journal of Psychiatry1993;22:39‐44. ">Addington 1993</a>) </p> <p>This nine‐item scale assesses depression in individuals with schizophrenia. A four‐point scoring system is used for all items with zero (absent) and three (severe). A score of seven or above is useful for predicting the presence of a major depressive episode for someone with schizophrenia (82% specificity and 85% sensitivity). A higher score indicates higher severity of symptoms. </p> <p>6.3.2 Hamilton Depression Rating Scale (HDRS abbreviated to HAM‐D) (<a href="./references#CD011943-bbs2-0037" title="HamiltonM . Rating depressive patients. Journal of Clinical Psychiatry1980;41(12 Pt 2):21‐4. ">Hamilton 1980</a>) </p> <p>This is one of the most commonly used scales for determining the severity of an individual’s depression prior to, during, and following treatment. The HAM‐D includes 21 items with 17 items used in scoring. Eight items, including insomnia and anxiety, are scored on a five‐point scale from zero (not present) to four (severe). The remaining nine items, including weight loss and insight, use a three‐point scoring system ranging from zero (absent), one (mild) and two (severe). Items assessed but not used in scoring include paranoia and obsessive/compulsive symptoms. A score of eight or above is indicative of depression, with a higher score indicating a higher severity of symptoms. </p> </section> <section id="CD011943-sec-0135"> <h6 class="title">6.4 Cognitive function scales</h6> <p>6.4.1 Wechsler Adult Intelligence Scale – Revised (WAIS‐R) (<a href="./references#CD011943-bbs2-0080" title="WechslerD . Wechsler Adult Intelligence Scale ‐ Revised. San Antonio: The Psychological Corporation, 1981. ">Wechsler 1981</a>) </p> <p>This is one of the most commonly used instruments for assessing overall cognitive ability. The WAIS‐R includes 11 subscales divided into two parts, verbal (VIQ with six subscales) and performance (PIQ with five subscales); a full scale IQ (FSIQ) is also provided. The verbal portion assesses areas such as information and similarities, with the performance portion assessing block design and digit symbols. The VIQ and PIQ are frequently reported separately, along with the FSIQ that is reported as a standard score with a mean of 100 and a standard deviation of 15. </p> <p>6.4.2 Wechsler Memory Scale (WMS) (<a href="./references#CD011943-bbs2-0079" title="WechslerDA . A standardized memory scale for clinical use. Journal of Psychology1945;19:87‐95. ">Wechsler 1945</a>; <a href="./references#CD011943-bbs2-0081" title="WechslerD . Wechsler Memory Scales ‐ Fourth Edition (WMS‐IV): Administration and Scoring Manual. Wechsler Memory Scales ‐ Fourth Edition (WMS‐IV): Administration and Scoring Manual. San Antonio: Pearson Clinical Assessment, 2009. ">Wechsler 2009</a>) </p> <p>This is the most commonly used instruments for measuring memory. It has been revised over time and is now in its fourth version (WMS‐IV). The WMS‐IV includes seven subscales. All subscales used in the studies included in this systematic review (verbal memory addressed through logical memory and verbal paired associations, with visual memory addressed through visual reproduction) were included in the tool prior to the latest revision (WMS‐III) and in the latest revision. A sum of the scaled scores is provided, as is an index score, percentile rank and qualitative description (ranging from extremely low to very superior). Higher scores indicate a lower severity of symptoms. </p> <p>6.4.3 Trail Making Test (TMT) (<a href="./references#CD011943-bbs2-0075" title="Army Individual TestBattery . Manual of Directions and Scoring. Washington, DC: War Department, Adjutant General's Office, 1944. ">US Army 1944</a>; <a href="./references#CD011943-bbs2-0065" title="ReitanRM , WolfsonD . The Halstead‐Reitan Neuropsychological Test Battery: Therapy and Clinical Interpretation. Tuscon: Neuropsychological Press, 1985. ">Reitan 1985</a>) </p> <p>This instrument was originally used by the United States Army for testing executive function (a set of cognitive processes needed for cognitive control of behaviour) and was eventually incorporated into the Halstead‐Reitan Battery. The TMT includes two parts, A (connecting circles numbered 1‐25 in correct order), and B (connecting numbered and lettered circles in correct order) and is to be completed by the individual as quickly as possible. Areas addressed by the TMT include speed of attention, eye‐hand co‐ordination, and information processing. The score for each part represents the time needed to complete the task; therefore, a higher score indicates higher symptom severity. </p> <p>6.4.4 Stroop Color‐Word Test (<a href="./references#CD011943-bbs2-0073" title="StroopJR . Studies of interference in serial verbal reactions. Journal of Experimental Psychology1935;18:643‐62. ">Stroop 1935</a>; <a href="./references#CD011943-bbs2-0047" title="JensenAR , Rohwer Jr.WD . The Stroop Color‐Word Test: a review. Acta Psychologica1966;25(1):36‐93. [DOI: 10.1016/0001‐6918(66)90004‐7.] ">Jensen 1966</a>) </p> <p>This instrument is used to measure executive functions including speed of processing and the cognitive ability to “sift through interference,” The test includes three parts, all timed: a) identifying the colour of dots, b) reading colour words, and c) identifying the colour of the font of the word shown, rather than the actual word shown. An example of part “C” is that the word “yellow” may be written in green and the correct answer would be green. Accuracy of answers and speed are included in scoring. Higher accuracy with lower speed is indicative of lower symptom severity. </p> <p>6.4.5 Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) (<a href="./references#CD011943-bbs2-0064" title="RandolphC , TierneyMC , MohrE , ChaseTN . The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): Preliminary clinical validity. Journal of Clinical and Experimental Neuropsychology1998;20(3):310‐9. [DOI: 10.1076/jcen.20.3.310.823] ">Randolph 1998</a>) </p> <p>This scale assesses abnormal cognitive decline. It is frequently used as it is brief, taking less than 30 minutes, and found effective in identifying and characterising cognitive decline of differing aetiologies. The RBANS includes five indexes (immediate memory, delayed memory, attention, language, and visuospatial/constructional abilities), and index scores have a mean of 100, with a SD of 15. Its 12 subtests have a mean of 10 and a SD of 3. Lower scores are indicative of higher symptom severity. </p> </section> <section id="CD011943-sec-0136"> <h6 class="title">6.5 Scales for the assessment of extrapyramidal side effects</h6> <p>6.5.1 Simpson‐Angus Scale (SAS) (<a href="./references#CD011943-bbs2-0071" title="SimpsonGM , AngusJW . A rating scale for extrapyramidal side‐effects. Acta Psychiatrica Scandinavica Supplementum1970;212:11‐9. ">Simpson 1970</a>) </p> <p>This scale measures symptoms of pseudoparkinsonism. The SAS includes 10 items and uses a five‐point rating system ranging from zero (normal) to five (severe degree of movement disorder). A higher score indicates higher severity of symptoms. </p> <p>6.5.2 Barnes Akathisa Scale (BAS) (<a href="./references#CD011943-bbs2-0017" title="BarnesTR . A rating scale for drug‐induced akathisia. British Journal of Psychiatry1989;154:672‐6. ">Barnes 1989</a>) </p> <p>This scale measures symptoms of akathisia, a drug‐related movement disorder. Three items are rated from zero (normal) to three (severe). These are observable restless movements, subjective feelings of restlessness, and distress. Additionally, a global severity score ranging from zero (normal) to five (severe) is available. </p> <p>6.5.3 Extrapyramidal Symptom Rating Scale (ESRS) (<a href="./references#CD011943-bbs2-0021" title="ChouinardG , ArnottW . Clinical review of risperidone. Canadian Journal of Psychiatry1993;38(Suppl 3):89‐95. ">Chouinard 1993</a>). </p> <p>This scale measures extrapyramidal symptoms by assessing parkinsonism through a nine‐item questionnaire, an eight‐item physical examination, and a clinical global impression of the presence and severity of tardive dyskinesia. Lower scores are indicative of milder symptom severity. </p> <p>Studies awaiting assessment Suggest this could be a Heading 3</p> <p>There is one study awaiting assessment (see <a href="./references#CD011943-sec-0240" title="">Characteristics of studies awaiting classification</a>). </p> </section> </section> </section> <section id="CD011943-sec-0137"> <h4 class="title">Excluded studies</h4> <p>There are no excluded studies, studies awaiting classification or ongoing studies in this review. </p> </section> </section> <section id="CD011943-sec-0138"> <h3 class="title">Risk of bias in included studies</h3> <p>Risk of bias was assessed for all nine included studies. Please refer to <a href="#CD011943-fig-0001">Figure 1</a> and <a href="#CD011943-fig-0002">Figure 2</a> for visual representations of the 'Risk of bias' assessment of included studies. </p> <section id="CD011943-sec-0139"> <h4 class="title">Allocation</h4> <p>All included studies were reported to be randomised. <a href="./references#CD011943-bbs2-0001" title="AbbasiSH , BehpourniaH , GhoreshiA , SalehiB , RaznahanM , RezazadehSA , et al. The effect of mirtazapine add on therapy to risperidone in the treatment of schizophrenia: A double‐blind randomized placebo‐controlled trial. Schizophrenia Research2010;116(2‐3):101‐6. [MEDLINE: 19959338] ">Abbasi 2010</a> randomised participants using a computer‐generated code, whereas <a href="./references#CD011943-bbs2-0006" title="PoyurovskyM . Mirtazapine for bipolar disorder and schizophrenia. Stanley Foundation Research Programs2009. PoyurovskyM , EpshteinS , FuchsC , SchneidmanM , WeizmanR , WeizmanA . Efficacy of low‐dose mirtazapine in neuroleptic‐induced akathisia: a double‐blind randomized placebo‐controlled pilot study. European Neuropsychopharmacology2002;12(Suppl. 3):S299. PoyurovskyM , EpshteinS , FuchsC , SchneidmanM , WeizmanR , WeizmanA . Efficacy of low‐dose mirtazapine in neuroleptic‐induced akathisia: a double‐blind randomized placebo‐controlled pilot study. Journal of Clinical Psychopharmacology2003;23(3):305‐8. [MEDLINE: 12826992] ">Poyurovsky 2003</a>, <a href="./references#CD011943-bbs2-0007" title="PoyurovskyM , PashinianA , WeizmanR , FuchsC , WeizmanA . Low‐dose mirtazapine: a new option in the treatment of antipsychotic‐induced akathisia. A randomized, double‐blind, placebo‐ and propranolol‐controlled trial. Biological Psychiatry2006;59(11):1071‐7. [MEDLINE: 16497273] ">Poyurovsky 2006</a>, and <a href="./references#CD011943-bbs2-0008" title="JoffeG . Efficacy of add‐on mirtazapine on clinical and neuropsychologic parameters in schizophrenic patients treated with conventional antipsychotics: a double‐blind, placebo‐controlled trial with an open‐label extension phase. isrctn.com/ISRCTN00721331. JoffeG . Mirtazapine for schizophrenia. Stanley Foundation Research Programs2009. JoffeG , TerevnikovV , JoffeM , StenbergJ‐H , BurkinM , TiihonenJ . Add‐on mirtazapine enhances antipsychotic effect of first generation antipsychotics in schizophrenia: a double‐blind, randomized, placebo‐controlled trial. Schizophrenia Research2009;108(1‐3):245‐51. [MEDLINE: 19144501] StenbergJ‐H , TerevnikovV , JoffeM , TiihonenJ , ChukhinE , BurkinM , et al. Predictors and mediators of add‐on mirtazapine‐induced cognitive enhancement in schizophrenia ‐ a path model investigation. Neuropharmacology2013;64:248‐53. StenbergJ‐H , TerevnikovV , JoffeM , TiihonenJ , TchoukhineE , BurkinM , et al. Effects of add‐on mirtazapine on neurocognition in schizophrenia ‐a double‐blind, randomized, placebo‐controlled study. Proceedings of the 15th Biennial Winter Workshop in Psychoses; 2009 Nov 15‐18; Barcelona, Spain. 2009. StenbergJ‐H , TerevnikovV , JoffeM , TiihonenJ , TchoukhineE , BurkinM , et al. More evidence on proneurocognitive effects of add‐on mirtazapine in schizophrenia. Progress in Neuro‐Psychopharmacology and Biological Psychiatry2011;35:1080‐6. StenbergJH , TerevnikovV , JoffeM , TiihonenJ , TchoukhineE , BurkinM , et al. Effects of add‐on mirtazapine on neurocognition in schizophrenia: A double‐blind, randomized, placebo‐controlled study. International Journal of Neuropsychopharmacology2010;13(4):433‐41. StenbergJH , TerevnikovV , JoffeM , TiihonenJ , TchoukhineE , BurkinM , et al. Effects of add‐on mirtazapine on neurocognition in schizophrenia: an open label extension phase of a double‐blind, randomized, placebo‐controlled study, and both phases. Schizophrenia Research2010;117(2‐3):377. TerevnikovV . Clinical effects of mirtazapine added to first generation antipsychotics in schizophrenia. Dissertation2013. TerevnikovV , StenbergJ H , TiihonenJ , ChukhinE , JoffeM , BurkinM , et al. Relationships between pharmacotherapy‐induced metabolic changes and improved psychopathology in schizophrenia: data from a mirtazapine and first‐generation antipsychotics combination trial. International Journal of Neuropsychopharmacology2013;16(7):1661‐6. TerevnikovV , StenbergJ‐H , TiihonenJ , JoffeM , BurkinM , TchoukhineE , et al. Add‐on mirtazapine improves depressive symptoms in schizophrenia: A double‐blind randomized placebo‐controlled study with an open‐label extension phase. Human Psychopharmacology2011;26(3):188‐93. TerevnikovV , StenbergJH , JoffeM , TiihonenJ , BurkinM , TchoukhineE , et al. More evidence on additive antipsychotic effect of adjunctive mirtazapine in schizophrenia: An extension phase of a randomized controlled trial. Human Psychopharmacology2010;25(6):431‐8. TerevnikovV , StenbergJH , TiihonenJ , BurkinM , JoffeG . Add‐on mirtazapine improves orgasmic functioning in patients with schizophrenia treated with first‐generation antipsychotics. Nordic Journal of Psychiatry2017;71(1):77‐80. TereynikovV , JoffeM , TiihonenJ , StenbergJ‐H , BurkinM , TchoukhineE , et al. More evidence on additive antipsychotic effect of adjunctive mirtazapine in schizophrenia: an extension phase of a randomized controlled trial. Proceedings of the 15th Biennial Winter Workshop in Psychoses; 2009 Nov 15‐18; Barcelona, Spain. 2009. ">Terevnikov 2013</a> randomised participants according to a table of random numbers. These four studies were deemed to be of low risk in the random sequence generation component of the selection bias appraisal. The remaining five studies did not report the specific method of randomisation, and were therefore deemed to be of unclear risk for random sequence generation. </p> <p>Only two studies reported allocation concealment. These were <a href="./references#CD011943-bbs2-0001" title="AbbasiSH , BehpourniaH , GhoreshiA , SalehiB , RaznahanM , RezazadehSA , et al. The effect of mirtazapine add on therapy to risperidone in the treatment of schizophrenia: A double‐blind randomized placebo‐controlled trial. Schizophrenia Research2010;116(2‐3):101‐6. [MEDLINE: 19959338] ">Abbasi 2010</a> and <a href="./references#CD011943-bbs2-0008" title="JoffeG . Efficacy of add‐on mirtazapine on clinical and neuropsychologic parameters in schizophrenic patients treated with conventional antipsychotics: a double‐blind, placebo‐controlled trial with an open‐label extension phase. isrctn.com/ISRCTN00721331. JoffeG . Mirtazapine for schizophrenia. Stanley Foundation Research Programs2009. JoffeG , TerevnikovV , JoffeM , StenbergJ‐H , BurkinM , TiihonenJ . Add‐on mirtazapine enhances antipsychotic effect of first generation antipsychotics in schizophrenia: a double‐blind, randomized, placebo‐controlled trial. Schizophrenia Research2009;108(1‐3):245‐51. [MEDLINE: 19144501] StenbergJ‐H , TerevnikovV , JoffeM , TiihonenJ , ChukhinE , BurkinM , et al. Predictors and mediators of add‐on mirtazapine‐induced cognitive enhancement in schizophrenia ‐ a path model investigation. Neuropharmacology2013;64:248‐53. StenbergJ‐H , TerevnikovV , JoffeM , TiihonenJ , TchoukhineE , BurkinM , et al. Effects of add‐on mirtazapine on neurocognition in schizophrenia ‐a double‐blind, randomized, placebo‐controlled study. Proceedings of the 15th Biennial Winter Workshop in Psychoses; 2009 Nov 15‐18; Barcelona, Spain. 2009. StenbergJ‐H , TerevnikovV , JoffeM , TiihonenJ , TchoukhineE , BurkinM , et al. More evidence on proneurocognitive effects of add‐on mirtazapine in schizophrenia. Progress in Neuro‐Psychopharmacology and Biological Psychiatry2011;35:1080‐6. StenbergJH , TerevnikovV , JoffeM , TiihonenJ , TchoukhineE , BurkinM , et al. Effects of add‐on mirtazapine on neurocognition in schizophrenia: A double‐blind, randomized, placebo‐controlled study. International Journal of Neuropsychopharmacology2010;13(4):433‐41. StenbergJH , TerevnikovV , JoffeM , TiihonenJ , TchoukhineE , BurkinM , et al. Effects of add‐on mirtazapine on neurocognition in schizophrenia: an open label extension phase of a double‐blind, randomized, placebo‐controlled study, and both phases. Schizophrenia Research2010;117(2‐3):377. TerevnikovV . Clinical effects of mirtazapine added to first generation antipsychotics in schizophrenia. Dissertation2013. TerevnikovV , StenbergJ H , TiihonenJ , ChukhinE , JoffeM , BurkinM , et al. Relationships between pharmacotherapy‐induced metabolic changes and improved psychopathology in schizophrenia: data from a mirtazapine and first‐generation antipsychotics combination trial. International Journal of Neuropsychopharmacology2013;16(7):1661‐6. TerevnikovV , StenbergJ‐H , TiihonenJ , JoffeM , BurkinM , TchoukhineE , et al. Add‐on mirtazapine improves depressive symptoms in schizophrenia: A double‐blind randomized placebo‐controlled study with an open‐label extension phase. Human Psychopharmacology2011;26(3):188‐93. TerevnikovV , StenbergJH , JoffeM , TiihonenJ , BurkinM , TchoukhineE , et al. More evidence on additive antipsychotic effect of adjunctive mirtazapine in schizophrenia: An extension phase of a randomized controlled trial. Human Psychopharmacology2010;25(6):431‐8. TerevnikovV , StenbergJH , TiihonenJ , BurkinM , JoffeG . Add‐on mirtazapine improves orgasmic functioning in patients with schizophrenia treated with first‐generation antipsychotics. Nordic Journal of Psychiatry2017;71(1):77‐80. TereynikovV , JoffeM , TiihonenJ , StenbergJ‐H , BurkinM , TchoukhineE , et al. More evidence on additive antipsychotic effect of adjunctive mirtazapine in schizophrenia: an extension phase of a randomized controlled trial. Proceedings of the 15th Biennial Winter Workshop in Psychoses; 2009 Nov 15‐18; Barcelona, Spain. 2009. ">Terevnikov 2013</a>, both of which utilised opaque envelopes to ensure allocation concealment and were given a low risk of bias in the allocation concealment component of the selection bias appraisal. The remaining seven studies did not describe allocation concealment and were therefore unclear risk. </p> </section> <section id="CD011943-sec-0140"> <h4 class="title">Blinding</h4> <p>All studies were stated to be double‐blind, and we considered it likely that though blinding of participants and personnel was not always fully described it is likely that all participants and personnel were blinded. Therefore, all nine trials were placed at low risk of performance bias. </p> <p>Only two studies, <a href="./references#CD011943-bbs2-0001" title="AbbasiSH , BehpourniaH , GhoreshiA , SalehiB , RaznahanM , RezazadehSA , et al. The effect of mirtazapine add on therapy to risperidone in the treatment of schizophrenia: A double‐blind randomized placebo‐controlled trial. Schizophrenia Research2010;116(2‐3):101‐6. [MEDLINE: 19959338] ">Abbasi 2010</a> and <a href="./references#CD011943-bbs2-0007" title="PoyurovskyM , PashinianA , WeizmanR , FuchsC , WeizmanA . Low‐dose mirtazapine: a new option in the treatment of antipsychotic‐induced akathisia. A randomized, double‐blind, placebo‐ and propranolol‐controlled trial. Biological Psychiatry2006;59(11):1071‐7. [MEDLINE: 16497273] ">Poyurovsky 2006</a>, described blinding of outcome assessors and were placed at low risk for detection bias. The remaining seven trials were therefore unclear risk for this domain. </p> </section> <section id="CD011943-sec-0141"> <h4 class="title">Incomplete outcome data</h4> <p>All studies reported how many participants were lost to follow‐up, and the reasons for attrition were, for the most part, clearly stated. Attrition rates did not exceed 50% of the sample size in any trial. </p> <p><a href="./references#CD011943-bbs2-0001" title="AbbasiSH , BehpourniaH , GhoreshiA , SalehiB , RaznahanM , RezazadehSA , et al. The effect of mirtazapine add on therapy to risperidone in the treatment of schizophrenia: A double‐blind randomized placebo‐controlled trial. Schizophrenia Research2010;116(2‐3):101‐6. [MEDLINE: 19959338] ">Abbasi 2010</a>, <a href="./references#CD011943-bbs2-0002" title="BerkM , IchimC , BrookS . Efficacy of mirtazapine add on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia: a double‐blind randomized placebo‐controlled study. Clinical Psychopharmacology2001;16(2):87‐92. [MEDLINE: 11236073] BerkM , IchimC , BrookS . Mirtazepine treatment of negative schizophrenia. Proceedings of the 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13‐18; Chicago, Illinois, USA. 2000. BerkM , IchimC , BrookS . Mirtazepine treatment of negative schizophrenia. Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. IchimC , BerkM , BrookS . Mirtazapine treatment of negative symptoms of schizophrenia: a double blind placebo controlled add on trial to treatment with haloperidol. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S112. ">Berk 2001</a>, <a href="./references#CD011943-bbs2-0006" title="PoyurovskyM . Mirtazapine for bipolar disorder and schizophrenia. Stanley Foundation Research Programs2009. PoyurovskyM , EpshteinS , FuchsC , SchneidmanM , WeizmanR , WeizmanA . Efficacy of low‐dose mirtazapine in neuroleptic‐induced akathisia: a double‐blind randomized placebo‐controlled pilot study. European Neuropsychopharmacology2002;12(Suppl. 3):S299. PoyurovskyM , EpshteinS , FuchsC , SchneidmanM , WeizmanR , WeizmanA . Efficacy of low‐dose mirtazapine in neuroleptic‐induced akathisia: a double‐blind randomized placebo‐controlled pilot study. Journal of Clinical Psychopharmacology2003;23(3):305‐8. [MEDLINE: 12826992] ">Poyurovsky 2003</a>, and <a href="./references#CD011943-bbs2-0007" title="PoyurovskyM , PashinianA , WeizmanR , FuchsC , WeizmanA . Low‐dose mirtazapine: a new option in the treatment of antipsychotic‐induced akathisia. A randomized, double‐blind, placebo‐ and propranolol‐controlled trial. Biological Psychiatry2006;59(11):1071‐7. [MEDLINE: 16497273] ">Poyurovsky 2006</a> used ITT analysis with last observation carried forward (LOCF). <a href="./references#CD011943-bbs2-0008" title="JoffeG . Efficacy of add‐on mirtazapine on clinical and neuropsychologic parameters in schizophrenic patients treated with conventional antipsychotics: a double‐blind, placebo‐controlled trial with an open‐label extension phase. isrctn.com/ISRCTN00721331. JoffeG . Mirtazapine for schizophrenia. Stanley Foundation Research Programs2009. JoffeG , TerevnikovV , JoffeM , StenbergJ‐H , BurkinM , TiihonenJ . Add‐on mirtazapine enhances antipsychotic effect of first generation antipsychotics in schizophrenia: a double‐blind, randomized, placebo‐controlled trial. Schizophrenia Research2009;108(1‐3):245‐51. [MEDLINE: 19144501] StenbergJ‐H , TerevnikovV , JoffeM , TiihonenJ , ChukhinE , BurkinM , et al. Predictors and mediators of add‐on mirtazapine‐induced cognitive enhancement in schizophrenia ‐ a path model investigation. Neuropharmacology2013;64:248‐53. StenbergJ‐H , TerevnikovV , JoffeM , TiihonenJ , TchoukhineE , BurkinM , et al. Effects of add‐on mirtazapine on neurocognition in schizophrenia ‐a double‐blind, randomized, placebo‐controlled study. Proceedings of the 15th Biennial Winter Workshop in Psychoses; 2009 Nov 15‐18; Barcelona, Spain. 2009. StenbergJ‐H , TerevnikovV , JoffeM , TiihonenJ , TchoukhineE , BurkinM , et al. More evidence on proneurocognitive effects of add‐on mirtazapine in schizophrenia. Progress in Neuro‐Psychopharmacology and Biological Psychiatry2011;35:1080‐6. StenbergJH , TerevnikovV , JoffeM , TiihonenJ , TchoukhineE , BurkinM , et al. Effects of add‐on mirtazapine on neurocognition in schizophrenia: A double‐blind, randomized, placebo‐controlled study. International Journal of Neuropsychopharmacology2010;13(4):433‐41. StenbergJH , TerevnikovV , JoffeM , TiihonenJ , TchoukhineE , BurkinM , et al. Effects of add‐on mirtazapine on neurocognition in schizophrenia: an open label extension phase of a double‐blind, randomized, placebo‐controlled study, and both phases. Schizophrenia Research2010;117(2‐3):377. TerevnikovV . Clinical effects of mirtazapine added to first generation antipsychotics in schizophrenia. Dissertation2013. TerevnikovV , StenbergJ H , TiihonenJ , ChukhinE , JoffeM , BurkinM , et al. Relationships between pharmacotherapy‐induced metabolic changes and improved psychopathology in schizophrenia: data from a mirtazapine and first‐generation antipsychotics combination trial. International Journal of Neuropsychopharmacology2013;16(7):1661‐6. TerevnikovV , StenbergJ‐H , TiihonenJ , JoffeM , BurkinM , TchoukhineE , et al. Add‐on mirtazapine improves depressive symptoms in schizophrenia: A double‐blind randomized placebo‐controlled study with an open‐label extension phase. Human Psychopharmacology2011;26(3):188‐93. TerevnikovV , StenbergJH , JoffeM , TiihonenJ , BurkinM , TchoukhineE , et al. More evidence on additive antipsychotic effect of adjunctive mirtazapine in schizophrenia: An extension phase of a randomized controlled trial. Human Psychopharmacology2010;25(6):431‐8. TerevnikovV , StenbergJH , TiihonenJ , BurkinM , JoffeG . Add‐on mirtazapine improves orgasmic functioning in patients with schizophrenia treated with first‐generation antipsychotics. Nordic Journal of Psychiatry2017;71(1):77‐80. TereynikovV , JoffeM , TiihonenJ , StenbergJ‐H , BurkinM , TchoukhineE , et al. More evidence on additive antipsychotic effect of adjunctive mirtazapine in schizophrenia: an extension phase of a randomized controlled trial. Proceedings of the 15th Biennial Winter Workshop in Psychoses; 2009 Nov 15‐18; Barcelona, Spain. 2009. ">Terevnikov 2013</a> used a modified ITT with LOCF whereby the study included a participant only when they had at least one on‐treatment measurement. <a href="./references#CD011943-bbs2-0004" title="BertolinoA . Placebo controlled randomized trial of augmentation of olanzapine treatment with mirtazapine in 30 patients with schizophrenia to ascertain possible effects on negative symptoms and working memory. Stanley Foundation Research Programs2002. CaforioG , DiGiorgioA , RampinoA , RizzoM , RomanoR , TaurisanoP , et al. Mirtazapine add‐on improves olanzapine effect on negative symptoms of schizophrenia. Journal of Clinical Psychopharmacology2013;33(6):810‐2. ">Caforio 2013</a> used mixed modelling for repeated measures analysis. Each of these six studies were placed at a low risk of attrition bias because the method of dealing with missing data was described, attrition rates did not exceed 50%, and the reasons for attrition were generally balanced between the mirtazapine and placebo groups. Three studies, <a href="./references#CD011943-bbs2-0003" title="BerkM , GamaCS , SundramS , HustigH , KoopowitzL , D'SouzaR , et al. Mirtazapine add‐on therapy in the treatment of schizophrenia with atypical antipsychotics: a double‐blind, randomised, placebo‐controlled clinical trial. Human Psychopharmacology2009;24(3):233‐8. [MEDLINE: 19330802] DoddS . Mirtazapine add‐on therapy in the treatment of schizophrenia with atypical neuroleptics: a double‐blind, randomised, placebo controlled trial. Australian New Zealand Clinical Trials Registry2004. DoddS , BerkM , D’SouzaR , HustigH , KoopowitzL , MonkhouseA , et al. Mirtazapine add‐on therapy in the treatment of schizophrenia with atypical antipsychotics: a double‐blind, randomised, placebo‐controlled clinical trial. International Journal of Neuropsychopharmacology2008;11(Suppl 1):139‐40. ">Berk 2009</a>, <a href="./references#CD011943-bbs2-0005" title="ChoSJ , YookK , KimB , ChoiTK , LeeKS , KimYW , et al. Mirtazapine augmentation enhances cognitive and reduces negative symptoms in schizophrenia patients treated with risperidone: A randomized controlled trial. Progress in Neuro‐Psychopharmacology &amp; Biological Psychiatry2011;35(1):208‐11. LeeJ , SungJC , KangSL , YookK , AhYC , LeeS , et al. The tolerability of mirtazapine augmentation in schizophrenic patients treated with risperidone: A preliminary randomized placebo‐controlled trial. Clinical Psychopharmacology and Neuroscience2011;9(2):73‐7. LeeSH . Mirtazapine augmentation enhances cognitive and negative symptoms in schizophrenic patients treated with risperidone: a randomised controlled trial. www.controlled‐trials.com2009. ">Cho 2011</a>, and <a href="./references#CD011943-bbs2-0009" title="ZoccaliR , MuscatelloMR , CedroC , NeriP , LaTorreD , SpinaE , et al. The effect of mirtazapine augmentation of clozapine in the treatment of negative symptoms of schizophrenia: a double‐blind, placebo‐controlled study. International Clinical Psychopharmacology2004;19(2):71‐6. [MEDLINE: 15076014] ZoccaliR , MuscatelloMR , TorreDL , MalaraG , CanaleA , CrucittiDDC , et al. Lack of a pharmacokinetic interaction between mirtazapine and the newer antipsychotics clozapine, risperidone and olanzapine in patients with chronic schizophrenia. Pharmacological Research2003;48(4):411‐4. ">Zoccali 2004</a>, only considered completers of the trials in their analyses and were placed at high risk for attrition bias. </p> </section> <section id="CD011943-sec-0142"> <h4 class="title">Selective reporting</h4> <p>Five of the included studies reported all their pre‐specified outcomes, which seemed to encompass most of the expected outcomes of interest (<a href="./references#CD011943-bbs2-0001" title="AbbasiSH , BehpourniaH , GhoreshiA , SalehiB , RaznahanM , RezazadehSA , et al. The effect of mirtazapine add on therapy to risperidone in the treatment of schizophrenia: A double‐blind randomized placebo‐controlled trial. Schizophrenia Research2010;116(2‐3):101‐6. [MEDLINE: 19959338] ">Abbasi 2010</a>; <a href="./references#CD011943-bbs2-0002" title="BerkM , IchimC , BrookS . Efficacy of mirtazapine add on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia: a double‐blind randomized placebo‐controlled study. Clinical Psychopharmacology2001;16(2):87‐92. [MEDLINE: 11236073] BerkM , IchimC , BrookS . Mirtazepine treatment of negative schizophrenia. Proceedings of the 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13‐18; Chicago, Illinois, USA. 2000. BerkM , IchimC , BrookS . Mirtazepine treatment of negative schizophrenia. Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. IchimC , BerkM , BrookS . Mirtazapine treatment of negative symptoms of schizophrenia: a double blind placebo controlled add on trial to treatment with haloperidol. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S112. ">Berk 2001</a>; <a href="./references#CD011943-bbs2-0004" title="BertolinoA . Placebo controlled randomized trial of augmentation of olanzapine treatment with mirtazapine in 30 patients with schizophrenia to ascertain possible effects on negative symptoms and working memory. Stanley Foundation Research Programs2002. CaforioG , DiGiorgioA , RampinoA , RizzoM , RomanoR , TaurisanoP , et al. Mirtazapine add‐on improves olanzapine effect on negative symptoms of schizophrenia. Journal of Clinical Psychopharmacology2013;33(6):810‐2. ">Caforio 2013</a>; <a href="./references#CD011943-bbs2-0007" title="PoyurovskyM , PashinianA , WeizmanR , FuchsC , WeizmanA . Low‐dose mirtazapine: a new option in the treatment of antipsychotic‐induced akathisia. A randomized, double‐blind, placebo‐ and propranolol‐controlled trial. Biological Psychiatry2006;59(11):1071‐7. [MEDLINE: 16497273] ">Poyurovsky 2006</a>; <a href="./references#CD011943-bbs2-0008" title="JoffeG . Efficacy of add‐on mirtazapine on clinical and neuropsychologic parameters in schizophrenic patients treated with conventional antipsychotics: a double‐blind, placebo‐controlled trial with an open‐label extension phase. isrctn.com/ISRCTN00721331. JoffeG . Mirtazapine for schizophrenia. Stanley Foundation Research Programs2009. JoffeG , TerevnikovV , JoffeM , StenbergJ‐H , BurkinM , TiihonenJ . Add‐on mirtazapine enhances antipsychotic effect of first generation antipsychotics in schizophrenia: a double‐blind, randomized, placebo‐controlled trial. Schizophrenia Research2009;108(1‐3):245‐51. [MEDLINE: 19144501] StenbergJ‐H , TerevnikovV , JoffeM , TiihonenJ , ChukhinE , BurkinM , et al. Predictors and mediators of add‐on mirtazapine‐induced cognitive enhancement in schizophrenia ‐ a path model investigation. Neuropharmacology2013;64:248‐53. StenbergJ‐H , TerevnikovV , JoffeM , TiihonenJ , TchoukhineE , BurkinM , et al. Effects of add‐on mirtazapine on neurocognition in schizophrenia ‐a double‐blind, randomized, placebo‐controlled study. Proceedings of the 15th Biennial Winter Workshop in Psychoses; 2009 Nov 15‐18; Barcelona, Spain. 2009. StenbergJ‐H , TerevnikovV , JoffeM , TiihonenJ , TchoukhineE , BurkinM , et al. More evidence on proneurocognitive effects of add‐on mirtazapine in schizophrenia. Progress in Neuro‐Psychopharmacology and Biological Psychiatry2011;35:1080‐6. StenbergJH , TerevnikovV , JoffeM , TiihonenJ , TchoukhineE , BurkinM , et al. Effects of add‐on mirtazapine on neurocognition in schizophrenia: A double‐blind, randomized, placebo‐controlled study. International Journal of Neuropsychopharmacology2010;13(4):433‐41. StenbergJH , TerevnikovV , JoffeM , TiihonenJ , TchoukhineE , BurkinM , et al. Effects of add‐on mirtazapine on neurocognition in schizophrenia: an open label extension phase of a double‐blind, randomized, placebo‐controlled study, and both phases. Schizophrenia Research2010;117(2‐3):377. TerevnikovV . Clinical effects of mirtazapine added to first generation antipsychotics in schizophrenia. Dissertation2013. TerevnikovV , StenbergJ H , TiihonenJ , ChukhinE , JoffeM , BurkinM , et al. Relationships between pharmacotherapy‐induced metabolic changes and improved psychopathology in schizophrenia: data from a mirtazapine and first‐generation antipsychotics combination trial. International Journal of Neuropsychopharmacology2013;16(7):1661‐6. TerevnikovV , StenbergJ‐H , TiihonenJ , JoffeM , BurkinM , TchoukhineE , et al. Add‐on mirtazapine improves depressive symptoms in schizophrenia: A double‐blind randomized placebo‐controlled study with an open‐label extension phase. Human Psychopharmacology2011;26(3):188‐93. TerevnikovV , StenbergJH , JoffeM , TiihonenJ , BurkinM , TchoukhineE , et al. More evidence on additive antipsychotic effect of adjunctive mirtazapine in schizophrenia: An extension phase of a randomized controlled trial. Human Psychopharmacology2010;25(6):431‐8. TerevnikovV , StenbergJH , TiihonenJ , BurkinM , JoffeG . Add‐on mirtazapine improves orgasmic functioning in patients with schizophrenia treated with first‐generation antipsychotics. Nordic Journal of Psychiatry2017;71(1):77‐80. TereynikovV , JoffeM , TiihonenJ , StenbergJ‐H , BurkinM , TchoukhineE , et al. More evidence on additive antipsychotic effect of adjunctive mirtazapine in schizophrenia: an extension phase of a randomized controlled trial. Proceedings of the 15th Biennial Winter Workshop in Psychoses; 2009 Nov 15‐18; Barcelona, Spain. 2009. ">Terevnikov 2013</a>). Protocols were not available for any of these five studies, so it was unclear whether there were additional pre‐specified outcomes. We therefore placed these studies at unclear risk of reporting bias. </p> <p>Four studies were determined to have high risk of reporting bias (<a href="./references#CD011943-bbs2-0003" title="BerkM , GamaCS , SundramS , HustigH , KoopowitzL , D'SouzaR , et al. Mirtazapine add‐on therapy in the treatment of schizophrenia with atypical antipsychotics: a double‐blind, randomised, placebo‐controlled clinical trial. Human Psychopharmacology2009;24(3):233‐8. [MEDLINE: 19330802] DoddS . Mirtazapine add‐on therapy in the treatment of schizophrenia with atypical neuroleptics: a double‐blind, randomised, placebo controlled trial. Australian New Zealand Clinical Trials Registry2004. DoddS , BerkM , D’SouzaR , HustigH , KoopowitzL , MonkhouseA , et al. Mirtazapine add‐on therapy in the treatment of schizophrenia with atypical antipsychotics: a double‐blind, randomised, placebo‐controlled clinical trial. International Journal of Neuropsychopharmacology2008;11(Suppl 1):139‐40. ">Berk 2009</a>; <a href="./references#CD011943-bbs2-0005" title="ChoSJ , YookK , KimB , ChoiTK , LeeKS , KimYW , et al. Mirtazapine augmentation enhances cognitive and reduces negative symptoms in schizophrenia patients treated with risperidone: A randomized controlled trial. Progress in Neuro‐Psychopharmacology &amp; Biological Psychiatry2011;35(1):208‐11. LeeJ , SungJC , KangSL , YookK , AhYC , LeeS , et al. The tolerability of mirtazapine augmentation in schizophrenic patients treated with risperidone: A preliminary randomized placebo‐controlled trial. Clinical Psychopharmacology and Neuroscience2011;9(2):73‐7. LeeSH . Mirtazapine augmentation enhances cognitive and negative symptoms in schizophrenic patients treated with risperidone: a randomised controlled trial. www.controlled‐trials.com2009. ">Cho 2011</a>; <a href="./references#CD011943-bbs2-0006" title="PoyurovskyM . Mirtazapine for bipolar disorder and schizophrenia. Stanley Foundation Research Programs2009. PoyurovskyM , EpshteinS , FuchsC , SchneidmanM , WeizmanR , WeizmanA . Efficacy of low‐dose mirtazapine in neuroleptic‐induced akathisia: a double‐blind randomized placebo‐controlled pilot study. European Neuropsychopharmacology2002;12(Suppl. 3):S299. PoyurovskyM , EpshteinS , FuchsC , SchneidmanM , WeizmanR , WeizmanA . Efficacy of low‐dose mirtazapine in neuroleptic‐induced akathisia: a double‐blind randomized placebo‐controlled pilot study. Journal of Clinical Psychopharmacology2003;23(3):305‐8. [MEDLINE: 12826992] ">Poyurovsky 2003</a>; <a href="./references#CD011943-bbs2-0009" title="ZoccaliR , MuscatelloMR , CedroC , NeriP , LaTorreD , SpinaE , et al. The effect of mirtazapine augmentation of clozapine in the treatment of negative symptoms of schizophrenia: a double‐blind, placebo‐controlled study. International Clinical Psychopharmacology2004;19(2):71‐6. [MEDLINE: 15076014] ZoccaliR , MuscatelloMR , TorreDL , MalaraG , CanaleA , CrucittiDDC , et al. Lack of a pharmacokinetic interaction between mirtazapine and the newer antipsychotics clozapine, risperidone and olanzapine in patients with chronic schizophrenia. Pharmacological Research2003;48(4):411‐4. ">Zoccali 2004</a>). <a href="./references#CD011943-bbs2-0003" title="BerkM , GamaCS , SundramS , HustigH , KoopowitzL , D'SouzaR , et al. Mirtazapine add‐on therapy in the treatment of schizophrenia with atypical antipsychotics: a double‐blind, randomised, placebo‐controlled clinical trial. Human Psychopharmacology2009;24(3):233‐8. [MEDLINE: 19330802] DoddS . Mirtazapine add‐on therapy in the treatment of schizophrenia with atypical neuroleptics: a double‐blind, randomised, placebo controlled trial. Australian New Zealand Clinical Trials Registry2004. DoddS , BerkM , D’SouzaR , HustigH , KoopowitzL , MonkhouseA , et al. Mirtazapine add‐on therapy in the treatment of schizophrenia with atypical antipsychotics: a double‐blind, randomised, placebo‐controlled clinical trial. International Journal of Neuropsychopharmacology2008;11(Suppl 1):139‐40. ">Berk 2009</a> did not report the full global impression scale it pre‐specified in the methods. <a href="./references#CD011943-bbs2-0005" title="ChoSJ , YookK , KimB , ChoiTK , LeeKS , KimYW , et al. Mirtazapine augmentation enhances cognitive and reduces negative symptoms in schizophrenia patients treated with risperidone: A randomized controlled trial. Progress in Neuro‐Psychopharmacology &amp; Biological Psychiatry2011;35(1):208‐11. LeeJ , SungJC , KangSL , YookK , AhYC , LeeS , et al. The tolerability of mirtazapine augmentation in schizophrenic patients treated with risperidone: A preliminary randomized placebo‐controlled trial. Clinical Psychopharmacology and Neuroscience2011;9(2):73‐7. LeeSH . Mirtazapine augmentation enhances cognitive and negative symptoms in schizophrenic patients treated with risperidone: a randomised controlled trial. www.controlled‐trials.com2009. ">Cho 2011</a> did not report outcomes of cognitive function in their entirety as described in the methods. <a href="./references#CD011943-bbs2-0006" title="PoyurovskyM . Mirtazapine for bipolar disorder and schizophrenia. Stanley Foundation Research Programs2009. PoyurovskyM , EpshteinS , FuchsC , SchneidmanM , WeizmanR , WeizmanA . Efficacy of low‐dose mirtazapine in neuroleptic‐induced akathisia: a double‐blind randomized placebo‐controlled pilot study. European Neuropsychopharmacology2002;12(Suppl. 3):S299. PoyurovskyM , EpshteinS , FuchsC , SchneidmanM , WeizmanR , WeizmanA . Efficacy of low‐dose mirtazapine in neuroleptic‐induced akathisia: a double‐blind randomized placebo‐controlled pilot study. Journal of Clinical Psychopharmacology2003;23(3):305‐8. [MEDLINE: 12826992] ">Poyurovsky 2003</a> included both an ITT and a non ITT analysis, but neglected to report most of the data from the ITT analysis. <a href="./references#CD011943-bbs2-0009" title="ZoccaliR , MuscatelloMR , CedroC , NeriP , LaTorreD , SpinaE , et al. The effect of mirtazapine augmentation of clozapine in the treatment of negative symptoms of schizophrenia: a double‐blind, placebo‐controlled study. International Clinical Psychopharmacology2004;19(2):71‐6. [MEDLINE: 15076014] ZoccaliR , MuscatelloMR , TorreDL , MalaraG , CanaleA , CrucittiDDC , et al. Lack of a pharmacokinetic interaction between mirtazapine and the newer antipsychotics clozapine, risperidone and olanzapine in patients with chronic schizophrenia. Pharmacological Research2003;48(4):411‐4. ">Zoccali 2004</a> measured depressive symptoms at baseline using the HAM‐D scale, but only reported the depressive subscale of the BPRS scale at endpoint. </p> </section> <section id="CD011943-sec-0143"> <h4 class="title">Other potential sources of bias</h4> <p>Three trials were identified to have either received funding from the pharmaceutical industry or have been co‐authored by researchers who report financial conflicts of interest (<a href="./references#CD011943-bbs2-0003" title="BerkM , GamaCS , SundramS , HustigH , KoopowitzL , D'SouzaR , et al. Mirtazapine add‐on therapy in the treatment of schizophrenia with atypical antipsychotics: a double‐blind, randomised, placebo‐controlled clinical trial. Human Psychopharmacology2009;24(3):233‐8. [MEDLINE: 19330802] DoddS . Mirtazapine add‐on therapy in the treatment of schizophrenia with atypical neuroleptics: a double‐blind, randomised, placebo controlled trial. Australian New Zealand Clinical Trials Registry2004. DoddS , BerkM , D’SouzaR , HustigH , KoopowitzL , MonkhouseA , et al. Mirtazapine add‐on therapy in the treatment of schizophrenia with atypical antipsychotics: a double‐blind, randomised, placebo‐controlled clinical trial. International Journal of Neuropsychopharmacology2008;11(Suppl 1):139‐40. ">Berk 2009</a>; <a href="./references#CD011943-bbs2-0004" title="BertolinoA . Placebo controlled randomized trial of augmentation of olanzapine treatment with mirtazapine in 30 patients with schizophrenia to ascertain possible effects on negative symptoms and working memory. Stanley Foundation Research Programs2002. CaforioG , DiGiorgioA , RampinoA , RizzoM , RomanoR , TaurisanoP , et al. Mirtazapine add‐on improves olanzapine effect on negative symptoms of schizophrenia. Journal of Clinical Psychopharmacology2013;33(6):810‐2. ">Caforio 2013</a>; <a href="./references#CD011943-bbs2-0008" title="JoffeG . Efficacy of add‐on mirtazapine on clinical and neuropsychologic parameters in schizophrenic patients treated with conventional antipsychotics: a double‐blind, placebo‐controlled trial with an open‐label extension phase. isrctn.com/ISRCTN00721331. JoffeG . Mirtazapine for schizophrenia. Stanley Foundation Research Programs2009. JoffeG , TerevnikovV , JoffeM , StenbergJ‐H , BurkinM , TiihonenJ . Add‐on mirtazapine enhances antipsychotic effect of first generation antipsychotics in schizophrenia: a double‐blind, randomized, placebo‐controlled trial. Schizophrenia Research2009;108(1‐3):245‐51. [MEDLINE: 19144501] StenbergJ‐H , TerevnikovV , JoffeM , TiihonenJ , ChukhinE , BurkinM , et al. Predictors and mediators of add‐on mirtazapine‐induced cognitive enhancement in schizophrenia ‐ a path model investigation. Neuropharmacology2013;64:248‐53. StenbergJ‐H , TerevnikovV , JoffeM , TiihonenJ , TchoukhineE , BurkinM , et al. Effects of add‐on mirtazapine on neurocognition in schizophrenia ‐a double‐blind, randomized, placebo‐controlled study. Proceedings of the 15th Biennial Winter Workshop in Psychoses; 2009 Nov 15‐18; Barcelona, Spain. 2009. StenbergJ‐H , TerevnikovV , JoffeM , TiihonenJ , TchoukhineE , BurkinM , et al. More evidence on proneurocognitive effects of add‐on mirtazapine in schizophrenia. Progress in Neuro‐Psychopharmacology and Biological Psychiatry2011;35:1080‐6. StenbergJH , TerevnikovV , JoffeM , TiihonenJ , TchoukhineE , BurkinM , et al. Effects of add‐on mirtazapine on neurocognition in schizophrenia: A double‐blind, randomized, placebo‐controlled study. International Journal of Neuropsychopharmacology2010;13(4):433‐41. StenbergJH , TerevnikovV , JoffeM , TiihonenJ , TchoukhineE , BurkinM , et al. Effects of add‐on mirtazapine on neurocognition in schizophrenia: an open label extension phase of a double‐blind, randomized, placebo‐controlled study, and both phases. Schizophrenia Research2010;117(2‐3):377. TerevnikovV . Clinical effects of mirtazapine added to first generation antipsychotics in schizophrenia. Dissertation2013. TerevnikovV , StenbergJ H , TiihonenJ , ChukhinE , JoffeM , BurkinM , et al. Relationships between pharmacotherapy‐induced metabolic changes and improved psychopathology in schizophrenia: data from a mirtazapine and first‐generation antipsychotics combination trial. International Journal of Neuropsychopharmacology2013;16(7):1661‐6. TerevnikovV , StenbergJ‐H , TiihonenJ , JoffeM , BurkinM , TchoukhineE , et al. Add‐on mirtazapine improves depressive symptoms in schizophrenia: A double‐blind randomized placebo‐controlled study with an open‐label extension phase. Human Psychopharmacology2011;26(3):188‐93. TerevnikovV , StenbergJH , JoffeM , TiihonenJ , BurkinM , TchoukhineE , et al. More evidence on additive antipsychotic effect of adjunctive mirtazapine in schizophrenia: An extension phase of a randomized controlled trial. Human Psychopharmacology2010;25(6):431‐8. TerevnikovV , StenbergJH , TiihonenJ , BurkinM , JoffeG . Add‐on mirtazapine improves orgasmic functioning in patients with schizophrenia treated with first‐generation antipsychotics. Nordic Journal of Psychiatry2017;71(1):77‐80. TereynikovV , JoffeM , TiihonenJ , StenbergJ‐H , BurkinM , TchoukhineE , et al. More evidence on additive antipsychotic effect of adjunctive mirtazapine in schizophrenia: an extension phase of a randomized controlled trial. Proceedings of the 15th Biennial Winter Workshop in Psychoses; 2009 Nov 15‐18; Barcelona, Spain. 2009. ">Terevnikov 2013</a>). The other six trials were not clearly free from bias and were therefore attributed an unclear risk of bias from other potential sources. </p> </section> </section> <section id="CD011943-sec-0144"> <h3 class="title" id="CD011943-sec-0144">Effects of interventions</h3> <p>See: <a href="./full#CD011943-tbl-0001"><b>Summary of findings for the main comparison</b> Mirtazapine adjunct versus placebo adjunct</a> </p> <section id="CD011943-sec-0145"> <h4 class="title">1. COMPARISON 1: Mirtazapine adjunct versus placebo adjunct ‐ short term</h4> <p>Studies relevant to this review fall into a single comparison. We identified nine randomised trials from which it was possible to extract numerical data. The trails reported useable data for 15 outcomes and unusable data for nine outcomes. </p> <section id="CD011943-sec-0146"> <h5 class="title">1.1 Mental state: specific ‐ 1a. Negative symptoms: clinically important change</h5> <section id="CD011943-sec-0147"> <h6 class="title">1.1.1 No important response (reduction in SANS overall score from baseline of at least 20%) </h6> <p>One trial (n = 20) defined a reduction in SANS overall score from baseline of at least 20% as no important response for negative symptoms. There was no evidence of a clear difference between the two treatments with similar numbers of participants from each group showing no important response to treatment (risk ratio (RR) 0.81, 95% confidence interval (CI) 0.57 to 1.14, very low‐quality evidence; <a href="./references#CD011943-fig-0004" title="">Analysis 1.1</a>). </p> </section> </section> <section id="CD011943-sec-0148"> <h5 class="title">1.2 Mental state: specific. 1b. Negative symptoms: average endpoint score (various scales) </h5> <section id="CD011943-sec-0149"> <h6 class="title">1.2.1 PANSS negative (high = poor)</h6> <p>Four trials (total n = 130) reported average endpoint PANSS negative scores. There was a clear difference in scores, favouring the mirtazapine adjunct group (mean difference (MD) ‐2.65, 95% CI ‐4.45 to ‐0.84; <a href="./references#CD011943-fig-0005" title="">Analysis 1.2</a>). </p> </section> <section id="CD011943-sec-0150"> <h6 class="title">1.2.2 SANS (high = poor)</h6> <p>Two trials, which included a total of 40 participants reported endpoint SANS scores. There was a clear difference in scores, favouring the mirtazapine adjunct group (MD ‐15.04, 95% CI ‐20.06 to ‐10.01; <a href="./references#CD011943-fig-0005" title="">Analysis 1.2</a>). </p> </section> </section> <section id="CD011943-sec-0151"> <h5 class="title">1.3 Mental state: specific. 1c. Negative symptoms: average endpoint score (PANSS negative, high = poor) ‐ skewed data </h5> <p><a href="./references#CD011943-bbs2-0002" title="BerkM , IchimC , BrookS . Efficacy of mirtazapine add on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia: a double‐blind randomized placebo‐controlled study. Clinical Psychopharmacology2001;16(2):87‐92. [MEDLINE: 11236073] BerkM , IchimC , BrookS . Mirtazepine treatment of negative schizophrenia. Proceedings of the 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13‐18; Chicago, Illinois, USA. 2000. BerkM , IchimC , BrookS . Mirtazepine treatment of negative schizophrenia. Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. IchimC , BerkM , BrookS . Mirtazapine treatment of negative symptoms of schizophrenia: a double blind placebo controlled add on trial to treatment with haloperidol. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S112. ">Berk 2001</a> and <a href="./references#CD011943-bbs2-0004" title="BertolinoA . Placebo controlled randomized trial of augmentation of olanzapine treatment with mirtazapine in 30 patients with schizophrenia to ascertain possible effects on negative symptoms and working memory. Stanley Foundation Research Programs2002. CaforioG , DiGiorgioA , RampinoA , RizzoM , RomanoR , TaurisanoP , et al. Mirtazapine add‐on improves olanzapine effect on negative symptoms of schizophrenia. Journal of Clinical Psychopharmacology2013;33(6):810‐2. ">Caforio 2013</a> also reported mental state scale data for negative symptoms. However, these continuous data were too skewed to enter into analyses and are presented as 'other data' (<a href="./references#CD011943-fig-0006" title="">Analysis 1.3</a>). </p> </section> <section id="CD011943-sec-0152"> <h5 class="title">1.4. Mental state: specific. 2a. Positive symptoms: average endpoint score (PANSS positive, high = poor) </h5> <p>One trial, (total n = 20), reported data for positive symptoms using the PANSS positive subscale. There was no evidence of a difference between mirtazapine adjunct and placebo for this outcome (MD ‐2.20, 95% CI ‐5.29 to 0.89; <a href="./references#CD011943-fig-0007" title="">Analysis 1.4</a>) </p> </section> <section id="CD011943-sec-0153"> <h5 class="title">1.5 Mental state: specific. 2b. Positive symptoms: average endpoint score (various scales) ‐ skewed data </h5> <p>Six trials also reported on positive symptoms using various mental state scales. However, these continuous data were too skewed to enter into analyses and are presented as 'other data' (<a href="./references#CD011943-fig-0008" title="">Analysis 1.5</a>). </p> </section> <section id="CD011943-sec-0154"> <h5 class="title">1.6 Mental state: overall. 3a. Clinically important change (at least 20 % change PANSS)</h5> <section id="CD011943-sec-0155"> <h6 class="title">1.6.1 No important response</h6> <p>Two trials (n = 77) reported no important response for overall mental state. There was evidence for this outcome, that more people in the placebo group showed no real response compared to those receiving mirtazapine adjunct (RR 0.69, 95% CI 0.51 to 0.92, very low‐quality evidence; <a href="./references#CD011943-fig-0009" title="">Analysis 1.6</a>). Heterogenity was high I<sup>2</sup> = 75%, </p> </section> </section> <section id="CD011943-sec-0156"> <h5 class="title">1.7 Mental state: overall 3b. Average endpoint score (various scales)</h5> <section id="CD011943-sec-0157"> <h6 class="title">1.7.1 PANSS (high = poor)</h6> <p>Six trials (n = 170) reported overall PANSS endpoints scores. There was evidence of clear difference between mirtazapine and placebo groups, that favoured mirtazapine adjunct for this outcome (MD ‐3.84, 95% CI ‐7.89 to 0.21; <a href="./references#CD011943-fig-0010" title="">Analysis 1.7</a>). There were important levels of heterogeneity (I<sup>2</sup> = 62%). </p> </section> <section id="CD011943-sec-0158"> <h6 class="title">1.7.2 BPRS (high = poor)</h6> <p>One trial (n = 20) reported BPRS endpoint scores. These data also showed a clear difference in scores, that favoured the mirtazapine adjunct group (MD ‐19.30, 95% CI ‐22.10 to ‐16.50; <a href="./references#CD011943-fig-0010" title="">Analysis 1.7</a>). </p> </section> </section> <section id="CD011943-sec-0159"> <h5 class="title">1.8 Mental state: overall. 3c. Average change scores (various scales) ‐ skewed data</h5> <p>Two trials reported change score from various mental state scales. However these continuous data were skewed and could not be used in analyses. They are presented as Other data (<a href="./references#CD011943-fig-0011" title="">Analysis 1.8</a>). </p> </section> <section id="CD011943-sec-0160"> <h5 class="title">1.9 Mental state: specific. 4a. Depressive symptoms: average endpoint score (HAM‐D, high = poor) </h5> <p>Two trials (total n = 53) reported useable endpoint HAM‐D scores. There was no evidence of a clear difference between the two treatment groups (MD 1.51, 95% CI ‐1.72 to 4.74; <a href="./references#CD011943-fig-0012" title="">Analysis 1.9</a>). </p> </section> <section id="CD011943-sec-0161"> <h5 class="title">1.10 Mental state: specific. 4b. Depressive symptoms: average change scores (various scales) ‐ skewed data </h5> <p>Five trials reported change scores from various depressive symptom scales. However these continuous data were skewed and could not be used in analyses. They are presented as Other data (<a href="./references#CD011943-fig-0013" title="">Analysis 1.10</a>). </p> </section> <section id="CD011943-sec-0162"> <h5 class="title">1.11 Leaving the study early for any reason</h5> <p>Nine studies, involving 310 participants reported useable data for this outcome. There was no evidence of a clear difference between the two treatment groups for numbers of participants leaving the study early (RR 1.03, 95% CI 0.64 to 1.66, moderate‐quality evidence; <a href="./references#CD011943-fig-0014" title="">Analysis 1.11</a>). </p> </section> <section id="CD011943-sec-0163"> <h5 class="title">1.12 Global state: 1a. Average endpoint score (CGI severity, high = poor)</h5> <p>One study with a total of 39 people reported useable data for this outcome. There was no evidence of a clear difference in scores between mirtazapine adjunct and placebo groups (MD ‐0.10, 95% CI ‐0.68 to 0.48, very low‐quality evidence; <a href="./references#CD011943-fig-0015" title="">Analysis 1.12</a>). </p> </section> <section id="CD011943-sec-0164"> <h5 class="title">1.13 Global state: 1b. Average change score (PGI, high = poor)</h5> <p>For this outcome a single study, with a total of 39 people reported useable data. There was a clear difference in scores, favouring the mirtazapine adjunct group (MD ‐0.54, 95% CI ‐0.97 to ‐0.11; <a href="./references#CD011943-fig-0016" title="">Analysis 1.13</a>). </p> </section> <section id="CD011943-sec-0165"> <h5 class="title">1.14 Global state: 1c. Average change score (various scales, skewed data)</h5> <p>Two trials reported change scores from various global state scales. However these continuous data were skewed and could not be used in analyses. They are presented as Other data (<a href="./references#CD011943-fig-0017" title="">Analysis 1.14</a>). </p> </section> <section id="CD011943-sec-0166"> <h5 class="title">1.15 Cognitive functioning: other data</h5> <p>Three RCTs reported outcomes of cognitive function. Because these data are in heterogeneous formats and involve different scales we could not conduct a meta‐analysis and therefore reported these data as Other data (<a href="./references#CD011943-fig-0018" title="">Analysis 1.15</a>). </p> </section> <section id="CD011943-sec-0167"> <h5 class="title">1.16 Adverse events: 1a. General (participants with at least one adverse event)</h5> <p>Two relevant studies (total n = 71) reported useable data for this outcome . There was not a clear difference in number of participants experiencing at least one adverse event between the mirtazapine adjunct and placebo groups (RR 0.96, 95% CI 0.81 to 1.12; <a href="./references#CD011943-fig-0019" title="">Analysis 1.16</a>). </p> </section> <section id="CD011943-sec-0168"> <h5 class="title">1.17 Adverse events: 1b. General (total number of adverse events) ‐ count data</h5> <p>Count data for number of events presented and exceeded number of participants (<a href="./references#CD011943-fig-0020" title="">Analysis 1.17</a>). </p> </section> <section id="CD011943-sec-0169"> <h5 class="title">1.18 Adverse effects: 2a. Extrapyramidal: clinically important change akathisia</h5> <section id="CD011943-sec-0170"> <h6 class="title">1.18.1 No clinically important response (reduction by at least 2 on BAS)</h6> <p>Two trials, with a total of 86 people reported clinically important change in the extrapyramidal side effect, akathisia. There was a clear difference between the groups with more participants showing no response in the placebo group compared to mirtazapine adjunct group (RR 0.33, 95% CI 0.2 to 0.52, low‐quality evidence; <a href="./references#CD011943-fig-0021" title="">Analysis 1.18</a>). This outcome had important levels of heterogeneity (Chi<sup>2</sup> = 2.55; df = 1.0; P = 0.11; I<sup>2</sup> = 61%). </p> </section> </section> <section id="CD011943-sec-0171"> <h5 class="title">1.19 Adverse effects: 2b. Extrapyramidal ‐ full resolution of akathisia</h5> <p>A single study involving 26 participants reported number of participants showing full resolution of akathisia. There was no clear difference between the treatment groups for this outcome (RR 11.00, 95% CI 0.67 to 180.65; <a href="./references#CD011943-fig-0022" title="">Analysis 1.19</a>). </p> </section> <section id="CD011943-sec-0172"> <h5 class="title">1.20 Adverse effects: 2c. Extrapyramidal ‐ specific events</h5> <section id="CD011943-sec-0173"> <h6 class="title">1.20.1 Parkinsonism</h6> <p>One trial (total n = 30) reported useable data for this outcome. There was no evidence of a clear difference between the two treatments (RR 0.60, 95% CI 0.29 to 1.23; <a href="./references#CD011943-fig-0023" title="">Analysis 1.20</a>). </p> </section> <section id="CD011943-sec-0174"> <h6 class="title">1.20.2 Akathisia</h6> <p>One trial (total n = 30) reported useable data for this outcome. There was no evidence of a clear difference between the two treatments (RR 0.14, 95% CI 0.01 to 2.55; <a href="./references#CD011943-fig-0023" title="">Analysis 1.20</a>). </p> </section> <section id="CD011943-sec-0175"> <h6 class="title">1.20.3 Dystonia</h6> <p>One trial (total n = 30) reported useable data for this outcome. There was no evidence of a clear difference between the two treatments (RR 0.33, 95% CI 0.01 to 7.58; <a href="./references#CD011943-fig-0023" title="">Analysis 1.20</a>). </p> </section> <section id="CD011943-sec-0176"> <h6 class="title">1.20.4 Additional anticholinergic drug use</h6> <p>One trial (total n = 30) reported useable data for this outcome. More participants in the placebo group required additional anticholinergic medication (RR 0.46, 95% CI 0.24 to 0.88; <a href="./references#CD011943-fig-0023" title="">Analysis 1.20</a>). </p> </section> <section id="CD011943-sec-0177"> <h6 class="title">1.20.5 Tremor</h6> <p>One trial (total n = 38) reported useable data for this outcome. There was no evidence of a clear difference between the two treatments (RR 1.00, 95% CI 0.16 to 6.38; <a href="./references#CD011943-fig-0023" title="">Analysis 1.20</a>). </p> </section> </section> <section id="CD011943-sec-0178"> <h5 class="title">1.21 Adverse effects: 2d. Extrapyramidal: average change score (various scales)</h5> <section id="CD011943-sec-0179"> <h6 class="title">1.21.1 SAS, high = poor</h6> <p>One trial (total n = 60) reported useable data for this outcome. There was no evidence of a clear difference between the two treatments (MD ‐0.27, 95% CI ‐1.97 to 1.43; <a href="./references#CD011943-fig-0024" title="">Analysis 1.21</a>). </p> </section> <section id="CD011943-sec-0180"> <h6 class="title">1.21.2 BAS, high = poor</h6> <p>One trial (total n = 60) reported useable data for this outcome. There was no evidence of a clear difference between the two treatments (MD ‐0.03, 95% CI ‐0.69 to 0.63; <a href="./references#CD011943-fig-0024" title="">Analysis 1.21</a>). </p> </section> </section> <section id="CD011943-sec-0181"> <h5 class="title">1.22 Adverse effects: 2e. Extrapyramidal: average endpoint score (various scales) ‐ skewed data </h5> <p>We were unable to use continuous data from four trials for this outcome. We, therefore, report these data in a Other data table (<a href="./references#CD011943-fig-0025" title="">Analysis 1.22</a>). </p> </section> <section id="CD011943-sec-0182"> <h5 class="title">1.23 Adverse effects: 2f. Extrapyramidal: treatment details ‐ skewed data</h5> <p>One trial reported data for this outcome. However these data were skewed and could not be used in analyses. They are presented as Other data (<a href="./references#CD011943-fig-0026" title="">Analysis 1.23</a>). </p> </section> <section id="CD011943-sec-0183"> <h5 class="title">1.24 Adverse effects: 3. Other specific effects</h5> <section id="CD011943-sec-0184"> <h6 class="title">1.24.1 Weight gain</h6> <p>Four trials, which included a total of 127 participants reported useable data for this outcome. We did find evidence that more people in the mirtazapine group experienced weight gain than in the placebo group (RR 3.19, 95% CI 1.17 to 8.65; <a href="./references#CD011943-fig-0027" title="">Analysis 1.24</a>). </p> </section> <section id="CD011943-sec-0185"> <h6 class="title">1.24.2 Headache</h6> <p>Four trials (total n = 157) reported useable data for this outcome. There was no evidence of a difference between the two treatment groups (RR 1.44, 95% CI 0.54 to 3.82; <a href="./references#CD011943-fig-0027" title="">Analysis 1.24</a>). </p> </section> <section id="CD011943-sec-0186"> <h6 class="title">1.24.3 Sedation/drowsiness</h6> <p>Seven trials reported useable data for this outcome (total n = 223). We found evidence of a clear difference, favouring placebo (RR 1.64, 95% CI 1.01 to 6.28; <a href="./references#CD011943-fig-0027" title="">Analysis 1.24</a>). </p> </section> <section id="CD011943-sec-0187"> <h6 class="title">1.24.4 Increased appetite</h6> <p>Two trials (total n = 77) reported useable data for this outcome. There was no evidence of a clear difference between the two treatments (RR 2.57, 95% CI 0.66 to 10.07; <a href="./references#CD011943-fig-0027" title="">Analysis 1.24</a>). </p> </section> <section id="CD011943-sec-0188"> <h6 class="title">1.24.5 Weakness</h6> <p>One trial (total n = 39) reported useable data for this outcome. There was no evidence of a clear difference between the two treatments (RR 2.86, 95% CI 0.12 to 66.11; <a href="./references#CD011943-fig-0027" title="">Analysis 1.24</a>). </p> </section> <section id="CD011943-sec-0189"> <h6 class="title">1.24.6 Hypersedimentaiton</h6> <p>One trial (total n = 39) reported useable data for this outcome. There was no evidence of a clear difference between the two treatments (RR 2.86, 95% CI 0.12 to 66.11; <a href="./references#CD011943-fig-0027" title="">Analysis 1.24</a>). </p> </section> <section id="CD011943-sec-0190"> <h6 class="title">1.24.7 Arrythmia/palpitations</h6> <p>One trial (total n = 60) reported useable data for this outcome. There was no evidence of a clear difference between the two treatments (RR 1.00, 95% CI 0.15 to 6.64; <a href="./references#CD011943-fig-0027" title="">Analysis 1.24</a>). </p> </section> <section id="CD011943-sec-0191"> <h6 class="title">1.24.8 Uterine myoma</h6> <p>One trial (total n = 39) reported useable data for this outcome. There was no evidence of a clear difference between the two treatments (RR 2.86, 95% CI 0.12 to 66.11; <a href="./references#CD011943-fig-0027" title="">Analysis 1.24</a>). </p> </section> <section id="CD011943-sec-0192"> <h6 class="title">1.24.9 Dizziness</h6> <p>Three trials (total n = 137) reported useable data for this outcome. There was no evidence of a clear difference between the two treatments (RR 2.32, 95% CI 0.83 to 6.51; <a href="./references#CD011943-fig-0027" title="">Analysis 1.24</a>). </p> </section> <section id="CD011943-sec-0193"> <h6 class="title">1.24.10 Collapse</h6> <p>One trial (total n = 39) reported useable data for this outcome. There was no evidence of a clear difference between the two treatments (RR 0.32, 95% CI 0.01 to 7.35; <a href="./references#CD011943-fig-0027" title="">Analysis 1.24</a>). </p> </section> <section id="CD011943-sec-0194"> <h6 class="title">1.24.11 Acute Respiratory Distress Syndrome</h6> <p>One trial (total n = 39) reported useable data for this outcome. There was no evidence of a clear difference between the two treatments (RR 0.32, 95% CI 0.01 to 7.35; <a href="./references#CD011943-fig-0027" title="">Analysis 1.24</a>). </p> </section> <section id="CD011943-sec-0195"> <h6 class="title">1.24.12 Nausea</h6> <p>Two trials (total n = 77) reported useable data for this outcome. There was no evidence of a clear difference between the two treatments (RR 1.55, 95% CI 0.45 to 5.41; <a href="./references#CD011943-fig-0027" title="">Analysis 1.24</a>). </p> </section> <section id="CD011943-sec-0196"> <h6 class="title">1.24.13 Agitation</h6> <p>Two trials (total n = 77) reported useable data for this outcome. There was no evidence of a clear difference between the two treatments (RR 0.70, 95% CI 0.15 to 3.32; <a href="./references#CD011943-fig-0027" title="">Analysis 1.24</a>). </p> </section> <section id="CD011943-sec-0197"> <h6 class="title">1.24.14 Sleep disturbance</h6> <p>Two trials (total n = 77) reported useable data for this outcome. There was no evidence of a clear difference between the two treatments (RR 0.20, 95% CI 0.02 to 1.61; <a href="./references#CD011943-fig-0027" title="">Analysis 1.24</a>). </p> </section> <section id="CD011943-sec-0198"> <h6 class="title">1.24.15 Dry mouth</h6> <p>Two trials (total n = 98) reported useable data for this outcome. There was no evidence of a clear difference between the two treatments (RR 2.25, 95% CI 0.74 to 6.81; <a href="./references#CD011943-fig-0027" title="">Analysis 1.24</a>). </p> </section> <section id="CD011943-sec-0199"> <h6 class="title">1.24.16 Blurred vision</h6> <p>One trial (total n = 60) reported useable data for this outcome. There was no evidence of a clear difference between the two treatments (RR 1.33, 95% CI 0.33 to 5.45; <a href="./references#CD011943-fig-0027" title="">Analysis 1.24</a>). </p> </section> <section id="CD011943-sec-0200"> <h6 class="title">1.24.17 Conjunctivitis</h6> <p>One trial (total n = 39) reported useable data for this outcome. There was no evidence of a clear difference between the two treatments (RR 0.32, 95% CI 0.01 to 7.35; <a href="./references#CD011943-fig-0027" title="">Analysis 1.24</a>). </p> </section> </section> <section id="CD011943-sec-0201"> <h5 class="title">Missing outcomes</h5> <p>No included study reported outcomes for quality of life, service utilisation, or economics.</p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD011943-sec-0202" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011943-sec-0202">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011943-sec-0328">Español</a> </li> </nav> </div> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD011943-sec-0202"></div> <section id="CD011943-sec-0203"> <h3 class="title" id="CD011943-sec-0203">Summary of main results</h3> <p>We noted slight improvement in overall mental state, and akathisia scores with the mirtazapine adjunct group. Mirtazapine adjunct was however not associated with improvements in the clinically important change in negative symptoms or any of the other main outcomes. For a tabulated representation of the summary of the main results, please refer to <a href="./full#CD011943-tbl-0001">summary of findings Table for the main comparison</a>. Of note, in addition to the main outcomes of interest, an important but perhaps not a surprising finding relating to adverse events was that the mirtazapine groups were associated with an increased risk of weight gain and sedation/drowsiness. A summary of these main results and others of note are below. </p> <section id="CD011943-sec-0204"> <h4 class="title">1. Mental state: specific</h4> <section id="CD011943-sec-0205"> <h5 class="title">1.1 Negative symptoms</h5> <p>Only one study including 20 participants defined and reported on clinically important change in negative symptoms (<a href="./references#CD011943-bbs2-0009" title="ZoccaliR , MuscatelloMR , CedroC , NeriP , LaTorreD , SpinaE , et al. The effect of mirtazapine augmentation of clozapine in the treatment of negative symptoms of schizophrenia: a double‐blind, placebo‐controlled study. International Clinical Psychopharmacology2004;19(2):71‐6. [MEDLINE: 15076014] ZoccaliR , MuscatelloMR , TorreDL , MalaraG , CanaleA , CrucittiDDC , et al. Lack of a pharmacokinetic interaction between mirtazapine and the newer antipsychotics clozapine, risperidone and olanzapine in patients with chronic schizophrenia. Pharmacological Research2003;48(4):411‐4. ">Zoccali 2004</a>). Clinically important response was defined as a reduction in SANS overall score from baseline of at least 20%. This study reported that mirtazapine adjunct was associated with a lower risk of no response, but the result did not reach statistical significance (RR 0.81, 95% 95% CI 0.57 to 1.14, very‐low quality evidence). Seven out of nine included studies reported negative symptom scores at endpoint. We were able to meta‐analyse Positive and Negative Syndrome Scale (PANSS) negative subscale data of 130 participants from four studies (<a href="./references#CD011943-bbs2-0001" title="AbbasiSH , BehpourniaH , GhoreshiA , SalehiB , RaznahanM , RezazadehSA , et al. The effect of mirtazapine add on therapy to risperidone in the treatment of schizophrenia: A double‐blind randomized placebo‐controlled trial. Schizophrenia Research2010;116(2‐3):101‐6. [MEDLINE: 19959338] ">Abbasi 2010</a>; <a href="./references#CD011943-bbs2-0003" title="BerkM , GamaCS , SundramS , HustigH , KoopowitzL , D'SouzaR , et al. Mirtazapine add‐on therapy in the treatment of schizophrenia with atypical antipsychotics: a double‐blind, randomised, placebo‐controlled clinical trial. Human Psychopharmacology2009;24(3):233‐8. [MEDLINE: 19330802] DoddS . Mirtazapine add‐on therapy in the treatment of schizophrenia with atypical neuroleptics: a double‐blind, randomised, placebo controlled trial. Australian New Zealand Clinical Trials Registry2004. DoddS , BerkM , D’SouzaR , HustigH , KoopowitzL , MonkhouseA , et al. Mirtazapine add‐on therapy in the treatment of schizophrenia with atypical antipsychotics: a double‐blind, randomised, placebo‐controlled clinical trial. International Journal of Neuropsychopharmacology2008;11(Suppl 1):139‐40. ">Berk 2009</a>; <a href="./references#CD011943-bbs2-0005" title="ChoSJ , YookK , KimB , ChoiTK , LeeKS , KimYW , et al. Mirtazapine augmentation enhances cognitive and reduces negative symptoms in schizophrenia patients treated with risperidone: A randomized controlled trial. Progress in Neuro‐Psychopharmacology &amp; Biological Psychiatry2011;35(1):208‐11. LeeJ , SungJC , KangSL , YookK , AhYC , LeeS , et al. The tolerability of mirtazapine augmentation in schizophrenic patients treated with risperidone: A preliminary randomized placebo‐controlled trial. Clinical Psychopharmacology and Neuroscience2011;9(2):73‐7. LeeSH . Mirtazapine augmentation enhances cognitive and negative symptoms in schizophrenic patients treated with risperidone: a randomised controlled trial. www.controlled‐trials.com2009. ">Cho 2011</a>; <a href="./references#CD011943-bbs2-0008" title="JoffeG . Efficacy of add‐on mirtazapine on clinical and neuropsychologic parameters in schizophrenic patients treated with conventional antipsychotics: a double‐blind, placebo‐controlled trial with an open‐label extension phase. isrctn.com/ISRCTN00721331. JoffeG . Mirtazapine for schizophrenia. Stanley Foundation Research Programs2009. JoffeG , TerevnikovV , JoffeM , StenbergJ‐H , BurkinM , TiihonenJ . Add‐on mirtazapine enhances antipsychotic effect of first generation antipsychotics in schizophrenia: a double‐blind, randomized, placebo‐controlled trial. Schizophrenia Research2009;108(1‐3):245‐51. [MEDLINE: 19144501] StenbergJ‐H , TerevnikovV , JoffeM , TiihonenJ , ChukhinE , BurkinM , et al. Predictors and mediators of add‐on mirtazapine‐induced cognitive enhancement in schizophrenia ‐ a path model investigation. Neuropharmacology2013;64:248‐53. StenbergJ‐H , TerevnikovV , JoffeM , TiihonenJ , TchoukhineE , BurkinM , et al. Effects of add‐on mirtazapine on neurocognition in schizophrenia ‐a double‐blind, randomized, placebo‐controlled study. Proceedings of the 15th Biennial Winter Workshop in Psychoses; 2009 Nov 15‐18; Barcelona, Spain. 2009. StenbergJ‐H , TerevnikovV , JoffeM , TiihonenJ , TchoukhineE , BurkinM , et al. More evidence on proneurocognitive effects of add‐on mirtazapine in schizophrenia. Progress in Neuro‐Psychopharmacology and Biological Psychiatry2011;35:1080‐6. StenbergJH , TerevnikovV , JoffeM , TiihonenJ , TchoukhineE , BurkinM , et al. Effects of add‐on mirtazapine on neurocognition in schizophrenia: A double‐blind, randomized, placebo‐controlled study. International Journal of Neuropsychopharmacology2010;13(4):433‐41. StenbergJH , TerevnikovV , JoffeM , TiihonenJ , TchoukhineE , BurkinM , et al. Effects of add‐on mirtazapine on neurocognition in schizophrenia: an open label extension phase of a double‐blind, randomized, placebo‐controlled study, and both phases. Schizophrenia Research2010;117(2‐3):377. TerevnikovV . Clinical effects of mirtazapine added to first generation antipsychotics in schizophrenia. Dissertation2013. TerevnikovV , StenbergJ H , TiihonenJ , ChukhinE , JoffeM , BurkinM , et al. Relationships between pharmacotherapy‐induced metabolic changes and improved psychopathology in schizophrenia: data from a mirtazapine and first‐generation antipsychotics combination trial. International Journal of Neuropsychopharmacology2013;16(7):1661‐6. TerevnikovV , StenbergJ‐H , TiihonenJ , JoffeM , BurkinM , TchoukhineE , et al. Add‐on mirtazapine improves depressive symptoms in schizophrenia: A double‐blind randomized placebo‐controlled study with an open‐label extension phase. Human Psychopharmacology2011;26(3):188‐93. TerevnikovV , StenbergJH , JoffeM , TiihonenJ , BurkinM , TchoukhineE , et al. More evidence on additive antipsychotic effect of adjunctive mirtazapine in schizophrenia: An extension phase of a randomized controlled trial. Human Psychopharmacology2010;25(6):431‐8. TerevnikovV , StenbergJH , TiihonenJ , BurkinM , JoffeG . Add‐on mirtazapine improves orgasmic functioning in patients with schizophrenia treated with first‐generation antipsychotics. Nordic Journal of Psychiatry2017;71(1):77‐80. TereynikovV , JoffeM , TiihonenJ , StenbergJ‐H , BurkinM , TchoukhineE , et al. More evidence on additive antipsychotic effect of adjunctive mirtazapine in schizophrenia: an extension phase of a randomized controlled trial. Proceedings of the 15th Biennial Winter Workshop in Psychoses; 2009 Nov 15‐18; Barcelona, Spain. 2009. ">Terevnikov 2013</a>), and Scale for the Assessment of Negative Symptoms (SANS) overall score data for 40 participants from two studies (<a href="./references#CD011943-bbs2-0005" title="ChoSJ , YookK , KimB , ChoiTK , LeeKS , KimYW , et al. Mirtazapine augmentation enhances cognitive and reduces negative symptoms in schizophrenia patients treated with risperidone: A randomized controlled trial. Progress in Neuro‐Psychopharmacology &amp; Biological Psychiatry2011;35(1):208‐11. LeeJ , SungJC , KangSL , YookK , AhYC , LeeS , et al. The tolerability of mirtazapine augmentation in schizophrenic patients treated with risperidone: A preliminary randomized placebo‐controlled trial. Clinical Psychopharmacology and Neuroscience2011;9(2):73‐7. LeeSH . Mirtazapine augmentation enhances cognitive and negative symptoms in schizophrenic patients treated with risperidone: a randomised controlled trial. www.controlled‐trials.com2009. ">Cho 2011</a>; <a href="./references#CD011943-bbs2-0009" title="ZoccaliR , MuscatelloMR , CedroC , NeriP , LaTorreD , SpinaE , et al. The effect of mirtazapine augmentation of clozapine in the treatment of negative symptoms of schizophrenia: a double‐blind, placebo‐controlled study. International Clinical Psychopharmacology2004;19(2):71‐6. [MEDLINE: 15076014] ZoccaliR , MuscatelloMR , TorreDL , MalaraG , CanaleA , CrucittiDDC , et al. Lack of a pharmacokinetic interaction between mirtazapine and the newer antipsychotics clozapine, risperidone and olanzapine in patients with chronic schizophrenia. Pharmacological Research2003;48(4):411‐4. ">Zoccali 2004</a>; <a href="./references#CD011943-fig-0005" title="">Analysis 1.2</a>). Two studies reported data on negative symptoms, which were skewed, preventing their inclusion in meta‐analysis (<a href="./references#CD011943-bbs2-0002" title="BerkM , IchimC , BrookS . Efficacy of mirtazapine add on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia: a double‐blind randomized placebo‐controlled study. Clinical Psychopharmacology2001;16(2):87‐92. [MEDLINE: 11236073] BerkM , IchimC , BrookS . Mirtazepine treatment of negative schizophrenia. Proceedings of the 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13‐18; Chicago, Illinois, USA. 2000. BerkM , IchimC , BrookS . Mirtazepine treatment of negative schizophrenia. Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. IchimC , BerkM , BrookS . Mirtazapine treatment of negative symptoms of schizophrenia: a double blind placebo controlled add on trial to treatment with haloperidol. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S112. ">Berk 2001</a>; <a href="./references#CD011943-bbs2-0004" title="BertolinoA . Placebo controlled randomized trial of augmentation of olanzapine treatment with mirtazapine in 30 patients with schizophrenia to ascertain possible effects on negative symptoms and working memory. Stanley Foundation Research Programs2002. CaforioG , DiGiorgioA , RampinoA , RizzoM , RomanoR , TaurisanoP , et al. Mirtazapine add‐on improves olanzapine effect on negative symptoms of schizophrenia. Journal of Clinical Psychopharmacology2013;33(6):810‐2. ">Caforio 2013</a>; <a href="./references#CD011943-fig-0006" title="">Analysis 1.3</a>). We found statistically significant improvement in negative symptoms in the PANSS negative subscale (N = 130, 4 RCTs, MD ‐2.65, 95% CI ‐4.45 to ‐0.84). We also found a statistically significant improvement in negative symptoms in the SANS overall score meta‐analysis (N = 40, 2 RCTs, MD ‐15.04, 95% CI ‐20.06 to ‐10.01). Additionally, the skewed data from <a href="./references#CD011943-bbs2-0002" title="BerkM , IchimC , BrookS . Efficacy of mirtazapine add on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia: a double‐blind randomized placebo‐controlled study. Clinical Psychopharmacology2001;16(2):87‐92. [MEDLINE: 11236073] BerkM , IchimC , BrookS . Mirtazepine treatment of negative schizophrenia. Proceedings of the 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13‐18; Chicago, Illinois, USA. 2000. BerkM , IchimC , BrookS . Mirtazepine treatment of negative schizophrenia. Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. IchimC , BerkM , BrookS . Mirtazapine treatment of negative symptoms of schizophrenia: a double blind placebo controlled add on trial to treatment with haloperidol. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S112. ">Berk 2001</a> and <a href="./references#CD011943-bbs2-0004" title="BertolinoA . Placebo controlled randomized trial of augmentation of olanzapine treatment with mirtazapine in 30 patients with schizophrenia to ascertain possible effects on negative symptoms and working memory. Stanley Foundation Research Programs2002. CaforioG , DiGiorgioA , RampinoA , RizzoM , RomanoR , TaurisanoP , et al. Mirtazapine add‐on improves olanzapine effect on negative symptoms of schizophrenia. Journal of Clinical Psychopharmacology2013;33(6):810‐2. ">Caforio 2013</a> both showed improvement in PANSS negative subscale scores associated with mirtazapine adjunct. Despite being statistically significant, it is important to remember that the reduction in scores shown by our meta‐analyses may not equate to clinically important benefit in participants. </p> </section> <section id="CD011943-sec-0206"> <h5 class="title">1. 2 Positive symptoms</h5> <p>None of the included studies defined a clinically important change on positive symptoms. Seven of the included studies reported on positive symptom scores at endpoint (<a href="./references#CD011943-bbs2-0001" title="AbbasiSH , BehpourniaH , GhoreshiA , SalehiB , RaznahanM , RezazadehSA , et al. The effect of mirtazapine add on therapy to risperidone in the treatment of schizophrenia: A double‐blind randomized placebo‐controlled trial. Schizophrenia Research2010;116(2‐3):101‐6. [MEDLINE: 19959338] ">Abbasi 2010</a>; <a href="./references#CD011943-bbs2-0002" title="BerkM , IchimC , BrookS . Efficacy of mirtazapine add on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia: a double‐blind randomized placebo‐controlled study. Clinical Psychopharmacology2001;16(2):87‐92. [MEDLINE: 11236073] BerkM , IchimC , BrookS . Mirtazepine treatment of negative schizophrenia. Proceedings of the 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13‐18; Chicago, Illinois, USA. 2000. BerkM , IchimC , BrookS . Mirtazepine treatment of negative schizophrenia. Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. IchimC , BerkM , BrookS . Mirtazapine treatment of negative symptoms of schizophrenia: a double blind placebo controlled add on trial to treatment with haloperidol. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S112. ">Berk 2001</a>; <a href="./references#CD011943-bbs2-0003" title="BerkM , GamaCS , SundramS , HustigH , KoopowitzL , D'SouzaR , et al. Mirtazapine add‐on therapy in the treatment of schizophrenia with atypical antipsychotics: a double‐blind, randomised, placebo‐controlled clinical trial. Human Psychopharmacology2009;24(3):233‐8. [MEDLINE: 19330802] DoddS . Mirtazapine add‐on therapy in the treatment of schizophrenia with atypical neuroleptics: a double‐blind, randomised, placebo controlled trial. Australian New Zealand Clinical Trials Registry2004. DoddS , BerkM , D’SouzaR , HustigH , KoopowitzL , MonkhouseA , et al. Mirtazapine add‐on therapy in the treatment of schizophrenia with atypical antipsychotics: a double‐blind, randomised, placebo‐controlled clinical trial. International Journal of Neuropsychopharmacology2008;11(Suppl 1):139‐40. ">Berk 2009</a>; <a href="./references#CD011943-bbs2-0004" title="BertolinoA . Placebo controlled randomized trial of augmentation of olanzapine treatment with mirtazapine in 30 patients with schizophrenia to ascertain possible effects on negative symptoms and working memory. Stanley Foundation Research Programs2002. CaforioG , DiGiorgioA , RampinoA , RizzoM , RomanoR , TaurisanoP , et al. Mirtazapine add‐on improves olanzapine effect on negative symptoms of schizophrenia. Journal of Clinical Psychopharmacology2013;33(6):810‐2. ">Caforio 2013</a>; <a href="./references#CD011943-bbs2-0005" title="ChoSJ , YookK , KimB , ChoiTK , LeeKS , KimYW , et al. Mirtazapine augmentation enhances cognitive and reduces negative symptoms in schizophrenia patients treated with risperidone: A randomized controlled trial. Progress in Neuro‐Psychopharmacology &amp; Biological Psychiatry2011;35(1):208‐11. LeeJ , SungJC , KangSL , YookK , AhYC , LeeS , et al. The tolerability of mirtazapine augmentation in schizophrenic patients treated with risperidone: A preliminary randomized placebo‐controlled trial. Clinical Psychopharmacology and Neuroscience2011;9(2):73‐7. LeeSH . Mirtazapine augmentation enhances cognitive and negative symptoms in schizophrenic patients treated with risperidone: a randomised controlled trial. www.controlled‐trials.com2009. ">Cho 2011</a>; <a href="./references#CD011943-bbs2-0008" title="JoffeG . Efficacy of add‐on mirtazapine on clinical and neuropsychologic parameters in schizophrenic patients treated with conventional antipsychotics: a double‐blind, placebo‐controlled trial with an open‐label extension phase. isrctn.com/ISRCTN00721331. JoffeG . Mirtazapine for schizophrenia. Stanley Foundation Research Programs2009. JoffeG , TerevnikovV , JoffeM , StenbergJ‐H , BurkinM , TiihonenJ . Add‐on mirtazapine enhances antipsychotic effect of first generation antipsychotics in schizophrenia: a double‐blind, randomized, placebo‐controlled trial. Schizophrenia Research2009;108(1‐3):245‐51. [MEDLINE: 19144501] StenbergJ‐H , TerevnikovV , JoffeM , TiihonenJ , ChukhinE , BurkinM , et al. Predictors and mediators of add‐on mirtazapine‐induced cognitive enhancement in schizophrenia ‐ a path model investigation. Neuropharmacology2013;64:248‐53. StenbergJ‐H , TerevnikovV , JoffeM , TiihonenJ , TchoukhineE , BurkinM , et al. Effects of add‐on mirtazapine on neurocognition in schizophrenia ‐a double‐blind, randomized, placebo‐controlled study. Proceedings of the 15th Biennial Winter Workshop in Psychoses; 2009 Nov 15‐18; Barcelona, Spain. 2009. StenbergJ‐H , TerevnikovV , JoffeM , TiihonenJ , TchoukhineE , BurkinM , et al. More evidence on proneurocognitive effects of add‐on mirtazapine in schizophrenia. Progress in Neuro‐Psychopharmacology and Biological Psychiatry2011;35:1080‐6. StenbergJH , TerevnikovV , JoffeM , TiihonenJ , TchoukhineE , BurkinM , et al. Effects of add‐on mirtazapine on neurocognition in schizophrenia: A double‐blind, randomized, placebo‐controlled study. International Journal of Neuropsychopharmacology2010;13(4):433‐41. StenbergJH , TerevnikovV , JoffeM , TiihonenJ , TchoukhineE , BurkinM , et al. Effects of add‐on mirtazapine on neurocognition in schizophrenia: an open label extension phase of a double‐blind, randomized, placebo‐controlled study, and both phases. Schizophrenia Research2010;117(2‐3):377. TerevnikovV . Clinical effects of mirtazapine added to first generation antipsychotics in schizophrenia. Dissertation2013. TerevnikovV , StenbergJ H , TiihonenJ , ChukhinE , JoffeM , BurkinM , et al. Relationships between pharmacotherapy‐induced metabolic changes and improved psychopathology in schizophrenia: data from a mirtazapine and first‐generation antipsychotics combination trial. International Journal of Neuropsychopharmacology2013;16(7):1661‐6. TerevnikovV , StenbergJ‐H , TiihonenJ , JoffeM , BurkinM , TchoukhineE , et al. Add‐on mirtazapine improves depressive symptoms in schizophrenia: A double‐blind randomized placebo‐controlled study with an open‐label extension phase. Human Psychopharmacology2011;26(3):188‐93. TerevnikovV , StenbergJH , JoffeM , TiihonenJ , BurkinM , TchoukhineE , et al. More evidence on additive antipsychotic effect of adjunctive mirtazapine in schizophrenia: An extension phase of a randomized controlled trial. Human Psychopharmacology2010;25(6):431‐8. TerevnikovV , StenbergJH , TiihonenJ , BurkinM , JoffeG . Add‐on mirtazapine improves orgasmic functioning in patients with schizophrenia treated with first‐generation antipsychotics. Nordic Journal of Psychiatry2017;71(1):77‐80. TereynikovV , JoffeM , TiihonenJ , StenbergJ‐H , BurkinM , TchoukhineE , et al. More evidence on additive antipsychotic effect of adjunctive mirtazapine in schizophrenia: an extension phase of a randomized controlled trial. Proceedings of the 15th Biennial Winter Workshop in Psychoses; 2009 Nov 15‐18; Barcelona, Spain. 2009. ">Terevnikov 2013</a>; <a href="./references#CD011943-bbs2-0009" title="ZoccaliR , MuscatelloMR , CedroC , NeriP , LaTorreD , SpinaE , et al. The effect of mirtazapine augmentation of clozapine in the treatment of negative symptoms of schizophrenia: a double‐blind, placebo‐controlled study. International Clinical Psychopharmacology2004;19(2):71‐6. [MEDLINE: 15076014] ZoccaliR , MuscatelloMR , TorreDL , MalaraG , CanaleA , CrucittiDDC , et al. Lack of a pharmacokinetic interaction between mirtazapine and the newer antipsychotics clozapine, risperidone and olanzapine in patients with chronic schizophrenia. Pharmacological Research2003;48(4):411‐4. ">Zoccali 2004</a>). One study, <a href="./references#CD011943-bbs2-0005" title="ChoSJ , YookK , KimB , ChoiTK , LeeKS , KimYW , et al. Mirtazapine augmentation enhances cognitive and reduces negative symptoms in schizophrenia patients treated with risperidone: A randomized controlled trial. Progress in Neuro‐Psychopharmacology &amp; Biological Psychiatry2011;35(1):208‐11. LeeJ , SungJC , KangSL , YookK , AhYC , LeeS , et al. The tolerability of mirtazapine augmentation in schizophrenic patients treated with risperidone: A preliminary randomized placebo‐controlled trial. Clinical Psychopharmacology and Neuroscience2011;9(2):73‐7. LeeSH . Mirtazapine augmentation enhances cognitive and negative symptoms in schizophrenic patients treated with risperidone: a randomised controlled trial. www.controlled‐trials.com2009. ">Cho 2011</a>, reported a statistically significant reduction (improvement) in PANSS positive subscale score at endpoint (MD ‐2.20, 95% CI ‐5.29 to 0.89). Data from the remaining six studies were skewed with varying directions of effect size. </p> </section> </section> <section id="CD011943-sec-0207"> <h4 class="title">2. Mental state: overall</h4> <p>Two studies defined and reported on clinically important change on overall mental state (<a href="./references#CD011943-bbs2-0001" title="AbbasiSH , BehpourniaH , GhoreshiA , SalehiB , RaznahanM , RezazadehSA , et al. The effect of mirtazapine add on therapy to risperidone in the treatment of schizophrenia: A double‐blind randomized placebo‐controlled trial. Schizophrenia Research2010;116(2‐3):101‐6. [MEDLINE: 19959338] ">Abbasi 2010</a>; <a href="./references#CD011943-bbs2-0008" title="JoffeG . Efficacy of add‐on mirtazapine on clinical and neuropsychologic parameters in schizophrenic patients treated with conventional antipsychotics: a double‐blind, placebo‐controlled trial with an open‐label extension phase. isrctn.com/ISRCTN00721331. JoffeG . Mirtazapine for schizophrenia. Stanley Foundation Research Programs2009. JoffeG , TerevnikovV , JoffeM , StenbergJ‐H , BurkinM , TiihonenJ . Add‐on mirtazapine enhances antipsychotic effect of first generation antipsychotics in schizophrenia: a double‐blind, randomized, placebo‐controlled trial. Schizophrenia Research2009;108(1‐3):245‐51. [MEDLINE: 19144501] StenbergJ‐H , TerevnikovV , JoffeM , TiihonenJ , ChukhinE , BurkinM , et al. Predictors and mediators of add‐on mirtazapine‐induced cognitive enhancement in schizophrenia ‐ a path model investigation. Neuropharmacology2013;64:248‐53. StenbergJ‐H , TerevnikovV , JoffeM , TiihonenJ , TchoukhineE , BurkinM , et al. Effects of add‐on mirtazapine on neurocognition in schizophrenia ‐a double‐blind, randomized, placebo‐controlled study. Proceedings of the 15th Biennial Winter Workshop in Psychoses; 2009 Nov 15‐18; Barcelona, Spain. 2009. StenbergJ‐H , TerevnikovV , JoffeM , TiihonenJ , TchoukhineE , BurkinM , et al. More evidence on proneurocognitive effects of add‐on mirtazapine in schizophrenia. Progress in Neuro‐Psychopharmacology and Biological Psychiatry2011;35:1080‐6. StenbergJH , TerevnikovV , JoffeM , TiihonenJ , TchoukhineE , BurkinM , et al. Effects of add‐on mirtazapine on neurocognition in schizophrenia: A double‐blind, randomized, placebo‐controlled study. International Journal of Neuropsychopharmacology2010;13(4):433‐41. StenbergJH , TerevnikovV , JoffeM , TiihonenJ , TchoukhineE , BurkinM , et al. Effects of add‐on mirtazapine on neurocognition in schizophrenia: an open label extension phase of a double‐blind, randomized, placebo‐controlled study, and both phases. Schizophrenia Research2010;117(2‐3):377. TerevnikovV . Clinical effects of mirtazapine added to first generation antipsychotics in schizophrenia. Dissertation2013. TerevnikovV , StenbergJ H , TiihonenJ , ChukhinE , JoffeM , BurkinM , et al. Relationships between pharmacotherapy‐induced metabolic changes and improved psychopathology in schizophrenia: data from a mirtazapine and first‐generation antipsychotics combination trial. International Journal of Neuropsychopharmacology2013;16(7):1661‐6. TerevnikovV , StenbergJ‐H , TiihonenJ , JoffeM , BurkinM , TchoukhineE , et al. Add‐on mirtazapine improves depressive symptoms in schizophrenia: A double‐blind randomized placebo‐controlled study with an open‐label extension phase. Human Psychopharmacology2011;26(3):188‐93. TerevnikovV , StenbergJH , JoffeM , TiihonenJ , BurkinM , TchoukhineE , et al. More evidence on additive antipsychotic effect of adjunctive mirtazapine in schizophrenia: An extension phase of a randomized controlled trial. Human Psychopharmacology2010;25(6):431‐8. TerevnikovV , StenbergJH , TiihonenJ , BurkinM , JoffeG . Add‐on mirtazapine improves orgasmic functioning in patients with schizophrenia treated with first‐generation antipsychotics. Nordic Journal of Psychiatry2017;71(1):77‐80. TereynikovV , JoffeM , TiihonenJ , StenbergJ‐H , BurkinM , TchoukhineE , et al. More evidence on additive antipsychotic effect of adjunctive mirtazapine in schizophrenia: an extension phase of a randomized controlled trial. Proceedings of the 15th Biennial Winter Workshop in Psychoses; 2009 Nov 15‐18; Barcelona, Spain. 2009. ">Terevnikov 2013</a>). <a href="./references#CD011943-bbs2-0001" title="AbbasiSH , BehpourniaH , GhoreshiA , SalehiB , RaznahanM , RezazadehSA , et al. The effect of mirtazapine add on therapy to risperidone in the treatment of schizophrenia: A double‐blind randomized placebo‐controlled trial. Schizophrenia Research2010;116(2‐3):101‐6. [MEDLINE: 19959338] ">Abbasi 2010</a> defined clinically important change as over 50% reduction in PANSS overall score at endpoint, and <a href="./references#CD011943-bbs2-0008" title="JoffeG . Efficacy of add‐on mirtazapine on clinical and neuropsychologic parameters in schizophrenic patients treated with conventional antipsychotics: a double‐blind, placebo‐controlled trial with an open‐label extension phase. isrctn.com/ISRCTN00721331. JoffeG . Mirtazapine for schizophrenia. Stanley Foundation Research Programs2009. JoffeG , TerevnikovV , JoffeM , StenbergJ‐H , BurkinM , TiihonenJ . Add‐on mirtazapine enhances antipsychotic effect of first generation antipsychotics in schizophrenia: a double‐blind, randomized, placebo‐controlled trial. Schizophrenia Research2009;108(1‐3):245‐51. [MEDLINE: 19144501] StenbergJ‐H , TerevnikovV , JoffeM , TiihonenJ , ChukhinE , BurkinM , et al. Predictors and mediators of add‐on mirtazapine‐induced cognitive enhancement in schizophrenia ‐ a path model investigation. Neuropharmacology2013;64:248‐53. StenbergJ‐H , TerevnikovV , JoffeM , TiihonenJ , TchoukhineE , BurkinM , et al. Effects of add‐on mirtazapine on neurocognition in schizophrenia ‐a double‐blind, randomized, placebo‐controlled study. Proceedings of the 15th Biennial Winter Workshop in Psychoses; 2009 Nov 15‐18; Barcelona, Spain. 2009. StenbergJ‐H , TerevnikovV , JoffeM , TiihonenJ , TchoukhineE , BurkinM , et al. More evidence on proneurocognitive effects of add‐on mirtazapine in schizophrenia. Progress in Neuro‐Psychopharmacology and Biological Psychiatry2011;35:1080‐6. StenbergJH , TerevnikovV , JoffeM , TiihonenJ , TchoukhineE , BurkinM , et al. Effects of add‐on mirtazapine on neurocognition in schizophrenia: A double‐blind, randomized, placebo‐controlled study. International Journal of Neuropsychopharmacology2010;13(4):433‐41. StenbergJH , TerevnikovV , JoffeM , TiihonenJ , TchoukhineE , BurkinM , et al. Effects of add‐on mirtazapine on neurocognition in schizophrenia: an open label extension phase of a double‐blind, randomized, placebo‐controlled study, and both phases. Schizophrenia Research2010;117(2‐3):377. TerevnikovV . Clinical effects of mirtazapine added to first generation antipsychotics in schizophrenia. Dissertation2013. TerevnikovV , StenbergJ H , TiihonenJ , ChukhinE , JoffeM , BurkinM , et al. Relationships between pharmacotherapy‐induced metabolic changes and improved psychopathology in schizophrenia: data from a mirtazapine and first‐generation antipsychotics combination trial. International Journal of Neuropsychopharmacology2013;16(7):1661‐6. TerevnikovV , StenbergJ‐H , TiihonenJ , JoffeM , BurkinM , TchoukhineE , et al. Add‐on mirtazapine improves depressive symptoms in schizophrenia: A double‐blind randomized placebo‐controlled study with an open‐label extension phase. Human Psychopharmacology2011;26(3):188‐93. TerevnikovV , StenbergJH , JoffeM , TiihonenJ , BurkinM , TchoukhineE , et al. More evidence on additive antipsychotic effect of adjunctive mirtazapine in schizophrenia: An extension phase of a randomized controlled trial. Human Psychopharmacology2010;25(6):431‐8. TerevnikovV , StenbergJH , TiihonenJ , BurkinM , JoffeG . Add‐on mirtazapine improves orgasmic functioning in patients with schizophrenia treated with first‐generation antipsychotics. Nordic Journal of Psychiatry2017;71(1):77‐80. TereynikovV , JoffeM , TiihonenJ , StenbergJ‐H , BurkinM , TchoukhineE , et al. More evidence on additive antipsychotic effect of adjunctive mirtazapine in schizophrenia: an extension phase of a randomized controlled trial. Proceedings of the 15th Biennial Winter Workshop in Psychoses; 2009 Nov 15‐18; Barcelona, Spain. 2009. ">Terevnikov 2013</a> defined it as over 20% reduction in PANSS overall score at endpoint. Meta‐analysis showed that mirtazapine adjunct was associated with a lower risk of having not improved by endpoint (RR 0.69, 95% CI 0.51 to 0.92; very low‐quality evidence). The large difference in the threshold for clinical significance set by each study places limitation on the interpretation of this meta‐analysis as a majority of studies in schizophrenia tend to use an improvement cut‐off of 20% on PANSS overall scores (<a href="./references#CD011943-bbs2-0053" title="LeuchtS , KisslingW , DavisJM . PANSS Should Be Rescaled. Schizophrenia Bulletin2010;36(3):461‐2. [DOI: 10.1093/schbul/sbq016] ">Leucht 2010</a>). All nine included studies reported overall mental state scores at endpoint. We included six studies with 170 participants in a meta‐analysis of PANSS overall score at endpoint (<a href="./references#CD011943-bbs2-0001" title="AbbasiSH , BehpourniaH , GhoreshiA , SalehiB , RaznahanM , RezazadehSA , et al. The effect of mirtazapine add on therapy to risperidone in the treatment of schizophrenia: A double‐blind randomized placebo‐controlled trial. Schizophrenia Research2010;116(2‐3):101‐6. [MEDLINE: 19959338] ">Abbasi 2010</a>; <a href="./references#CD011943-bbs2-0003" title="BerkM , GamaCS , SundramS , HustigH , KoopowitzL , D'SouzaR , et al. Mirtazapine add‐on therapy in the treatment of schizophrenia with atypical antipsychotics: a double‐blind, randomised, placebo‐controlled clinical trial. Human Psychopharmacology2009;24(3):233‐8. [MEDLINE: 19330802] DoddS . Mirtazapine add‐on therapy in the treatment of schizophrenia with atypical neuroleptics: a double‐blind, randomised, placebo controlled trial. Australian New Zealand Clinical Trials Registry2004. DoddS , BerkM , D’SouzaR , HustigH , KoopowitzL , MonkhouseA , et al. Mirtazapine add‐on therapy in the treatment of schizophrenia with atypical antipsychotics: a double‐blind, randomised, placebo‐controlled clinical trial. International Journal of Neuropsychopharmacology2008;11(Suppl 1):139‐40. ">Berk 2009</a>; <a href="./references#CD011943-bbs2-0004" title="BertolinoA . Placebo controlled randomized trial of augmentation of olanzapine treatment with mirtazapine in 30 patients with schizophrenia to ascertain possible effects on negative symptoms and working memory. Stanley Foundation Research Programs2002. CaforioG , DiGiorgioA , RampinoA , RizzoM , RomanoR , TaurisanoP , et al. Mirtazapine add‐on improves olanzapine effect on negative symptoms of schizophrenia. Journal of Clinical Psychopharmacology2013;33(6):810‐2. ">Caforio 2013</a>; <a href="./references#CD011943-bbs2-0005" title="ChoSJ , YookK , KimB , ChoiTK , LeeKS , KimYW , et al. Mirtazapine augmentation enhances cognitive and reduces negative symptoms in schizophrenia patients treated with risperidone: A randomized controlled trial. Progress in Neuro‐Psychopharmacology &amp; Biological Psychiatry2011;35(1):208‐11. LeeJ , SungJC , KangSL , YookK , AhYC , LeeS , et al. The tolerability of mirtazapine augmentation in schizophrenic patients treated with risperidone: A preliminary randomized placebo‐controlled trial. Clinical Psychopharmacology and Neuroscience2011;9(2):73‐7. LeeSH . Mirtazapine augmentation enhances cognitive and negative symptoms in schizophrenic patients treated with risperidone: a randomised controlled trial. www.controlled‐trials.com2009. ">Cho 2011</a>; <a href="./references#CD011943-bbs2-0006" title="PoyurovskyM . Mirtazapine for bipolar disorder and schizophrenia. Stanley Foundation Research Programs2009. PoyurovskyM , EpshteinS , FuchsC , SchneidmanM , WeizmanR , WeizmanA . Efficacy of low‐dose mirtazapine in neuroleptic‐induced akathisia: a double‐blind randomized placebo‐controlled pilot study. European Neuropsychopharmacology2002;12(Suppl. 3):S299. PoyurovskyM , EpshteinS , FuchsC , SchneidmanM , WeizmanR , WeizmanA . Efficacy of low‐dose mirtazapine in neuroleptic‐induced akathisia: a double‐blind randomized placebo‐controlled pilot study. Journal of Clinical Psychopharmacology2003;23(3):305‐8. [MEDLINE: 12826992] ">Poyurovsky 2003</a>; <a href="./references#CD011943-bbs2-0008" title="JoffeG . Efficacy of add‐on mirtazapine on clinical and neuropsychologic parameters in schizophrenic patients treated with conventional antipsychotics: a double‐blind, placebo‐controlled trial with an open‐label extension phase. isrctn.com/ISRCTN00721331. JoffeG . Mirtazapine for schizophrenia. Stanley Foundation Research Programs2009. JoffeG , TerevnikovV , JoffeM , StenbergJ‐H , BurkinM , TiihonenJ . Add‐on mirtazapine enhances antipsychotic effect of first generation antipsychotics in schizophrenia: a double‐blind, randomized, placebo‐controlled trial. Schizophrenia Research2009;108(1‐3):245‐51. [MEDLINE: 19144501] StenbergJ‐H , TerevnikovV , JoffeM , TiihonenJ , ChukhinE , BurkinM , et al. Predictors and mediators of add‐on mirtazapine‐induced cognitive enhancement in schizophrenia ‐ a path model investigation. Neuropharmacology2013;64:248‐53. StenbergJ‐H , TerevnikovV , JoffeM , TiihonenJ , TchoukhineE , BurkinM , et al. Effects of add‐on mirtazapine on neurocognition in schizophrenia ‐a double‐blind, randomized, placebo‐controlled study. Proceedings of the 15th Biennial Winter Workshop in Psychoses; 2009 Nov 15‐18; Barcelona, Spain. 2009. StenbergJ‐H , TerevnikovV , JoffeM , TiihonenJ , TchoukhineE , BurkinM , et al. More evidence on proneurocognitive effects of add‐on mirtazapine in schizophrenia. Progress in Neuro‐Psychopharmacology and Biological Psychiatry2011;35:1080‐6. StenbergJH , TerevnikovV , JoffeM , TiihonenJ , TchoukhineE , BurkinM , et al. Effects of add‐on mirtazapine on neurocognition in schizophrenia: A double‐blind, randomized, placebo‐controlled study. International Journal of Neuropsychopharmacology2010;13(4):433‐41. StenbergJH , TerevnikovV , JoffeM , TiihonenJ , TchoukhineE , BurkinM , et al. Effects of add‐on mirtazapine on neurocognition in schizophrenia: an open label extension phase of a double‐blind, randomized, placebo‐controlled study, and both phases. Schizophrenia Research2010;117(2‐3):377. TerevnikovV . Clinical effects of mirtazapine added to first generation antipsychotics in schizophrenia. Dissertation2013. TerevnikovV , StenbergJ H , TiihonenJ , ChukhinE , JoffeM , BurkinM , et al. Relationships between pharmacotherapy‐induced metabolic changes and improved psychopathology in schizophrenia: data from a mirtazapine and first‐generation antipsychotics combination trial. International Journal of Neuropsychopharmacology2013;16(7):1661‐6. TerevnikovV , StenbergJ‐H , TiihonenJ , JoffeM , BurkinM , TchoukhineE , et al. Add‐on mirtazapine improves depressive symptoms in schizophrenia: A double‐blind randomized placebo‐controlled study with an open‐label extension phase. Human Psychopharmacology2011;26(3):188‐93. TerevnikovV , StenbergJH , JoffeM , TiihonenJ , BurkinM , TchoukhineE , et al. More evidence on additive antipsychotic effect of adjunctive mirtazapine in schizophrenia: An extension phase of a randomized controlled trial. Human Psychopharmacology2010;25(6):431‐8. TerevnikovV , StenbergJH , TiihonenJ , BurkinM , JoffeG . Add‐on mirtazapine improves orgasmic functioning in patients with schizophrenia treated with first‐generation antipsychotics. Nordic Journal of Psychiatry2017;71(1):77‐80. TereynikovV , JoffeM , TiihonenJ , StenbergJ‐H , BurkinM , TchoukhineE , et al. More evidence on additive antipsychotic effect of adjunctive mirtazapine in schizophrenia: an extension phase of a randomized controlled trial. Proceedings of the 15th Biennial Winter Workshop in Psychoses; 2009 Nov 15‐18; Barcelona, Spain. 2009. ">Terevnikov 2013</a>), and one study had useable data on the Brief Psychiatric Rating Scale (BPRS) score at endpoint (<a href="./references#CD011943-bbs2-0009" title="ZoccaliR , MuscatelloMR , CedroC , NeriP , LaTorreD , SpinaE , et al. The effect of mirtazapine augmentation of clozapine in the treatment of negative symptoms of schizophrenia: a double‐blind, placebo‐controlled study. International Clinical Psychopharmacology2004;19(2):71‐6. [MEDLINE: 15076014] ZoccaliR , MuscatelloMR , TorreDL , MalaraG , CanaleA , CrucittiDDC , et al. Lack of a pharmacokinetic interaction between mirtazapine and the newer antipsychotics clozapine, risperidone and olanzapine in patients with chronic schizophrenia. Pharmacological Research2003;48(4):411‐4. ">Zoccali 2004</a>; <a href="./references#CD011943-fig-0010" title="">Analysis 1.7</a>). Data from <a href="./references#CD011943-bbs2-0002" title="BerkM , IchimC , BrookS . Efficacy of mirtazapine add on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia: a double‐blind randomized placebo‐controlled study. Clinical Psychopharmacology2001;16(2):87‐92. [MEDLINE: 11236073] BerkM , IchimC , BrookS . Mirtazepine treatment of negative schizophrenia. Proceedings of the 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13‐18; Chicago, Illinois, USA. 2000. BerkM , IchimC , BrookS . Mirtazepine treatment of negative schizophrenia. Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. IchimC , BerkM , BrookS . Mirtazapine treatment of negative symptoms of schizophrenia: a double blind placebo controlled add on trial to treatment with haloperidol. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S112. ">Berk 2001</a> and <a href="./references#CD011943-bbs2-0007" title="PoyurovskyM , PashinianA , WeizmanR , FuchsC , WeizmanA . Low‐dose mirtazapine: a new option in the treatment of antipsychotic‐induced akathisia. A randomized, double‐blind, placebo‐ and propranolol‐controlled trial. Biological Psychiatry2006;59(11):1071‐7. [MEDLINE: 16497273] ">Poyurovsky 2006</a> were skewed and excluded from these analyses. We found an improvement on PANSS overall score at endpoint associated with mirtazapine adjunct (MD ‐3.84, 95% CI ‐7.89 to 0.21), but the result was not statistically significant. <a href="./references#CD011943-bbs2-0009" title="ZoccaliR , MuscatelloMR , CedroC , NeriP , LaTorreD , SpinaE , et al. The effect of mirtazapine augmentation of clozapine in the treatment of negative symptoms of schizophrenia: a double‐blind, placebo‐controlled study. International Clinical Psychopharmacology2004;19(2):71‐6. [MEDLINE: 15076014] ZoccaliR , MuscatelloMR , TorreDL , MalaraG , CanaleA , CrucittiDDC , et al. Lack of a pharmacokinetic interaction between mirtazapine and the newer antipsychotics clozapine, risperidone and olanzapine in patients with chronic schizophrenia. Pharmacological Research2003;48(4):411‐4. ">Zoccali 2004</a> reported an improvement of BPRS score at endpoint associated with mirtazapine group (MD ‐19.30, 95% CI ‐22.10 to ‐16.50). </p> </section> <section id="CD011943-sec-0208"> <h4 class="title">3. Mental state: depressive symptoms</h4> <p>Six out of the nine included studies reported on depressive symptoms, although data from all but two studies were skewed and not included in the meta‐analysis. The meta‐analysis of the two eligible studies (<a href="./references#CD011943-fig-0012" title="">Analysis 1.9</a>), did not find a statistically significant difference in depressive symptom scores between groups at endpoint. We had hoped that there would be more useable data on the impact of mirtazapine adjunct on depressive symptoms to give some insight as to whether a reduction in depressive symptoms associated with mirtazapine adjunct might have meaningfully confounded the analysis of negative symptoms. However, due to this lack of useable data and majority of studies excluding participants with current depressive episode or use of another psychotropic drug, it is unlikely that the antidepressant effect of mirtazapine adjunct substantially confounded the other analyses. </p> </section> <section id="CD011943-sec-0209"> <h4 class="title">4. Leaving the study early for any reason</h4> <p>All nine studies had useable data on leaving the study early for any reason. Participants from the mirtazapine groups (n = 156) appeared no more or less likely to leave the study early for any reason than those in the placebo group (n = 154) (RR 1.03, 95% CI 0.64 to 1.66; moderate‐quality evidence). </p> </section> <section id="CD011943-sec-0210"> <h4 class="title">5. Global state</h4> <p>There was a paucity of usable data on global state outcomes. Only data from one study with 39 participants were useable (<a href="./references#CD011943-bbs2-0008" title="JoffeG . Efficacy of add‐on mirtazapine on clinical and neuropsychologic parameters in schizophrenic patients treated with conventional antipsychotics: a double‐blind, placebo‐controlled trial with an open‐label extension phase. isrctn.com/ISRCTN00721331. JoffeG . Mirtazapine for schizophrenia. Stanley Foundation Research Programs2009. JoffeG , TerevnikovV , JoffeM , StenbergJ‐H , BurkinM , TiihonenJ . Add‐on mirtazapine enhances antipsychotic effect of first generation antipsychotics in schizophrenia: a double‐blind, randomized, placebo‐controlled trial. Schizophrenia Research2009;108(1‐3):245‐51. [MEDLINE: 19144501] StenbergJ‐H , TerevnikovV , JoffeM , TiihonenJ , ChukhinE , BurkinM , et al. Predictors and mediators of add‐on mirtazapine‐induced cognitive enhancement in schizophrenia ‐ a path model investigation. Neuropharmacology2013;64:248‐53. StenbergJ‐H , TerevnikovV , JoffeM , TiihonenJ , TchoukhineE , BurkinM , et al. Effects of add‐on mirtazapine on neurocognition in schizophrenia ‐a double‐blind, randomized, placebo‐controlled study. Proceedings of the 15th Biennial Winter Workshop in Psychoses; 2009 Nov 15‐18; Barcelona, Spain. 2009. StenbergJ‐H , TerevnikovV , JoffeM , TiihonenJ , TchoukhineE , BurkinM , et al. More evidence on proneurocognitive effects of add‐on mirtazapine in schizophrenia. Progress in Neuro‐Psychopharmacology and Biological Psychiatry2011;35:1080‐6. StenbergJH , TerevnikovV , JoffeM , TiihonenJ , TchoukhineE , BurkinM , et al. Effects of add‐on mirtazapine on neurocognition in schizophrenia: A double‐blind, randomized, placebo‐controlled study. International Journal of Neuropsychopharmacology2010;13(4):433‐41. StenbergJH , TerevnikovV , JoffeM , TiihonenJ , TchoukhineE , BurkinM , et al. Effects of add‐on mirtazapine on neurocognition in schizophrenia: an open label extension phase of a double‐blind, randomized, placebo‐controlled study, and both phases. Schizophrenia Research2010;117(2‐3):377. TerevnikovV . Clinical effects of mirtazapine added to first generation antipsychotics in schizophrenia. Dissertation2013. TerevnikovV , StenbergJ H , TiihonenJ , ChukhinE , JoffeM , BurkinM , et al. Relationships between pharmacotherapy‐induced metabolic changes and improved psychopathology in schizophrenia: data from a mirtazapine and first‐generation antipsychotics combination trial. International Journal of Neuropsychopharmacology2013;16(7):1661‐6. TerevnikovV , StenbergJ‐H , TiihonenJ , JoffeM , BurkinM , TchoukhineE , et al. Add‐on mirtazapine improves depressive symptoms in schizophrenia: A double‐blind randomized placebo‐controlled study with an open‐label extension phase. Human Psychopharmacology2011;26(3):188‐93. TerevnikovV , StenbergJH , JoffeM , TiihonenJ , BurkinM , TchoukhineE , et al. More evidence on additive antipsychotic effect of adjunctive mirtazapine in schizophrenia: An extension phase of a randomized controlled trial. Human Psychopharmacology2010;25(6):431‐8. TerevnikovV , StenbergJH , TiihonenJ , BurkinM , JoffeG . Add‐on mirtazapine improves orgasmic functioning in patients with schizophrenia treated with first‐generation antipsychotics. Nordic Journal of Psychiatry2017;71(1):77‐80. TereynikovV , JoffeM , TiihonenJ , StenbergJ‐H , BurkinM , TchoukhineE , et al. More evidence on additive antipsychotic effect of adjunctive mirtazapine in schizophrenia: an extension phase of a randomized controlled trial. Proceedings of the 15th Biennial Winter Workshop in Psychoses; 2009 Nov 15‐18; Barcelona, Spain. 2009. ">Terevnikov 2013</a>). <a href="./references#CD011943-bbs2-0002" title="BerkM , IchimC , BrookS . Efficacy of mirtazapine add on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia: a double‐blind randomized placebo‐controlled study. Clinical Psychopharmacology2001;16(2):87‐92. [MEDLINE: 11236073] BerkM , IchimC , BrookS . Mirtazepine treatment of negative schizophrenia. Proceedings of the 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13‐18; Chicago, Illinois, USA. 2000. BerkM , IchimC , BrookS . Mirtazepine treatment of negative schizophrenia. Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. IchimC , BerkM , BrookS . Mirtazapine treatment of negative symptoms of schizophrenia: a double blind placebo controlled add on trial to treatment with haloperidol. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S112. ">Berk 2001</a> also reported outcomes of global state, but data were skewed. </p> </section> <section id="CD011943-sec-0211"> <h4 class="title">6. Cognitive functioning</h4> <p>Four studies reported on outcomes of cognitive functioning (<a href="./references#CD011943-bbs2-0003" title="BerkM , GamaCS , SundramS , HustigH , KoopowitzL , D'SouzaR , et al. Mirtazapine add‐on therapy in the treatment of schizophrenia with atypical antipsychotics: a double‐blind, randomised, placebo‐controlled clinical trial. Human Psychopharmacology2009;24(3):233‐8. [MEDLINE: 19330802] DoddS . Mirtazapine add‐on therapy in the treatment of schizophrenia with atypical neuroleptics: a double‐blind, randomised, placebo controlled trial. Australian New Zealand Clinical Trials Registry2004. DoddS , BerkM , D’SouzaR , HustigH , KoopowitzL , MonkhouseA , et al. Mirtazapine add‐on therapy in the treatment of schizophrenia with atypical antipsychotics: a double‐blind, randomised, placebo‐controlled clinical trial. International Journal of Neuropsychopharmacology2008;11(Suppl 1):139‐40. ">Berk 2009</a>; <a href="./references#CD011943-bbs2-0004" title="BertolinoA . Placebo controlled randomized trial of augmentation of olanzapine treatment with mirtazapine in 30 patients with schizophrenia to ascertain possible effects on negative symptoms and working memory. Stanley Foundation Research Programs2002. CaforioG , DiGiorgioA , RampinoA , RizzoM , RomanoR , TaurisanoP , et al. Mirtazapine add‐on improves olanzapine effect on negative symptoms of schizophrenia. Journal of Clinical Psychopharmacology2013;33(6):810‐2. ">Caforio 2013</a>; <a href="./references#CD011943-bbs2-0005" title="ChoSJ , YookK , KimB , ChoiTK , LeeKS , KimYW , et al. Mirtazapine augmentation enhances cognitive and reduces negative symptoms in schizophrenia patients treated with risperidone: A randomized controlled trial. Progress in Neuro‐Psychopharmacology &amp; Biological Psychiatry2011;35(1):208‐11. LeeJ , SungJC , KangSL , YookK , AhYC , LeeS , et al. The tolerability of mirtazapine augmentation in schizophrenic patients treated with risperidone: A preliminary randomized placebo‐controlled trial. Clinical Psychopharmacology and Neuroscience2011;9(2):73‐7. LeeSH . Mirtazapine augmentation enhances cognitive and negative symptoms in schizophrenic patients treated with risperidone: a randomised controlled trial. www.controlled‐trials.com2009. ">Cho 2011</a>; <a href="./references#CD011943-bbs2-0008" title="JoffeG . Efficacy of add‐on mirtazapine on clinical and neuropsychologic parameters in schizophrenic patients treated with conventional antipsychotics: a double‐blind, placebo‐controlled trial with an open‐label extension phase. isrctn.com/ISRCTN00721331. JoffeG . Mirtazapine for schizophrenia. Stanley Foundation Research Programs2009. JoffeG , TerevnikovV , JoffeM , StenbergJ‐H , BurkinM , TiihonenJ . Add‐on mirtazapine enhances antipsychotic effect of first generation antipsychotics in schizophrenia: a double‐blind, randomized, placebo‐controlled trial. Schizophrenia Research2009;108(1‐3):245‐51. [MEDLINE: 19144501] StenbergJ‐H , TerevnikovV , JoffeM , TiihonenJ , ChukhinE , BurkinM , et al. Predictors and mediators of add‐on mirtazapine‐induced cognitive enhancement in schizophrenia ‐ a path model investigation. Neuropharmacology2013;64:248‐53. StenbergJ‐H , TerevnikovV , JoffeM , TiihonenJ , TchoukhineE , BurkinM , et al. Effects of add‐on mirtazapine on neurocognition in schizophrenia ‐a double‐blind, randomized, placebo‐controlled study. Proceedings of the 15th Biennial Winter Workshop in Psychoses; 2009 Nov 15‐18; Barcelona, Spain. 2009. StenbergJ‐H , TerevnikovV , JoffeM , TiihonenJ , TchoukhineE , BurkinM , et al. More evidence on proneurocognitive effects of add‐on mirtazapine in schizophrenia. Progress in Neuro‐Psychopharmacology and Biological Psychiatry2011;35:1080‐6. StenbergJH , TerevnikovV , JoffeM , TiihonenJ , TchoukhineE , BurkinM , et al. Effects of add‐on mirtazapine on neurocognition in schizophrenia: A double‐blind, randomized, placebo‐controlled study. International Journal of Neuropsychopharmacology2010;13(4):433‐41. StenbergJH , TerevnikovV , JoffeM , TiihonenJ , TchoukhineE , BurkinM , et al. Effects of add‐on mirtazapine on neurocognition in schizophrenia: an open label extension phase of a double‐blind, randomized, placebo‐controlled study, and both phases. Schizophrenia Research2010;117(2‐3):377. TerevnikovV . Clinical effects of mirtazapine added to first generation antipsychotics in schizophrenia. Dissertation2013. TerevnikovV , StenbergJ H , TiihonenJ , ChukhinE , JoffeM , BurkinM , et al. Relationships between pharmacotherapy‐induced metabolic changes and improved psychopathology in schizophrenia: data from a mirtazapine and first‐generation antipsychotics combination trial. International Journal of Neuropsychopharmacology2013;16(7):1661‐6. TerevnikovV , StenbergJ‐H , TiihonenJ , JoffeM , BurkinM , TchoukhineE , et al. Add‐on mirtazapine improves depressive symptoms in schizophrenia: A double‐blind randomized placebo‐controlled study with an open‐label extension phase. Human Psychopharmacology2011;26(3):188‐93. TerevnikovV , StenbergJH , JoffeM , TiihonenJ , BurkinM , TchoukhineE , et al. More evidence on additive antipsychotic effect of adjunctive mirtazapine in schizophrenia: An extension phase of a randomized controlled trial. Human Psychopharmacology2010;25(6):431‐8. TerevnikovV , StenbergJH , TiihonenJ , BurkinM , JoffeG . Add‐on mirtazapine improves orgasmic functioning in patients with schizophrenia treated with first‐generation antipsychotics. Nordic Journal of Psychiatry2017;71(1):77‐80. TereynikovV , JoffeM , TiihonenJ , StenbergJ‐H , BurkinM , TchoukhineE , et al. More evidence on additive antipsychotic effect of adjunctive mirtazapine in schizophrenia: an extension phase of a randomized controlled trial. Proceedings of the 15th Biennial Winter Workshop in Psychoses; 2009 Nov 15‐18; Barcelona, Spain. 2009. ">Terevnikov 2013</a>). Due to selective reporting, all cognitive function data from <a href="./references#CD011943-bbs2-0005" title="ChoSJ , YookK , KimB , ChoiTK , LeeKS , KimYW , et al. Mirtazapine augmentation enhances cognitive and reduces negative symptoms in schizophrenia patients treated with risperidone: A randomized controlled trial. Progress in Neuro‐Psychopharmacology &amp; Biological Psychiatry2011;35(1):208‐11. LeeJ , SungJC , KangSL , YookK , AhYC , LeeS , et al. The tolerability of mirtazapine augmentation in schizophrenic patients treated with risperidone: A preliminary randomized placebo‐controlled trial. Clinical Psychopharmacology and Neuroscience2011;9(2):73‐7. LeeSH . Mirtazapine augmentation enhances cognitive and negative symptoms in schizophrenic patients treated with risperidone: a randomised controlled trial. www.controlled‐trials.com2009. ">Cho 2011</a> were excluded from this review, leaving three studies with useable data. <a href="./references#CD011943-bbs2-0003" title="BerkM , GamaCS , SundramS , HustigH , KoopowitzL , D'SouzaR , et al. Mirtazapine add‐on therapy in the treatment of schizophrenia with atypical antipsychotics: a double‐blind, randomised, placebo‐controlled clinical trial. Human Psychopharmacology2009;24(3):233‐8. [MEDLINE: 19330802] DoddS . Mirtazapine add‐on therapy in the treatment of schizophrenia with atypical neuroleptics: a double‐blind, randomised, placebo controlled trial. Australian New Zealand Clinical Trials Registry2004. DoddS , BerkM , D’SouzaR , HustigH , KoopowitzL , MonkhouseA , et al. Mirtazapine add‐on therapy in the treatment of schizophrenia with atypical antipsychotics: a double‐blind, randomised, placebo‐controlled clinical trial. International Journal of Neuropsychopharmacology2008;11(Suppl 1):139‐40. ">Berk 2009</a> reported no significant differences between the mirtazapine and placebo groups for digit span, word learning, trail making, and verbal fluency tests. <a href="./references#CD011943-bbs2-0004" title="BertolinoA . Placebo controlled randomized trial of augmentation of olanzapine treatment with mirtazapine in 30 patients with schizophrenia to ascertain possible effects on negative symptoms and working memory. Stanley Foundation Research Programs2002. CaforioG , DiGiorgioA , RampinoA , RizzoM , RomanoR , TaurisanoP , et al. Mirtazapine add‐on improves olanzapine effect on negative symptoms of schizophrenia. Journal of Clinical Psychopharmacology2013;33(6):810‐2. ">Caforio 2013</a> also reported no significant differences between groups for the series of N‐back tasks they conducted. <a href="./references#CD011943-bbs2-0008" title="JoffeG . Efficacy of add‐on mirtazapine on clinical and neuropsychologic parameters in schizophrenic patients treated with conventional antipsychotics: a double‐blind, placebo‐controlled trial with an open‐label extension phase. isrctn.com/ISRCTN00721331. JoffeG . Mirtazapine for schizophrenia. Stanley Foundation Research Programs2009. JoffeG , TerevnikovV , JoffeM , StenbergJ‐H , BurkinM , TiihonenJ . Add‐on mirtazapine enhances antipsychotic effect of first generation antipsychotics in schizophrenia: a double‐blind, randomized, placebo‐controlled trial. Schizophrenia Research2009;108(1‐3):245‐51. [MEDLINE: 19144501] StenbergJ‐H , TerevnikovV , JoffeM , TiihonenJ , ChukhinE , BurkinM , et al. Predictors and mediators of add‐on mirtazapine‐induced cognitive enhancement in schizophrenia ‐ a path model investigation. Neuropharmacology2013;64:248‐53. StenbergJ‐H , TerevnikovV , JoffeM , TiihonenJ , TchoukhineE , BurkinM , et al. Effects of add‐on mirtazapine on neurocognition in schizophrenia ‐a double‐blind, randomized, placebo‐controlled study. Proceedings of the 15th Biennial Winter Workshop in Psychoses; 2009 Nov 15‐18; Barcelona, Spain. 2009. StenbergJ‐H , TerevnikovV , JoffeM , TiihonenJ , TchoukhineE , BurkinM , et al. More evidence on proneurocognitive effects of add‐on mirtazapine in schizophrenia. Progress in Neuro‐Psychopharmacology and Biological Psychiatry2011;35:1080‐6. StenbergJH , TerevnikovV , JoffeM , TiihonenJ , TchoukhineE , BurkinM , et al. Effects of add‐on mirtazapine on neurocognition in schizophrenia: A double‐blind, randomized, placebo‐controlled study. International Journal of Neuropsychopharmacology2010;13(4):433‐41. StenbergJH , TerevnikovV , JoffeM , TiihonenJ , TchoukhineE , BurkinM , et al. Effects of add‐on mirtazapine on neurocognition in schizophrenia: an open label extension phase of a double‐blind, randomized, placebo‐controlled study, and both phases. Schizophrenia Research2010;117(2‐3):377. TerevnikovV . Clinical effects of mirtazapine added to first generation antipsychotics in schizophrenia. Dissertation2013. TerevnikovV , StenbergJ H , TiihonenJ , ChukhinE , JoffeM , BurkinM , et al. Relationships between pharmacotherapy‐induced metabolic changes and improved psychopathology in schizophrenia: data from a mirtazapine and first‐generation antipsychotics combination trial. International Journal of Neuropsychopharmacology2013;16(7):1661‐6. TerevnikovV , StenbergJ‐H , TiihonenJ , JoffeM , BurkinM , TchoukhineE , et al. Add‐on mirtazapine improves depressive symptoms in schizophrenia: A double‐blind randomized placebo‐controlled study with an open‐label extension phase. Human Psychopharmacology2011;26(3):188‐93. TerevnikovV , StenbergJH , JoffeM , TiihonenJ , BurkinM , TchoukhineE , et al. More evidence on additive antipsychotic effect of adjunctive mirtazapine in schizophrenia: An extension phase of a randomized controlled trial. Human Psychopharmacology2010;25(6):431‐8. TerevnikovV , StenbergJH , TiihonenJ , BurkinM , JoffeG . Add‐on mirtazapine improves orgasmic functioning in patients with schizophrenia treated with first‐generation antipsychotics. Nordic Journal of Psychiatry2017;71(1):77‐80. TereynikovV , JoffeM , TiihonenJ , StenbergJ‐H , BurkinM , TchoukhineE , et al. More evidence on additive antipsychotic effect of adjunctive mirtazapine in schizophrenia: an extension phase of a randomized controlled trial. Proceedings of the 15th Biennial Winter Workshop in Psychoses; 2009 Nov 15‐18; Barcelona, Spain. 2009. ">Terevnikov 2013</a> performed a more comprehensive battery of cognitive function tests, and reported a statistically significant improvement in five out of 21 parameters tested in the mirtazapine group compared with one out of 21 in the placebo group. The between‐group comparison in <a href="./references#CD011943-bbs2-0008" title="JoffeG . Efficacy of add‐on mirtazapine on clinical and neuropsychologic parameters in schizophrenic patients treated with conventional antipsychotics: a double‐blind, placebo‐controlled trial with an open‐label extension phase. isrctn.com/ISRCTN00721331. JoffeG . Mirtazapine for schizophrenia. Stanley Foundation Research Programs2009. JoffeG , TerevnikovV , JoffeM , StenbergJ‐H , BurkinM , TiihonenJ . Add‐on mirtazapine enhances antipsychotic effect of first generation antipsychotics in schizophrenia: a double‐blind, randomized, placebo‐controlled trial. Schizophrenia Research2009;108(1‐3):245‐51. [MEDLINE: 19144501] StenbergJ‐H , TerevnikovV , JoffeM , TiihonenJ , ChukhinE , BurkinM , et al. Predictors and mediators of add‐on mirtazapine‐induced cognitive enhancement in schizophrenia ‐ a path model investigation. Neuropharmacology2013;64:248‐53. StenbergJ‐H , TerevnikovV , JoffeM , TiihonenJ , TchoukhineE , BurkinM , et al. Effects of add‐on mirtazapine on neurocognition in schizophrenia ‐a double‐blind, randomized, placebo‐controlled study. Proceedings of the 15th Biennial Winter Workshop in Psychoses; 2009 Nov 15‐18; Barcelona, Spain. 2009. StenbergJ‐H , TerevnikovV , JoffeM , TiihonenJ , TchoukhineE , BurkinM , et al. More evidence on proneurocognitive effects of add‐on mirtazapine in schizophrenia. Progress in Neuro‐Psychopharmacology and Biological Psychiatry2011;35:1080‐6. StenbergJH , TerevnikovV , JoffeM , TiihonenJ , TchoukhineE , BurkinM , et al. Effects of add‐on mirtazapine on neurocognition in schizophrenia: A double‐blind, randomized, placebo‐controlled study. International Journal of Neuropsychopharmacology2010;13(4):433‐41. StenbergJH , TerevnikovV , JoffeM , TiihonenJ , TchoukhineE , BurkinM , et al. Effects of add‐on mirtazapine on neurocognition in schizophrenia: an open label extension phase of a double‐blind, randomized, placebo‐controlled study, and both phases. Schizophrenia Research2010;117(2‐3):377. TerevnikovV . Clinical effects of mirtazapine added to first generation antipsychotics in schizophrenia. Dissertation2013. TerevnikovV , StenbergJ H , TiihonenJ , ChukhinE , JoffeM , BurkinM , et al. Relationships between pharmacotherapy‐induced metabolic changes and improved psychopathology in schizophrenia: data from a mirtazapine and first‐generation antipsychotics combination trial. International Journal of Neuropsychopharmacology2013;16(7):1661‐6. TerevnikovV , StenbergJ‐H , TiihonenJ , JoffeM , BurkinM , TchoukhineE , et al. Add‐on mirtazapine improves depressive symptoms in schizophrenia: A double‐blind randomized placebo‐controlled study with an open‐label extension phase. Human Psychopharmacology2011;26(3):188‐93. TerevnikovV , StenbergJH , JoffeM , TiihonenJ , BurkinM , TchoukhineE , et al. More evidence on additive antipsychotic effect of adjunctive mirtazapine in schizophrenia: An extension phase of a randomized controlled trial. Human Psychopharmacology2010;25(6):431‐8. TerevnikovV , StenbergJH , TiihonenJ , BurkinM , JoffeG . Add‐on mirtazapine improves orgasmic functioning in patients with schizophrenia treated with first‐generation antipsychotics. Nordic Journal of Psychiatry2017;71(1):77‐80. TereynikovV , JoffeM , TiihonenJ , StenbergJ‐H , BurkinM , TchoukhineE , et al. More evidence on additive antipsychotic effect of adjunctive mirtazapine in schizophrenia: an extension phase of a randomized controlled trial. Proceedings of the 15th Biennial Winter Workshop in Psychoses; 2009 Nov 15‐18; Barcelona, Spain. 2009. ">Terevnikov 2013</a> showed that mirtazapine adjunct outperformed placebo adjunct with statistical significance in just two out of 21 tested parameters. Due to the two neutral results, and the results of <a href="./references#CD011943-bbs2-0008" title="JoffeG . Efficacy of add‐on mirtazapine on clinical and neuropsychologic parameters in schizophrenic patients treated with conventional antipsychotics: a double‐blind, placebo‐controlled trial with an open‐label extension phase. isrctn.com/ISRCTN00721331. JoffeG . Mirtazapine for schizophrenia. Stanley Foundation Research Programs2009. JoffeG , TerevnikovV , JoffeM , StenbergJ‐H , BurkinM , TiihonenJ . Add‐on mirtazapine enhances antipsychotic effect of first generation antipsychotics in schizophrenia: a double‐blind, randomized, placebo‐controlled trial. Schizophrenia Research2009;108(1‐3):245‐51. [MEDLINE: 19144501] StenbergJ‐H , TerevnikovV , JoffeM , TiihonenJ , ChukhinE , BurkinM , et al. Predictors and mediators of add‐on mirtazapine‐induced cognitive enhancement in schizophrenia ‐ a path model investigation. Neuropharmacology2013;64:248‐53. StenbergJ‐H , TerevnikovV , JoffeM , TiihonenJ , TchoukhineE , BurkinM , et al. Effects of add‐on mirtazapine on neurocognition in schizophrenia ‐a double‐blind, randomized, placebo‐controlled study. Proceedings of the 15th Biennial Winter Workshop in Psychoses; 2009 Nov 15‐18; Barcelona, Spain. 2009. StenbergJ‐H , TerevnikovV , JoffeM , TiihonenJ , TchoukhineE , BurkinM , et al. More evidence on proneurocognitive effects of add‐on mirtazapine in schizophrenia. Progress in Neuro‐Psychopharmacology and Biological Psychiatry2011;35:1080‐6. StenbergJH , TerevnikovV , JoffeM , TiihonenJ , TchoukhineE , BurkinM , et al. Effects of add‐on mirtazapine on neurocognition in schizophrenia: A double‐blind, randomized, placebo‐controlled study. International Journal of Neuropsychopharmacology2010;13(4):433‐41. StenbergJH , TerevnikovV , JoffeM , TiihonenJ , TchoukhineE , BurkinM , et al. Effects of add‐on mirtazapine on neurocognition in schizophrenia: an open label extension phase of a double‐blind, randomized, placebo‐controlled study, and both phases. Schizophrenia Research2010;117(2‐3):377. TerevnikovV . Clinical effects of mirtazapine added to first generation antipsychotics in schizophrenia. Dissertation2013. TerevnikovV , StenbergJ H , TiihonenJ , ChukhinE , JoffeM , BurkinM , et al. Relationships between pharmacotherapy‐induced metabolic changes and improved psychopathology in schizophrenia: data from a mirtazapine and first‐generation antipsychotics combination trial. International Journal of Neuropsychopharmacology2013;16(7):1661‐6. TerevnikovV , StenbergJ‐H , TiihonenJ , JoffeM , BurkinM , TchoukhineE , et al. Add‐on mirtazapine improves depressive symptoms in schizophrenia: A double‐blind randomized placebo‐controlled study with an open‐label extension phase. Human Psychopharmacology2011;26(3):188‐93. TerevnikovV , StenbergJH , JoffeM , TiihonenJ , BurkinM , TchoukhineE , et al. More evidence on additive antipsychotic effect of adjunctive mirtazapine in schizophrenia: An extension phase of a randomized controlled trial. Human Psychopharmacology2010;25(6):431‐8. TerevnikovV , StenbergJH , TiihonenJ , BurkinM , JoffeG . Add‐on mirtazapine improves orgasmic functioning in patients with schizophrenia treated with first‐generation antipsychotics. Nordic Journal of Psychiatry2017;71(1):77‐80. TereynikovV , JoffeM , TiihonenJ , StenbergJ‐H , BurkinM , TchoukhineE , et al. More evidence on additive antipsychotic effect of adjunctive mirtazapine in schizophrenia: an extension phase of a randomized controlled trial. Proceedings of the 15th Biennial Winter Workshop in Psychoses; 2009 Nov 15‐18; Barcelona, Spain. 2009. ">Terevnikov 2013</a>, only demonstrating superiority of mirtazapine adjunct over placebo adjunct in just two neurocognitive parameters tested, we consider it unlikely that there is a substantial effect of mirtazapine adjunct on cognitive function based on available evidence. </p> </section> <section id="CD011943-sec-0212"> <h4 class="title">7. Adverse effects/events</h4> <p>All nine studies reported on adverse effects/events. Studies described these outcomes in several different ways, but often did not include information on the distribution of count data of individual adverse events, making it impossible to conduct meta‐analysis to derive meaningful information on number of adverse events per participant. What data we do have suggest that mirtazapine adjunct is associated with statistically significant increased risk for some adverse effects such as weight gain (RR 3.19, 95% CI 1.17 to 8.65), and sedation/drowsiness (RR 3.16, 95% CI 1.59 to 6.28). </p> <p>Five studies reported on extrapyramidal side effects (<a href="./references#CD011943-bbs2-0001" title="AbbasiSH , BehpourniaH , GhoreshiA , SalehiB , RaznahanM , RezazadehSA , et al. The effect of mirtazapine add on therapy to risperidone in the treatment of schizophrenia: A double‐blind randomized placebo‐controlled trial. Schizophrenia Research2010;116(2‐3):101‐6. [MEDLINE: 19959338] ">Abbasi 2010</a>; <a href="./references#CD011943-bbs2-0002" title="BerkM , IchimC , BrookS . Efficacy of mirtazapine add on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia: a double‐blind randomized placebo‐controlled study. Clinical Psychopharmacology2001;16(2):87‐92. [MEDLINE: 11236073] BerkM , IchimC , BrookS . Mirtazepine treatment of negative schizophrenia. Proceedings of the 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13‐18; Chicago, Illinois, USA. 2000. BerkM , IchimC , BrookS . Mirtazepine treatment of negative schizophrenia. Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002. IchimC , BerkM , BrookS . Mirtazapine treatment of negative symptoms of schizophrenia: a double blind placebo controlled add on trial to treatment with haloperidol. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S112. ">Berk 2001</a>; <a href="./references#CD011943-bbs2-0006" title="PoyurovskyM . Mirtazapine for bipolar disorder and schizophrenia. Stanley Foundation Research Programs2009. PoyurovskyM , EpshteinS , FuchsC , SchneidmanM , WeizmanR , WeizmanA . Efficacy of low‐dose mirtazapine in neuroleptic‐induced akathisia: a double‐blind randomized placebo‐controlled pilot study. European Neuropsychopharmacology2002;12(Suppl. 3):S299. PoyurovskyM , EpshteinS , FuchsC , SchneidmanM , WeizmanR , WeizmanA . Efficacy of low‐dose mirtazapine in neuroleptic‐induced akathisia: a double‐blind randomized placebo‐controlled pilot study. Journal of Clinical Psychopharmacology2003;23(3):305‐8. [MEDLINE: 12826992] ">Poyurovsky 2003</a>; <a href="./references#CD011943-bbs2-0007" title="PoyurovskyM , PashinianA , WeizmanR , FuchsC , WeizmanA . Low‐dose mirtazapine: a new option in the treatment of antipsychotic‐induced akathisia. A randomized, double‐blind, placebo‐ and propranolol‐controlled trial. Biological Psychiatry2006;59(11):1071‐7. [MEDLINE: 16497273] ">Poyurovsky 2006</a>; <a href="./references#CD011943-bbs2-0008" title="JoffeG . Efficacy of add‐on mirtazapine on clinical and neuropsychologic parameters in schizophrenic patients treated with conventional antipsychotics: a double‐blind, placebo‐controlled trial with an open‐label extension phase. isrctn.com/ISRCTN00721331. JoffeG . Mirtazapine for schizophrenia. Stanley Foundation Research Programs2009. JoffeG , TerevnikovV , JoffeM , StenbergJ‐H , BurkinM , TiihonenJ . Add‐on mirtazapine enhances antipsychotic effect of first generation antipsychotics in schizophrenia: a double‐blind, randomized, placebo‐controlled trial. Schizophrenia Research2009;108(1‐3):245‐51. [MEDLINE: 19144501] StenbergJ‐H , TerevnikovV , JoffeM , TiihonenJ , ChukhinE , BurkinM , et al. Predictors and mediators of add‐on mirtazapine‐induced cognitive enhancement in schizophrenia ‐ a path model investigation. Neuropharmacology2013;64:248‐53. StenbergJ‐H , TerevnikovV , JoffeM , TiihonenJ , TchoukhineE , BurkinM , et al. Effects of add‐on mirtazapine on neurocognition in schizophrenia ‐a double‐blind, randomized, placebo‐controlled study. Proceedings of the 15th Biennial Winter Workshop in Psychoses; 2009 Nov 15‐18; Barcelona, Spain. 2009. StenbergJ‐H , TerevnikovV , JoffeM , TiihonenJ , TchoukhineE , BurkinM , et al. More evidence on proneurocognitive effects of add‐on mirtazapine in schizophrenia. Progress in Neuro‐Psychopharmacology and Biological Psychiatry2011;35:1080‐6. StenbergJH , TerevnikovV , JoffeM , TiihonenJ , TchoukhineE , BurkinM , et al. Effects of add‐on mirtazapine on neurocognition in schizophrenia: A double‐blind, randomized, placebo‐controlled study. International Journal of Neuropsychopharmacology2010;13(4):433‐41. StenbergJH , TerevnikovV , JoffeM , TiihonenJ , TchoukhineE , BurkinM , et al. Effects of add‐on mirtazapine on neurocognition in schizophrenia: an open label extension phase of a double‐blind, randomized, placebo‐controlled study, and both phases. Schizophrenia Research2010;117(2‐3):377. TerevnikovV . Clinical effects of mirtazapine added to first generation antipsychotics in schizophrenia. Dissertation2013. TerevnikovV , StenbergJ H , TiihonenJ , ChukhinE , JoffeM , BurkinM , et al. Relationships between pharmacotherapy‐induced metabolic changes and improved psychopathology in schizophrenia: data from a mirtazapine and first‐generation antipsychotics combination trial. International Journal of Neuropsychopharmacology2013;16(7):1661‐6. TerevnikovV , StenbergJ‐H , TiihonenJ , JoffeM , BurkinM , TchoukhineE , et al. Add‐on mirtazapine improves depressive symptoms in schizophrenia: A double‐blind randomized placebo‐controlled study with an open‐label extension phase. Human Psychopharmacology2011;26(3):188‐93. TerevnikovV , StenbergJH , JoffeM , TiihonenJ , BurkinM , TchoukhineE , et al. More evidence on additive antipsychotic effect of adjunctive mirtazapine in schizophrenia: An extension phase of a randomized controlled trial. Human Psychopharmacology2010;25(6):431‐8. TerevnikovV , StenbergJH , TiihonenJ , BurkinM , JoffeG . Add‐on mirtazapine improves orgasmic functioning in patients with schizophrenia treated with first‐generation antipsychotics. Nordic Journal of Psychiatry2017;71(1):77‐80. TereynikovV , JoffeM , TiihonenJ , StenbergJ‐H , BurkinM , TchoukhineE , et al. More evidence on additive antipsychotic effect of adjunctive mirtazapine in schizophrenia: an extension phase of a randomized controlled trial. Proceedings of the 15th Biennial Winter Workshop in Psychoses; 2009 Nov 15‐18; Barcelona, Spain. 2009. ">Terevnikov 2013</a>). <a href="./references#CD011943-bbs2-0006" title="PoyurovskyM . Mirtazapine for bipolar disorder and schizophrenia. Stanley Foundation Research Programs2009. PoyurovskyM , EpshteinS , FuchsC , SchneidmanM , WeizmanR , WeizmanA . Efficacy of low‐dose mirtazapine in neuroleptic‐induced akathisia: a double‐blind randomized placebo‐controlled pilot study. European Neuropsychopharmacology2002;12(Suppl. 3):S299. PoyurovskyM , EpshteinS , FuchsC , SchneidmanM , WeizmanR , WeizmanA . Efficacy of low‐dose mirtazapine in neuroleptic‐induced akathisia: a double‐blind randomized placebo‐controlled pilot study. Journal of Clinical Psychopharmacology2003;23(3):305‐8. [MEDLINE: 12826992] ">Poyurovsky 2003</a> and <a href="./references#CD011943-bbs2-0007" title="PoyurovskyM , PashinianA , WeizmanR , FuchsC , WeizmanA . Low‐dose mirtazapine: a new option in the treatment of antipsychotic‐induced akathisia. A randomized, double‐blind, placebo‐ and propranolol‐controlled trial. Biological Psychiatry2006;59(11):1071‐7. [MEDLINE: 16497273] ">Poyurovsky 2006</a> each defined a clinically significant response on akathisia symptoms, and when combined in a meta‐analysis (<a href="./references#CD011943-fig-0021" title="">Analysis 1.18</a>), these data showed a statistically significant improvement associated with mirtazapine adjunct. Because the SAS and Extrapyramidal Symptom Rating Scale (ESRS) scores appear not to differ between groups in the other trials and much of these data are skewed, the effect of mirtazapine adjunct on extrapyramidal side effects appears limited to treating akathisia. </p> </section> <section id="CD011943-sec-0213"> <h4 class="title">8. Missing outcomes</h4> <p>No included study reported outcomes for quality of life, service utilisation, or economics. This was somewhat disappointing, particularly regarding the lack of data on quality of life for the recipients of care, as improving quality of life is a fundamentally patient‐centred end in caring for people with schizophrenia. </p> </section> </section> <section id="CD011943-sec-0214"> <h3 class="title" id="CD011943-sec-0214">Overall completeness and applicability of evidence</h3> <p>There are several study characteristics that strengthen and several that weaken the external validity of this review. Study attributes that increase the applicability of this review are the variety of antipsychotic drugs used in combination with mirtazapine, the inclusion of participants at various stages of illness across the trials, and the diverse clinical and geographical settings. Factors that reduce the applicability of this review include the absence of both long‐term and quality of life outcome data in all nine studies, the exclusion of participants with psychiatric and medical comorbidities, the substantial attrition rates within included studies, and the inherent difficulty in translating scale‐derived measures of effect size into meaningful 'real‐world' clinical importance. On balance, the overall completeness of the evidence is insufficient to address the objective of this review in full. </p> </section> <section id="CD011943-sec-0215"> <h3 class="title" id="CD011943-sec-0215">Quality of the evidence</h3> <p>All nine studies were randomised and likely blinded, however the details of random sequence generation, blinding, and allocation concealment were commonly not provided. Selective reporting was detected in four studies, and three studies were either sponsored by the pharmaceutical industry, or had at least one author with a financial conflict of interest. All included studies were short term. Each of these factors lowers the overall quality of the evidence, resulting in grades for pre‐specified key outcomes ranging from moderate to very low (<a href="./full#CD011943-tbl-0001">summary of findings Table for the main comparison</a>). </p> </section> <section id="CD011943-sec-0216"> <h3 class="title" id="CD011943-sec-0216">Potential biases in the review process</h3> <p>We added several outcomes of potential interest after reviewing results of the search, see <a href="#CD011943-sec-0233">Differences between protocol and review</a>. We are not aware of any other potential biases in the review process. </p> </section> <section id="CD011943-sec-0217"> <h3 class="title" id="CD011943-sec-0217">Agreements and disagreements with other studies or reviews</h3> <p>We identified two systematic reviews on similar topics (<a href="./references#CD011943-bbs2-0063" title="PhanSV , KreysTJ . Adjunct mirtazapine for negative symptoms of schizophrenia. Pharmacotherapy2011;31(10):1017‐30. ">Phan 2011</a>; <a href="./references#CD011943-bbs2-0077" title="VidalC , Reess , C , FischerBA , Chiapelli , J , HimelhochS . Meta‐analysis of efficacy of mirtazapine as an adjunctive treatment of negative symptoms in schizophrenia. Clinical Schizophrenia &amp; Related Psychoses2015;9(2):88‐95. ">Vidal 2015</a>). Our review includes additional trials and examined additional outcomes, and therefore contributes new and improved knowledge to this area of study. Despite this, the conclusions of these previous works are similar to those of this review: that mirtazapine as an add on treatment to antipsychotic medication may slightly improve overall mental state of people with schizophrenia, but the evidence is not yet convincing. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD011943-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011943.pub2/media/CDSR/CD011943/urn:x-wiley:14651858:media:CD011943:CD011943-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011943.pub2/media/CDSR/CD011943/image_t/tCD011943-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011943-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011943.pub2/media/CDSR/CD011943/image_n/nCD011943-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011943.pub2/full#CD011943-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011943.pub2/media/CDSR/CD011943/image_n/nCD011943-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011943-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011943.pub2/media/CDSR/CD011943/urn:x-wiley:14651858:media:CD011943:CD011943-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011943.pub2/media/CDSR/CD011943/image_t/tCD011943-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD011943-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011943.pub2/media/CDSR/CD011943/image_n/nCD011943-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011943.pub2/full#CD011943-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011943.pub2/media/CDSR/CD011943/image_n/nCD011943-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011943-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011943.pub2/media/CDSR/CD011943/urn:x-wiley:14651858:media:CD011943:CD011943-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011943.pub2/media/CDSR/CD011943/image_t/tCD011943-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD011943-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011943.pub2/media/CDSR/CD011943/image_n/nCD011943-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011943.pub2/full#CD011943-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011943.pub2/media/CDSR/CD011943/image_n/nCD011943-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011943-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011943.pub2/media/CDSR/CD011943/urn:x-wiley:14651858:media:CD011943:CD011943-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011943.pub2/media/CDSR/CD011943/image_t/tCD011943-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Mirtazapine adjunct versus placebo adjunct ‐ short term, Outcome 1 Mental state: specific. 1a. Negative symptoms: clinically important change." data-id="CD011943-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011943.pub2/media/CDSR/CD011943/image_n/nCD011943-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Mirtazapine adjunct versus placebo adjunct ‐ short term, Outcome 1 Mental state: specific. 1a. Negative symptoms: clinically important change. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011943.pub2/references#CD011943-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011943.pub2/media/CDSR/CD011943/image_n/nCD011943-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011943-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011943.pub2/media/CDSR/CD011943/urn:x-wiley:14651858:media:CD011943:CD011943-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011943.pub2/media/CDSR/CD011943/image_t/tCD011943-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Mirtazapine adjunct versus placebo adjunct ‐ short term, Outcome 2 Mental state: specific. 1b. Negative symptoms: average endpoint score (various scales)." data-id="CD011943-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011943.pub2/media/CDSR/CD011943/image_n/nCD011943-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Mirtazapine adjunct versus placebo adjunct ‐ short term, Outcome 2 Mental state: specific. 1b. Negative symptoms: average endpoint score (various scales). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011943.pub2/references#CD011943-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011943.pub2/media/CDSR/CD011943/image_n/nCD011943-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011943-fig-0006"> <p> <div class="table" id="CD011943-tblf-0001"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mirtazapine</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Placebo</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Berk 2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PANSS negative at endpoint, high = poor</p> <p>mean = 13.9</p> <p>SD = 22.076</p> <p>N = 15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PANSS negative at endpoint, high = poor</p> <p>mean = 23.9</p> <p>SD = 21.689</p> <p>N = 15</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Caforio 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PANSS negative at endpoint, high = poor</p> <p>mean = 15.2</p> <p>SD = 5.3</p> <p>N = 9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PANSS negative at endpoint, high = poor</p> <p>mean = 18.8</p> <p>SD = 8.6</p> <p>N = 11</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Mirtazapine adjunct versus placebo adjunct ‐ short term, Outcome 3 Mental sate: specific. 1c. Negative symptoms: average endpoint score (PANSS negative, high = poor) ‐skewed data. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011943.pub2/references#CD011943-fig-0006">Navigate to figure in review</a></div> </div> <div class="figure" id="CD011943-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011943.pub2/media/CDSR/CD011943/urn:x-wiley:14651858:media:CD011943:CD011943-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011943.pub2/media/CDSR/CD011943/image_t/tCD011943-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Mirtazapine adjunct versus placebo adjunct ‐ short term, Outcome 4 Mental state: specific. 2a. Positive symptoms: average endpoint score (PANSS, high = poor)." data-id="CD011943-fig-0007" src="/cdsr/doi/10.1002/14651858.CD011943.pub2/media/CDSR/CD011943/image_n/nCD011943-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Mirtazapine adjunct versus placebo adjunct ‐ short term, Outcome 4 Mental state: specific. 2a. Positive symptoms: average endpoint score (PANSS, high = poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011943.pub2/references#CD011943-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011943.pub2/media/CDSR/CD011943/image_n/nCD011943-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011943-fig-0008"> <p> <div class="table" id="CD011943-tblf-0002"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mirtazapine</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Placebo</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abbasi 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PANSS (at endpoint)</p> <p>Mean = 11.875</p> <p>SD = 5.625</p> <p>N = 19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PANSS (at endpoint)</p> <p>Mean = 13.75</p> <p>SD = 3.75</p> <p>N = 19</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Berk 2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PANSS (at endpoint)</p> <p>Mean = 9.6</p> <p>SD = 20.5268</p> <p>N = 15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PANSS (at endpoint)</p> <p>Mean = 8.2</p> <p>SD = 7.7459</p> <p>N = 15</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Berk 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PANSS (at endpoint)</p> <p>Mean = 18.47</p> <p>SD = 6.44</p> <p>N = 16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PANSS (at endpoint)</p> <p>Mean = 14.44</p> <p>SD = 5.65</p> <p>N = 17</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Caforio 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PANSS (at endpoint)</p> <p>Mean = 10.05</p> <p>SD = 1.86</p> <p>N = 9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PANSS (at endpoint)</p> <p>Mean = 12.8</p> <p>SD = 3.73</p> <p>N = 11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Terevnikov 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PANSS (at endpoint)</p> <p>Mean = 18.1</p> <p>SD = 7.2086</p> <p>N = 20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PANSS (at endpoint)</p> <p>Mean = 18.42</p> <p>SD = 6.0226</p> <p>N = 19</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoccali 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SAPS (at endpoint)</p> <p>Mean = 6.6</p> <p>SD = 2.2</p> <p>N = 10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SAPS (at endpoint)</p> <p>Mean = 8.5</p> <p>SD = 4.3</p> <p>N = 10</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Mirtazapine adjunct versus placebo adjunct ‐ short term, Outcome 5 Mental state: specific. 2b. Positive symptoms: average endpoint score (various scales) ‐ skewed data. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011943.pub2/references#CD011943-fig-0008">Navigate to figure in review</a></div> </div> <div class="figure" id="CD011943-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011943.pub2/media/CDSR/CD011943/urn:x-wiley:14651858:media:CD011943:CD011943-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011943.pub2/media/CDSR/CD011943/image_t/tCD011943-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Mirtazapine adjunct versus placebo adjunct ‐ short term, Outcome 6 Mental state: overall. 3a. Clinically important change (at least 20% change PANSS)." data-id="CD011943-fig-0009" src="/cdsr/doi/10.1002/14651858.CD011943.pub2/media/CDSR/CD011943/image_n/nCD011943-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Mirtazapine adjunct versus placebo adjunct ‐ short term, Outcome 6 Mental state: overall. 3a. Clinically important change (at least 20% change PANSS). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011943.pub2/references#CD011943-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011943.pub2/media/CDSR/CD011943/image_n/nCD011943-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011943-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011943.pub2/media/CDSR/CD011943/urn:x-wiley:14651858:media:CD011943:CD011943-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011943.pub2/media/CDSR/CD011943/image_t/tCD011943-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Mirtazapine adjunct versus placebo adjunct ‐ short term, Outcome 7 Mental state: overall. 3b. Average endpoint score (various scales)." data-id="CD011943-fig-0010" src="/cdsr/doi/10.1002/14651858.CD011943.pub2/media/CDSR/CD011943/image_n/nCD011943-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Mirtazapine adjunct versus placebo adjunct ‐ short term, Outcome 7 Mental state: overall. 3b. Average endpoint score (various scales). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011943.pub2/references#CD011943-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011943.pub2/media/CDSR/CD011943/image_n/nCD011943-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011943-fig-0011"> <p> <div class="table" id="CD011943-tblf-0003"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mirtazapine</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Placebo</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Berk 2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PANSS (at endpoint)</p> <p>Mean = 46.7</p> <p>SD = 67.003</p> <p>N = 15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PANSS (at endpoint)</p> <p>Mean = 58.9</p> <p>SD = 48.412</p> <p>N = 15</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Poyurovsky 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BPRS (change data, positive is reduction in score and improvement in overall mental state) </p> <p>Mean = 0.3</p> <p>SD = 6.3</p> <p>N = 30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BPRS (change data, positive is reduction in score and improvement in overall mental state) </p> <p>Mean = 0.07</p> <p>SD = 6.44</p> <p>N = 30</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Mirtazapine adjunct versus placebo adjunct ‐ short term, Outcome 8 Mental state: overall. 3c. Average change score (various scales) ‐ skewed data. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011943.pub2/references#CD011943-fig-0011">Navigate to figure in review</a></div> </div> <div class="figure" id="CD011943-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011943.pub2/media/CDSR/CD011943/urn:x-wiley:14651858:media:CD011943:CD011943-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011943.pub2/media/CDSR/CD011943/image_t/tCD011943-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Mirtazapine adjunct versus placebo adjunct ‐ short term, Outcome 9 Mental state: specific. 4a. Depressive symptoms: average endpoint score (HAM‐D, high = poor)." data-id="CD011943-fig-0012" src="/cdsr/doi/10.1002/14651858.CD011943.pub2/media/CDSR/CD011943/image_n/nCD011943-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Mirtazapine adjunct versus placebo adjunct ‐ short term, Outcome 9 Mental state: specific. 4a. Depressive symptoms: average endpoint score (HAM‐D, high = poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011943.pub2/references#CD011943-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011943.pub2/media/CDSR/CD011943/image_n/nCD011943-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011943-fig-0013"> <p> <div class="table" id="CD011943-tblf-0004"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mirtazapine</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Placebo</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Berk 2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HAMD (at endpoint)</p> <p>Mean = 3.05</p> <p>SD = 10.0697</p> <p>N = 15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HAMD (at endpoint)</p> <p>Mean = 4.5</p> <p>SD = 7.7459</p> <p>N = 15</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Berk 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDSS (at endpoint)</p> <p>Mean = 3.94</p> <p>SD = 3.73</p> <p>N = 16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDSS (at endpoint)</p> <p>Mean = 3.35</p> <p>SD = 3.35</p> <p>N = 17</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Caforio 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDSS (at endpoint)</p> <p>No significant difference detected between groups. P = 0.26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDSS (at endpoint)</p> <p>No significant difference detected between groups. P = 0.26</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Poyurovsky 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HAMD (change data, positive is reduction in HAMD and improvement in symptoms)</p> <p>Mean = 0.6</p> <p>SD = 3.87</p> <p>N = 30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HAMD (change data, positive is reduction in HAMD and improvement in symptoms)</p> <p>Mean = 0.4</p> <p>SD = 3.5</p> <p>N = 30</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Terevnikov 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDSS (at endpoint)</p> <p>Mean = 2.4</p> <p>SD = 7.7607</p> <p>N = 20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CDSS (at endpoint)</p> <p>Mean = 3.32</p> <p>SD = 6.7771</p> <p>N = 20</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Mirtazapine adjunct versus placebo adjunct ‐ short term, Outcome 10 Mental state: specific. 4b. Depressive symptoms: average change score (various scales) ‐ skewed data. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011943.pub2/references#CD011943-fig-0013">Navigate to figure in review</a></div> </div> <div class="figure" id="CD011943-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011943.pub2/media/CDSR/CD011943/urn:x-wiley:14651858:media:CD011943:CD011943-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011943.pub2/media/CDSR/CD011943/image_t/tCD011943-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Mirtazapine adjunct versus placebo adjunct ‐ short term, Outcome 11 Leaving the study early for any reason." data-id="CD011943-fig-0014" src="/cdsr/doi/10.1002/14651858.CD011943.pub2/media/CDSR/CD011943/image_n/nCD011943-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Mirtazapine adjunct versus placebo adjunct ‐ short term, Outcome 11 Leaving the study early for any reason. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011943.pub2/references#CD011943-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011943.pub2/media/CDSR/CD011943/image_n/nCD011943-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011943-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011943.pub2/media/CDSR/CD011943/urn:x-wiley:14651858:media:CD011943:CD011943-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011943.pub2/media/CDSR/CD011943/image_t/tCD011943-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Mirtazapine adjunct versus placebo adjunct ‐ short term, Outcome 12 Global state: 1. Average endpoint score (CGI severity, high = poor)." data-id="CD011943-fig-0015" src="/cdsr/doi/10.1002/14651858.CD011943.pub2/media/CDSR/CD011943/image_n/nCD011943-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Mirtazapine adjunct versus placebo adjunct ‐ short term, Outcome 12 Global state: 1. Average endpoint score (CGI severity, high = poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011943.pub2/references#CD011943-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011943.pub2/media/CDSR/CD011943/image_n/nCD011943-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011943-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011943.pub2/media/CDSR/CD011943/urn:x-wiley:14651858:media:CD011943:CD011943-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011943.pub2/media/CDSR/CD011943/image_t/tCD011943-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Mirtazapine adjunct versus placebo adjunct ‐ short term, Outcome 13 Global state: 2a. Average change score (PGI, high = poor)." data-id="CD011943-fig-0016" src="/cdsr/doi/10.1002/14651858.CD011943.pub2/media/CDSR/CD011943/image_n/nCD011943-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 Mirtazapine adjunct versus placebo adjunct ‐ short term, Outcome 13 Global state: 2a. Average change score (PGI, high = poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011943.pub2/references#CD011943-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011943.pub2/media/CDSR/CD011943/image_n/nCD011943-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011943-fig-0017"> <p> <div class="table" id="CD011943-tblf-0005"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mirtazapine</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Placebo</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Berk 2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CGI severity</p> <p>Mean = 2.31</p> <p>SD = 2.09</p> <p>N = 15</p> <p>F = 12.7, P = 0.001, df = 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CGI severity</p> <p>Mean = 3.61</p> <p>SD = 2.09</p> <p>N = 15</p> <p>F = 12.7, P = 0.001, df = 1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Berk 2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CGI improvement</p> <p>Mean = 1.41</p> <p>SD = 1.81</p> <p>N = 15</p> <p>F = 14.62, df = 1, P &lt; 0.001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CGI improvement</p> <p>Mean = 2.52</p> <p>SD = 1.81</p> <p>N = 15</p> <p>F = 14.62, df = 1, P &lt; 0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Terevnikov 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Terevnikov 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CGI improvement (change data ‐ positive is reduction in score and improvement in CGI)</p> <p>Mean change = 0.80</p> <p>SD = 0.62</p> <p>N = 20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CGI improvement (change data ‐ positive is reduction in score and improvement in CGI)</p> <p>Mean change = 0.05</p> <p>SD = 0.52</p> <p>N = 19</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 Mirtazapine adjunct versus placebo adjunct ‐ short term, Outcome 14 Global state: 2b. Average change date (various scales) ‐ skewed data. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011943.pub2/references#CD011943-fig-0017">Navigate to figure in review</a></div> </div> <div class="figure" id="CD011943-fig-0018"> <p> <div class="table" id="CD011943-tblf-0006"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mirtazapine</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Placebo</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Other data tables</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Berk 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some improvement from baseline to week 6 was observed in both treatment arms for all measures of cognition. </p> <p>Digit span: no significant differences between groups at endpoint.</p> <p>Word learning: no significant differences between groups at endpoint.</p> <p>Trail making: significantly worse than in placebo group at endpoint.</p> <p>Verbal fluency: significantly worse than in placebo group at endpoint.</p> <p>No further details were provided.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Some improvement from baseline to week 6 was observed in both treatment arms for all measures of cognition. </p> <p>Digit span: no significant differences between groups at endpoint.</p> <p>Word learning: no significant differences between groups at endpoint.</p> <p>Trail making: significantly worse than in placebo group at endpoint.</p> <p>Verbal fluency: significantly worse than in placebo group at endpoint.</p> <p>No further details were provided.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Caforio 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No statistically significant difference was found between the two treatment groups for measures of working memory tested. </p> <p><b>1‐Back accuracy (% correct) (at endpoint)</b> </p> <p>Mean = 69</p> <p>SD = 21.9</p> <p>N = 14</p> <p>P = 0.1</p> <p><b>2‐Back accuracy (% correct) (at endpoint)</b> </p> <p>Mean = 53.8</p> <p>SD = 14.1</p> <p>N = 14</p> <p>P = 0.8</p> <p><b>1‐Back reaction time (ms) (at endpoint)</b> </p> <p>Mean = 906</p> <p>SD = 144.4</p> <p>N = 14</p> <p>P = 0.4</p> <p><b>2‐Back reaction time (ms) (at endpoint)</b> </p> <p>Mean = 933.6</p> <p>SD = 193.5</p> <p>N = 14</p> <p>P = 0.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No statistically significant difference was found between the two treatment groups for measures of working memory tested. </p> <p><b>1‐Back accuracy (% correct) (at endpoint)</b> </p> <p>Mean = 79.1</p> <p>SD = 25.2</p> <p>N = 14</p> <p>P = 0.1</p> <p><b>2‐Back accuracy (% correct) (at endpoint)</b> </p> <p>Mean = 57.7</p> <p>SD = 24.9</p> <p>N = 14</p> <p>P = 0.8</p> <p><b>1‐Back reaction time (ms) (at endpoint)</b> </p> <p>Mean = 616.8</p> <p>SD = 389</p> <p>N = 14</p> <p>P = 0.4</p> <p><b>2‐Back reaction time (ms) (at endpoint)</b> </p> <p>Mean = 643.2</p> <p>SD = 348</p> <p>N = 14</p> <p>P = 0.1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Terevnikov 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The following data are presented as change from baseline at endpoint. Negative changes for points, and positive changes for time or for number of mistakes means improvement. </p> <p><b>WAIS‐R Block design (points)</b> </p> <p>Mean = ‐4.94</p> <p>SD = 4.61</p> <p>N = 19</p> <p>P = 0.021</p> <p><b>Wechsler Memory Scale Digit Symbol (points)</b> </p> <p>Mean = ‐1.17</p> <p>SD = 5.59</p> <p>N = 19</p> <p>P = 0.437</p> <p><b>Wechsler Memory Scale digit span forward (points)</b> </p> <p>Mean = ‐0.21</p> <p>SD = 1.18</p> <p>N = 19</p> <p>P = 0.421</p> <p><b>Wechsler Memory Scale digit span backward (points)</b> </p> <p>Mean = ‐0.5</p> <p>SD = 1.29</p> <p>N = 19</p> <p>P = 0.206</p> <p><b>Wechsler Memory Scale digit span total (points)</b> </p> <p>Mean = ‐0.79</p> <p>SD = 1.99</p> <p>N = 19</p> <p>P = 0.233</p> <p><b>Wechsler Memory Scale logical memory (points)</b> </p> <p>Mean = ‐1.84 (2.73)</p> <p>SD = 2.73</p> <p>N = 19</p> <p>P = 0.044</p> <p><b>Wechsler Memory Scale logical memory delayed (points)</b> </p> <p>Mean = ‐1.50</p> <p>SD = 1.79</p> <p>N = 19</p> <p>P = 0.044</p> <p><b>Wechsler Memory Scale verbal paired associations (points)</b> </p> <p>Mean = ‐1.61</p> <p>SD = 2.73</p> <p>N = 19</p> <p>P = 0.091</p> <p><b>Wechsler Memory Scale verbal paired associations delayed (points)</b> </p> <p>Mean = ‐1.11</p> <p>SD = 1.71</p> <p>N = 19</p> <p>P = 0.091</p> <p><b>Wechsler Memory Scale visual reproduction (points)</b> </p> <p>Mean = ‐0.78</p> <p>SD = 1.66</p> <p>N = 19</p> <p>P = 0.206</p> <p><b>Wechsler Memory Scale visual reproduction delayed (points)</b> </p> <p>Mean = ‐1.29</p> <p>SD = 2.08</p> <p>N = 19</p> <p>P = 0.065</p> <p><b>Stroop dots (time)</b> </p> <p>Mean = 15.17</p> <p>SD = 23.47</p> <p>N = 19</p> <p>P = 0.044</p> <p><b>Stroop dots (number of mistakes)</b> </p> <p>Mean = 0.28</p> <p>SD = 2.11</p> <p>N = 19</p> <p>P = 0.421</p> <p><b>Stroop coloured words (time)</b> </p> <p>Mean = 16.00</p> <p>SD = 34.20</p> <p>N = 19</p> <p>P = 0.164</p> <p><b>Stroop coloured words (number of mistakes)</b> </p> <p>Mean = 0.89</p> <p>SD = 1.91</p> <p>N = 19</p> <p>P = 0.208</p> <p><b>Trail making test Part A (time)</b> </p> <p>Mean = 17.44</p> <p>SD = 15.98</p> <p>N = 19</p> <p>P = 0.018</p> <p><b>Trail making test Part A (number of mistakes)</b> </p> <p>Mean = 0</p> <p>SD = 0.34</p> <p>N = 19</p> <p>P = 0.659</p> <p><b>Trail making test Part B (time)</b> </p> <p>Mean = 21.76</p> <p>SD = 37.33</p> <p>N = 19</p> <p>P = 0.053</p> <p><b>Trail making test Part B (number of mistakes)</b> </p> <p>Mean = 0.18</p> <p>SD = 1.63</p> <p>N = 19</p> <p>P = 0.421</p> <p><b>Word fluency letter words</b> </p> <p>Mean = ‐1.16</p> <p>SD = 2.61</p> <p>N = 19</p> <p>P = 0.199</p> <p><b>Word fluency semantic</b> </p> <p>Mean = ‐0.95</p> <p>SD = 2.97</p> <p>N = 19</p> <p>P = 0.313</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The following data are presented as change from baseline at endpoint. Negative changes for points, and positive changes for time or for number of mistakes means improvement. </p> <p><b>WAIS‐R Block design (points)</b> </p> <p>Mean = ‐1.18</p> <p>SD = 2.90</p> <p>N = 19</p> <p>P = 0.313</p> <p><b>Wechsler Memory Scale Digit Symbol (points)</b> </p> <p>Mean = ‐1.53</p> <p>SD = 5.62</p> <p>N = 19</p> <p>P = 0.347</p> <p><b>Wechsler Memory Scale digit span forward (points)</b> </p> <p>Mean = ‐0.11</p> <p>SD = 0.58</p> <p>N = 19</p> <p>P = 0.438</p> <p><b>Wechsler Memory Scale digit span backward (points)</b> </p> <p>Mean = 0.12</p> <p>SD = 1.02</p> <p>N = 19</p> <p>P = 0.528</p> <p><b>Wechsler Memory Scale digit span total (points)</b> </p> <p>Mean = 0.0</p> <p>SD = 0.97</p> <p>N = 19</p> <p>P = 0.659</p> <p><b>Wechsler Memory Scale logical memory (points)</b> </p> <p>Mean = ‐2.28</p> <p>SD = 2.40</p> <p>N = 19</p> <p>P = 0.039</p> <p><b>Wechsler Memory Scale logical memory delayed (points)</b> </p> <p>Mean = ‐1.00</p> <p>SD = 2.14</p> <p>N = 19</p> <p>P = 0.200</p> <p><b>Wechsler Memory Scale verbal paired associations (points)</b> </p> <p>Mean = ‐1.1</p> <p>SD = 3.77</p> <p>N = 19</p> <p>P = 0.4960</p> <p><b>Wechsler Memory Scale verbal paired associations delayed (points)</b> </p> <p>Mean = ‐0.55</p> <p>SD = 2.17</p> <p>N = 19</p> <p>P = 0.437</p> <p><b>Wechsler Memory Scale visual reproduction (points)</b> </p> <p>Mean = 0.01</p> <p>SD = 2.14</p> <p>N = 19</p> <p>P = 0.559</p> <p><b>Wechsler Memory Scale visual reproduction delayed (points)</b> </p> <p>Mean = ‐1.50</p> <p>SD = 2.96</p> <p>N = 19</p> <p>P = 0.0720</p> <p><b>Stroop dots (time)</b> </p> <p>Mean = ‐0.22</p> <p>SD = 35.93</p> <p>N = 19</p> <p>P = 0.525</p> <p><b>Stroop dots (number of mistakes)</b> </p> <p>Mean = 0.06</p> <p>SD = 1.51</p> <p>N = 19</p> <p>P = 0.559</p> <p><b>Stroop coloured words (time)</b> </p> <p>Mean = 16.18</p> <p>SD = 68.05</p> <p>N = 19</p> <p>P = 0.421</p> <p><b>Stroop coloured words (number of mistakes)</b> </p> <p>Mean = ‐0.06</p> <p>SD = 4.41</p> <p>N = 19</p> <p>P = 0.497</p> <p><b>Trail making test Part A (time)</b> </p> <p>Mean = 14.29</p> <p>SD = 40.41</p> <p>N = 19</p> <p>P = 0.421</p> <p><b>Trail making test Part A (number of mistakes)</b> </p> <p>Mean = ‐0.12</p> <p>SD = 0.48</p> <p>N = 19</p> <p>P = 0.421</p> <p><b>Trail making test Part B (time)</b> </p> <p>Mean = ‐13.44</p> <p>SD = 75.53</p> <p>N = 19</p> <p>P = 0.659</p> <p><b>Trail making test Part B (number of mistakes)</b> </p> <p>Mean = 0.07</p> <p>SD = 1.58</p> <p>N = 19</p> <p>P = 0.4210.540</p> <p><b>Word fluency letter words (points)</b> </p> <p>Mean = ‐0.22</p> <p>SD = 2.60</p> <p>N = 19</p> <p>P = 0.659</p> <p><b>Word fluency semantic (points)</b> </p> <p>Mean = ‐0.78</p> <p>SD = 3.04</p> <p>N = 19</p> <p>P = 0.421</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1 Mirtazapine adjunct versus placebo adjunct ‐ short term, Outcome 15 Cognitive functioning: other data. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011943.pub2/references#CD011943-fig-0018">Navigate to figure in review</a></div> </div> <div class="figure" id="CD011943-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011943.pub2/media/CDSR/CD011943/urn:x-wiley:14651858:media:CD011943:CD011943-CMP-001-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011943.pub2/media/CDSR/CD011943/image_t/tCD011943-CMP-001-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Mirtazapine adjunct versus placebo adjunct ‐ short term, Outcome 16 Adverse events: 1a. General (participants with at least one adverse event)." data-id="CD011943-fig-0019" src="/cdsr/doi/10.1002/14651858.CD011943.pub2/media/CDSR/CD011943/image_n/nCD011943-CMP-001-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1 Mirtazapine adjunct versus placebo adjunct ‐ short term, Outcome 16 Adverse events: 1a. General (participants with at least one adverse event). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011943.pub2/references#CD011943-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011943.pub2/media/CDSR/CD011943/image_n/nCD011943-CMP-001-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011943-fig-0020"> <p> <div class="table" id="CD011943-tblf-0007"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of events (mirtazapine)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of participants (mirtazapine)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of events (placebo)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of participants (placebo)</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abbasi 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Berk 2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Berk 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Caforio 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cho 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Poyurovsky 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Poyurovsky 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Terevnikov 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zoccali 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1 Mirtazapine adjunct versus placebo adjunct ‐ short term, Outcome 17 Adverse events: 1b. General (total number of adverse events) ‐ count data. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011943.pub2/references#CD011943-fig-0020">Navigate to figure in review</a></div> </div> <div class="figure" id="CD011943-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011943.pub2/media/CDSR/CD011943/urn:x-wiley:14651858:media:CD011943:CD011943-CMP-001-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011943.pub2/media/CDSR/CD011943/image_t/tCD011943-CMP-001-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Mirtazapine adjunct versus placebo adjunct ‐ short term, Outcome 18 Adverse effects: 2a. Extrapyramidal: clinically important change akathisia." data-id="CD011943-fig-0021" src="/cdsr/doi/10.1002/14651858.CD011943.pub2/media/CDSR/CD011943/image_n/nCD011943-CMP-001-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1 Mirtazapine adjunct versus placebo adjunct ‐ short term, Outcome 18 Adverse effects: 2a. Extrapyramidal: clinically important change akathisia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011943.pub2/references#CD011943-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011943.pub2/media/CDSR/CD011943/image_n/nCD011943-CMP-001-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011943-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011943.pub2/media/CDSR/CD011943/urn:x-wiley:14651858:media:CD011943:CD011943-CMP-001-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011943.pub2/media/CDSR/CD011943/image_t/tCD011943-CMP-001-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Mirtazapine adjunct versus placebo adjunct ‐ short term, Outcome 19 Adverse effects: 2b. Extrapyramidal ‐ full resolution of akathisia." data-id="CD011943-fig-0022" src="/cdsr/doi/10.1002/14651858.CD011943.pub2/media/CDSR/CD011943/image_n/nCD011943-CMP-001-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.19</div> <div class="figure-caption"> <p>Comparison 1 Mirtazapine adjunct versus placebo adjunct ‐ short term, Outcome 19 Adverse effects: 2b. Extrapyramidal ‐ full resolution of akathisia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011943.pub2/references#CD011943-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011943.pub2/media/CDSR/CD011943/image_n/nCD011943-CMP-001-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011943-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011943.pub2/media/CDSR/CD011943/urn:x-wiley:14651858:media:CD011943:CD011943-CMP-001-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011943.pub2/media/CDSR/CD011943/image_t/tCD011943-CMP-001-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Mirtazapine adjunct versus placebo adjunct ‐ short term, Outcome 20 Adverse effects: 2c. Extrapyramidal ‐ specific effects." data-id="CD011943-fig-0023" src="/cdsr/doi/10.1002/14651858.CD011943.pub2/media/CDSR/CD011943/image_n/nCD011943-CMP-001-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.20</div> <div class="figure-caption"> <p>Comparison 1 Mirtazapine adjunct versus placebo adjunct ‐ short term, Outcome 20 Adverse effects: 2c. Extrapyramidal ‐ specific effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011943.pub2/references#CD011943-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011943.pub2/media/CDSR/CD011943/image_n/nCD011943-CMP-001-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011943-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011943.pub2/media/CDSR/CD011943/urn:x-wiley:14651858:media:CD011943:CD011943-CMP-001-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011943.pub2/media/CDSR/CD011943/image_t/tCD011943-CMP-001-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Mirtazapine adjunct versus placebo adjunct ‐ short term, Outcome 21 Adverse effects: 2d. Extrapyramidal: average change score (various scales)." data-id="CD011943-fig-0024" src="/cdsr/doi/10.1002/14651858.CD011943.pub2/media/CDSR/CD011943/image_n/nCD011943-CMP-001-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.21</div> <div class="figure-caption"> <p>Comparison 1 Mirtazapine adjunct versus placebo adjunct ‐ short term, Outcome 21 Adverse effects: 2d. Extrapyramidal: average change score (various scales). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011943.pub2/references#CD011943-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011943.pub2/media/CDSR/CD011943/image_n/nCD011943-CMP-001-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011943-fig-0025"> <p> <div class="table" id="CD011943-tblf-0008"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mirtazapine</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Placebo</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abbasi 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean ESRS scores for placebo group were higher throughout the trial, but the difference was not statistically significant: F = 2.05, df = 1, P = 0.16. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean ESRS scores for placebo group were higher throughout the trial, but the difference was not statistically significant: F = 2.05, df = 1, P = 0.16. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Berk 2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SAS measured at endpoint with no statistical significance found between groups (specifics not reported). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SAS measured at endpoint with no statistical significance found between groups (specifics not reported). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Poyurovsky 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SAS (endpoint)</p> <p>Mean = 4.9</p> <p>SD = 2.4</p> <p>N = 10</p> <p>BAS (endpoint)</p> <p>Mean = 2.90</p> <p>SD = 1.60</p> <p>N = 10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SAS (endpoint)</p> <p>Mean = 6</p> <p>SD = 5.5</p> <p>N = 10</p> <p>BAS (endpoint)</p> <p>Mean = 6.5</p> <p>SD = 1.55</p> <p>N = 10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Terevnikov 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SAS (endpoint)</p> <p>Mean = 10.00</p> <p>SD = 7.60</p> <p>N = 20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SAS (endpoint)</p> <p>Mean = 9.58</p> <p>SD = 5.77</p> <p>N = 19</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.22</div> <div class="figure-caption"> <p>Comparison 1 Mirtazapine adjunct versus placebo adjunct ‐ short term, Outcome 22 Adverse effects: 2e. Extrapyramidal: average endpoint score (various scales) ‐ skewed or unusable data. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011943.pub2/references#CD011943-fig-0025">Navigate to figure in review</a></div> </div> <div class="figure" id="CD011943-fig-0026"> <p> <div class="table" id="CD011943-tblf-0009"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mirtazapine</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Placebo</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abbasi 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Biperiden dose (mg)</p> <p>Mean = 104.04</p> <p>SD = 109.215</p> <p>N = 20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Biperiden dose (mg)</p> <p>Mean = 125.09</p> <p>SD = 88.28</p> <p>N = 20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abbasi 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cumulative biperiden dose (mg) = 2568</p> <p>N = 20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cumulative biperiden dose (mg) = 3108</p> <p>N = 20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abbasi 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Days of biperiden treatment</p> <p>Mean = 16.38</p> <p>SD = 17.54</p> <p>N = 20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Days of biperiden treatment</p> <p>Mean = 21.22</p> <p>SD = 12.48</p> <p>N = 20</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.23</div> <div class="figure-caption"> <p>Comparison 1 Mirtazapine adjunct versus placebo adjunct ‐ short term, Outcome 23 Adverse effects: 2f. Extrapyramidal: treatment details ‐ skewed data. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011943.pub2/references#CD011943-fig-0026">Navigate to figure in review</a></div> </div> <div class="figure" id="CD011943-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011943.pub2/media/CDSR/CD011943/urn:x-wiley:14651858:media:CD011943:CD011943-CMP-001-24" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011943.pub2/media/CDSR/CD011943/image_t/tCD011943-CMP-001-24.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Mirtazapine adjunct versus placebo adjunct ‐ short term, Outcome 24 Adverse events: 3. Other specific effects." data-id="CD011943-fig-0027" src="/cdsr/doi/10.1002/14651858.CD011943.pub2/media/CDSR/CD011943/image_n/nCD011943-CMP-001-24.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.24</div> <div class="figure-caption"> <p>Comparison 1 Mirtazapine adjunct versus placebo adjunct ‐ short term, Outcome 24 Adverse events: 3. Other specific effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011943.pub2/references#CD011943-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011943.pub2/media/CDSR/CD011943/image_n/nCD011943-CMP-001-24.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table data-id="CD011943-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Suggested design of future study</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Methods</b> </p> <p><b>Participants</b> </p> <p><b>Interventions</b> </p> <p><b>Outcomes</b> </p> <p><b>General</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Allocation:</b> random (with adequate description of sequence generation and allocation concealment) </p> <p><b>Blinding:</b> double (described and tested) </p> <p><b>Duration:</b> 6 months </p> <p><b>Setting:</b> multiple centres, inpatient and outpatient units </p> <p><b>Diagnosis:</b> schizophrenia (DSM‐V / ICD ‐ 10) </p> <p><b>Age:</b> adults </p> <p><b>Size:</b> N &gt; 300 </p> <p><b>Sex:</b> both </p> <p><b>Stage of illness:</b> any </p> <p><b>Antipsychotic:</b> any </p> <p><b>Exclusions:</b> current major depressive episode or antidepressant drug use </p> <p>1. mirtazapine 30 mg plus regular antipsychotic</p> <p>2. placebo plus regular antipsychotic</p> <p><b>Primary outcome:</b> quality of life </p> <p><b>Other outcomes:</b> family/caretaker satisfaction, service utilisation, employment, leaving the study early, mental state (PANSS including subscales), global impression (CGI), adverse events. </p> <p>Prospectively registered and free from industry funding.</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="2"> <div class="table-footnote"> <p>CGI: Clinical Global Impression</p> <p>DSM‐V: American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders ‐ 5th edition </p> <p>ICD ‐ 10: International Statistical Classification of Diseases and Related Health Problems 10th Revision </p> <p>mg: milligram</p> <p>N: number</p> <p>PANSS: Positive and Negative Syndrome Scale</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Suggested design of future study</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011943.pub2/full#CD011943-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011943-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Mirtazapine adjunct versus placebo adjunct</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Mirtazapine versus placebo</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> schizophrenia<br/> <b>Setting: inpatient</b> <br/> <b>Intervention:</b> mirtazapine plus standard care<br/> <b>Comparison:</b> placebo plus standard care </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with mirtazapine</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mental state: specific negative symptoms ‐ clinically important change (no important response) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.81<br/> (0.57 to 1.14) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>20<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1, 2 ,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Clinically important change was defined as a reduction of 20% or greater on SANS.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1000 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>810 per 1000<br/> (570 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mental state: overall mental state ‐ clinically important change*</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 0.69<br/> (0.51 to 0.92) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>77<br/> (2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>6, 8,9</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>* Mental state: clinically important change positive symptoms data not available.</p> <p>Improvement in overall mental state was defined by</p> <p><a href="https://archie.cochrane.org/sections/documents/view?version=z1711231310158220868921020452083%26format=REVMAN#STD-Abbasi-2010" target="_blank">Abbasi 2010</a> as improvement in PANSS total of &gt;50%. <a href="https://archie.cochrane.org/sections/documents/view?version=z1711231310158220868921020452083%26format=REVMAN#STD-Terevnikov-2013" target="_blank">Terevnikov 2013</a>: defined as improvement of PANSS total by &gt; 20%. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>816 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>563 per 1000<br/> (416 to 751 </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Leaving the study early for any reason</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.03<br/> (0.64 to 1.66) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>310<br/> (9 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>162 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>167 per 1000<br/> (104 to 269) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Global state: average endpoint score (CGI severity, high = poor)*</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean global state: average score at endpoint (CGI severity) was 4</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.10 lower<br/> (0.68 lower to 0.48 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1,3,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data for clinically important change not reported.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life: clinically important change</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported data for this important outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Service utilisation: number of days in hospital</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported data for this important outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse effects: extrapyramidal ‐ clinically important change akathisia</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.33<br/> (0.20 to 0.52) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>86<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>6,7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Both studies defined important change as reduction of BAS by at least 2</p> <p>Adverse events ‐ incidence of serious adverse events: data on variability was not available, preventing meta‐analysis of these count data. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>930 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>307 per 1000<br/> (186 to 484) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>BAS:</b> Barnes Akathisa Scale; <b>BPRS:</b> Brief Psychiatric Rating Scale; <b>CGI:</b> Clinical Global Impression; <b>CI:</b> Confidence interval; <b>HAM‐D:</b> Hamilton Depression Rating Scale; <b>MD:</b> Mean difference; <b>RR:</b> Risk ratio; <b>RCT:</b> Randomised controlled trial; <b>SANS:</b> Scale for the Assessment of Negative Symptoms. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Risk of bias: serious (downgraded by 1). This study did not describe blinding of outcome assessors, only analysed data from study completers (per protocol analysis) </p> <p><sup>2</sup> Risk of bias: serious (downgraded by 1).This study recorded depressive symptoms with HAM‐D at baseline, and used the depressive subscale of BPRS at follow‐up. </p> <p><sup>3</sup> Imprecision (downgraded by 1). Although the CI around the estimate of effect is relatively tight, the sample size was smaller than the optimal information size (one small study only N &lt; 200). </p> <p><sup>4</sup> Risk of bias: serious (downgraded by 1). Several studies have unclear risk of bias, particularly regarding random sequence generation and blinding, as well as failure to describe allocation concealment. This bias is likely to lower confidence in the estimate of the effect. </p> <p><sup>5</sup> Indirectness: serious (downgraded by 1). Not clinically meaningful binary data </p> <p><sup>6</sup> Imprecision: serious (downgraded by 1). Although the CI around the estimate of effect is relatively tight, the sample size was smaller than the optimal information size (two small studies N &lt; 200) </p> <p><sup>7</sup>Risk of bias: serious (downgraded by 1). One of the included studies did not report intention‐to‐treat data and had a high risk of bias. </p> <p><sup>8</sup> There was a moderate‐high degree of heterogeneity for this outcome I<sup>2</sup> = 75% </p> <p><sup>9</sup> The two studies had different cutoffs for clinical significance. <a href="https://archie.cochrane.org/sections/documents/view?version=z1711231310158220868921020452083%26format=REVMAN#STD-Abbasi-2010" target="_blank">Abbasi 2010</a>: defined as improvement in PANSS total of &gt;50%. <a href="https://archie.cochrane.org/sections/documents/view?version=z1711231310158220868921020452083%26format=REVMAN#STD-Terevnikov-2013" target="_blank">Terevnikov 2013</a>: defined as improvement of PANSS total by &gt; 20%. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Mirtazapine adjunct versus placebo adjunct</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011943.pub2/full#CD011943-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011943-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Mirtazapine adjunct versus placebo adjunct ‐ short term</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mental state: specific. 1a. Negative symptoms: clinically important change <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.57, 1.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 No important response (reduction in SANS overall score from baseline of at least 20%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.57, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Mental state: specific. 1b. Negative symptoms: average endpoint score (various scales) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 PANSS negative (high = poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.65 [‐4.45, ‐0.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 SANS (high = poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐15.04 [‐20.06, ‐10.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Mental sate: specific. 1c. Negative symptoms: average endpoint score (PANSS negative, high = poor) ‐skewed data <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Mental state: specific. 2a. Positive symptoms: average endpoint score (PANSS, high = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.20 [‐5.29, 0.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Mental state: specific. 2b. Positive symptoms: average endpoint score (various scales) ‐ skewed data <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Mental state: overall. 3a. Clinically important change (at least 20% change PANSS) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.51, 0.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 No response</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.51, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Mental state: overall. 3b. Average endpoint score (various scales) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 PANSS (high = poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>170</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.84 [‐7.89, 0.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 BPRS (high = poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐19.30 [‐22.10, ‐16.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Mental state: overall. 3c. Average change score (various scales) ‐ skewed data <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Mental state: specific. 4a. Depressive symptoms: average endpoint score (HAM‐D, high = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.51 [‐1.72, 4.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Mental state: specific. 4b. Depressive symptoms: average change score (various scales) ‐ skewed data <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Leaving the study early for any reason <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>310</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.64, 1.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Global state: 1. Average endpoint score (CGI severity, high = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐0.68, 0.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Global state: 2a. Average change score (PGI, high = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.54 [‐0.97, ‐0.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Global state: 2b. Average change date (various scales) ‐ skewed data <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Cognitive functioning: other data <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 Other data tables</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Adverse events: 1a. General (participants with at least one adverse event) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.81, 1.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Adverse events: 1b. General (total number of adverse events) ‐ count data <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Adverse effects: 2a. Extrapyramidal: clinically important change akathisia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.20, 0.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1 No clinically important response (reduction of at least 2 on BAS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.20, 0.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Adverse effects: 2b. Extrapyramidal ‐ full resolution of akathisia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Adverse effects: 2c. Extrapyramidal ‐ specific effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.1 Parkinsonism</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.6 [0.29, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.2 Akathisia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.01, 2.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.3 Dystonia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.4 Additional anticholinergic drug use</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.24, 0.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.5 Tremor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.16, 6.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 Adverse effects: 2d. Extrapyramidal: average change score (various scales) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.1 SAS, high = poor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.27 [‐1.97, 1.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.2 BAS , high = poor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.03 [‐0.69, 0.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22 Adverse effects: 2e. Extrapyramidal: average endpoint score (various scales) ‐ skewed or unusable data <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23 Adverse effects: 2f. Extrapyramidal: treatment details ‐ skewed data <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">24 Adverse events: 3. Other specific effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.1 Weight gain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.19 [1.17, 8.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.2 Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>157</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.44 [0.54, 3.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.3 Sedation/drowsiness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>223</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.64 [1.01, 2.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.4 Increased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.57 [0.66, 10.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.5 Weakness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.86 [0.12, 66.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.6 Hypersedimentaiton</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.86 [0.12, 66.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.7 Arrythmia/palpitations</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.15, 6.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.8 Uterine myoma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.86 [0.12, 66.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.9 Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>137</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.32 [0.83, 6.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.10 Collapse</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.01, 7.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.11 Acute Respiratory Distress Syndrome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.01, 7.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.12 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.55 [0.45, 5.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.13 Agitation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.15, 3.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.14 Sleep disturbance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.02, 1.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.15 Dry mouth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.25 [0.74, 6.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.16 Blurred vision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [0.33, 5.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.17 Conjunctivitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.01, 7.35]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Mirtazapine adjunct versus placebo adjunct ‐ short term</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011943.pub2/references#CD011943-tbl-0003">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD011943.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD011943-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD011943-note-0007">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD011943-note-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD011943-note-0006">Français</a> </li> <li class="section-language"> <a class="" href="ms#CD011943-note-0005">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pt#CD011943-note-0004">Português</a> </li> <li class="section-language"> <a class="" href="ru#CD011943-note-0003">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD011943-note-0002">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011943\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011943\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011943\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011943\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011943\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011943\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011943\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011943\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011943\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011943\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011943\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011943\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011943\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011943\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011943\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011943\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011943\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011943\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=6iOnQIUh&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011943.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011943.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD011943.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD011943.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011943.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740718411896"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011943.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740718411900"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011943.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dcf94ee69935f',t:'MTc0MDcxODQxNC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 